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ABSTRACT
Small molecule mediated chemical intervention of biological processes using nucleic
acid targets has proven extremely successful and is continually providing exciting new
avenues for the development of anti-cancer agents and molecular probes. Correlation between
structure and potential biological functions have been explored for DNA conformations that
deviate from the standard B-form duplex–including triplexes, quadruplexes, i-motifs and so
on. G-quadruplexes has certainly garnered much recognition due to an overwhelming rise in
the evidences supporting their involvement in diverse biological process, and potential
opportunities exist for regulation of biochemical processes through quadruplex-dependent
mechanisms.
Small molecules that have been shown to induce and stabilize telomeric quadruplex
conformations are found to have telomerase inhibition activity. The grooves of the
quadruplexes offer an alternate recognition site for ligand interactions with potentially higher
selectivity than the traditional terminal stacking sites. DB832, a bifuryl-phenyl diamidine, was
recently reported to selectively recognize human telomeric G-quadruplex, as a stacked species,

with significant selectivity over duplex sequences. A series of biophysical studies were
conducted to test the groove-binding mode of DB832, along with the selectivity for diverse
quadruplex forming sequences. To gain better understanding of quadruplex grooverecognition by DB832, a series of structurally similar heterocyclic diamidines were also
evaluated. The unique binding mode of DB832 as well as its selectivity for its DNA target may
allow it to serve as a paradigm for the design of new class of highly selective quadruplex
groove-binding molecules.

Beyond the alternative secondary structures, it is also becoming increasingly apparent
that the structure and dynamics of the canonical Watson–Crick DNA double helix play pivotal
roles in diverse biological functions. In recent years, compounds preferentially binding to
duplex GC sequences have attracted the scientific community to further understand the DNA
recognition rules. DB1878, a phenyl-furan-indole diamidine, was shown to recognize a mixed
GC/AT motif as a stacked antiparallel dimer. Here, we have conducted detailed NMR structural
studies of the complex of DB1878 with a GC/AT sequence. The structure reported here is
completely different from the traditional DNA recognition exhibited by lexitropsins, and
represents an entirely new motif for DNA minor groove recognition.
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1.1

INTRODUCTION
PERSPECTIVE
A great mystery of life is how a single-celled entity, beginning from the time of

conception to birth to development, dividing and subdividing in an orderly manner, becomes
in time a complex, individual organism. Science has, to a great extent, helped us in our neverending quest for understanding the complex process of development by probing down to the
level of atoms and molecules, to decode their fundamental properties how they are related to,
contribute, and control diverse biochemical processes within the cells. The last fifty years have
completely changed the way biological and medical researchers study and understand life,
susceptibility to infectious and inherited diseases, and the molecular mechanisms of metabolic
processes. One reason that brought about this understanding lies in the ability to access the
information contained in biological macromolecules. Breakthroughs, combined with
unanticipated discoveries, at various stages over decades have led to the creation of what is
termed as modern-day medicine that has significantly altered the perception of human body.
The reductionist's approach – the study of chemistry and physics of life – created an enormous
wealth of biochemical and genetic data available for the rational design of drugs and the
manipulation of the genome. The scientific advancements over the years have considerably
increased our potential to understand and defend against lethal diseases. Science has gone to a
great extent to solve the mystery of life, but it still is at an early stage. With the current
knowledge, we can at least make an assertion that many of the underlying processes that guide
the complex biochemical processes occurring in our body can be explained through science.
Nevertheless, the fact remains that the more we decipher the secrets of the human body
through science, the more complex it seems to be.
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1.2

THE CENTRAL DOGMA
Within the countless number of cells in the human body, there are infinite number of

biochemical processes undergoing, at any given time in a well-orchestrated manner, almost all
of which involve the basic biomolecules: carbohydrates, lipids, proteins and nucleic acids. The
five bases and twenty amino acids, which make the repertoire of nucleic acids and proteins
respectively, are very well conserved throughout nature and, essentially, control and guide
most of the biochemical processes occurring in the body. The central dogma of molecular
biology, which formulates the sequential information from DNA to protein to be deterministic,
was first articulated by Francis Crick in 1958[1]. This model summarizes the transfer of the
most complex hereditary information in a very simplistic, but elegant way. Nucleic acids in all
organisms carry the genetic information in the form of DNA, although some viruses use RNA
as their genetic material. By the process of transcription, a stretch of DNA for a gene dictates
the sequence for its correlative mRNA, and then the same mRNA serves as a template for the
translation of amino acids into a sequence of polypeptides, which form a protein. Thus, the
central dogma reveals a predictable chain of information from DNA to protein, whereupon
sequential information for any one component offers determinative sequence information for
the other components. The transfer of this information in unidirectional (i.e., DNA  RNA 
PROTEINS), and each step is tightly regulated to maintain a balance between the individual
components, a hallmark of normal cells. Cancer cells and viruses, however, exhibit
deregulated signaling of all or any of the components of the central dogma, resulting in their
unbridled proliferation. Also, the flow of information in cancer cells is not in accord with the
simplest principles set forth by central dogma, reverse-transcriptase[2] and prion proteins[3]
being prime examples.

Complex human diseases encompass a spectrum of genetic and environmental
attributes that together affect the normal functioning of several molecular and cellular
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pathways. They occur commonly in the population and are a major source of disability and
death worldwide. The genes that contribute to complex diseases are notoriously difficult to
identify, because they typically exert small effects on disease risk; in addition, the magnitude of
their effects is likely to be modified by other unrelated genes as well as environmental
factors[4]. One of the greatest challenges facing researchers today is to sort out how these
contributing factors interact in a way that translates into effective strategies for disease
diagnosis, prevention, and therapy. While major inroads have been made in identifying the
genetic causes of disorders, little progress has been made in the discovery of common gene
variations that predispose to complex diseases. On an exciting note, the genome sequencing
projects have provided a step toward a broader and more complete understanding of
challenges and opportunities in addressing some of the underlying questions for a successful
therapeutic intervention. Further extensive investigation will help discover hitherto unknown
biological functions and provide clues to the occurrence and control of many diseases.

1.3

BEYOND THE DOUBLE HELIX
Ever since the discovery of double stranded DNA, various higher order DNA structures

have been discovered

[5].

The remarkable ability of single strand oligonucleotides to form a

multitude of structures is attributed to an excellent array of hydrogen bond donors and
acceptors that nature has precisely incorporated among the nucleobases, and also various
external factors such as salt, ion concentration, pH and the extent of hydration. The network of
hydrogen bond donors and acceptors among the bases enable them to fold into structures that
deviate from the classical Watson-Crick base pairing. Various triplexes[6], cruciforms[7], and imotif[8] architectures have been reported in designed DNA sequences that have shown to
exhibit interesting hydrogen-bonding patterns between the nucleotides (Figure 1.1). Multistranded DNA structures have assumed great importance in recent years with the realization
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that they play important roles in various biological processes such as DNA recombination,
replication, translation, gene expression and disease control, to name a few[9]. There is
mounting evidence that DNA structural properties beyond the double helix significantly affect
its interactions with proteins and play an important role in a number of biological
processes[10].

1.4

G-QUADRUPLEXES
Guanosine molecules show a remarkable ability to self-assemble into highly complex

patterns [11]. The self-association of guanine-rich DNA motifs under physiologically feasible ion
concentrations led to the hypothesis that these structures might have significant biological
importance. Guanine-rich DNA sequences, under certain physiological conditions, can form
unique structures known as G-quadruplexes that have structural properties very different
from the canonical DNA [5a, 12]. Stacking of G-tetrads leads to the formation of G-quadruplexes;
complex and highly ordered helical structures. The G-tetrad motif is composed of four
guanines arrayed in a square planar configuration and can self-assemble in the presence of
cations (Figure 1.2, A). Adjacent guanine bases in a tetrad are hydrogen-bonded on their
Watson-Crick and Hoogsteen edges, with their carbonyl groups oriented towards the centre of
the quadruplex. Within a tetrad, the N1 imino proton and the C2 amino proton of a guanine
residue are hydrogen bonded respectively to the C6 carbonyl oxygen and the N7 of the
neighboring guanine residue, and a similar hydrogen bonding pattern continues until all the
four guanines in a tetrad are cyclically connected by hydrogen bonds. Overall, eight hydrogen
bonds are observed in a tetrad adding significant stability to the tetrads. The quadruplex is
further stabilized through π-π stacking interactions of the stacked tetrads as well as by
coordination with cations located between or within the tetrads. These structures exhibit
extensive structural diversity and polymorphism relative to duplex DNA. In general, structural
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polymorphism arises mostly from the nature of the loop, such as variations of strand
stoichiometry, strand polarity, glycosidic torsion angle, and the location of the loops that link
the guanine strands

[5a, 12].

Meanwhile, the solution environment, such as proteins, ligands, or

molecular crowding conditions, may also influence the topology of quadruplex

[13].

G-

quadruplexes can be folded from a single G-rich sequence intramolecularly or by the
intermolecular association of dimeric or tetrameric strands. Other self-assembling motifs, like
G-ribbons, were also identified in lipophilic guanosine derivatives

[14].

Switching between G-

ribbon and G-quadruplex structures was observed as a function of the solvent and cations in
the solution [15].

1.4.1 Biological Role of G-Quadruplexes
Despite the fact that these unique structures were discovered and have been known for
more than half a century, it is only during the past decade or so these G-quadruplex structures
have come into the limelight, due to an overwhelming rise in the evidences supporting various
hypotheses about the relevant role of G-quadruplexes in wide range of biological processes [16].
Potential quadruplex forming guanine rich sequences are found in biologically important
regions of the genome including telomeres

[12, 17],

transcriptional regulatory regions of genes

(such as insulin, VEGF, fragile X mental retardation gene)

[8a, 18],

immunoglobulin switch

regions [19], promoter regions of oncogenes (such as c-myc, c-kit, bcl-2, ret, k-ras) [20] thereby
raising exciting possibilities of moderating gene expression with the aid of G-quadruplexes.
Because of their apparent role in controlling gene expression and their putative involvement in
the inhibition of telomerase activity, G-quadruplexes are potential targets in cancer research
[21].

Recent bioinformatics studies have shown that human genome contain as many as

376,000 potential quadruplex-forming sequences and an astounding 40% of these gene
promoter regions have at least one quadruplex forming motif [22].
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The discovery of a number of proteins in various organisms, such as yeast and
oxytricha that can bind to telomeric DNA suggests that these quadruplex structures may also
exist in vivo

[23]

and, interestingly, recent studies from different labs have provided evidence

that these quadruplex structures do form in vivo. Autoradiography studies of metaphase
chromosomes of normal and cancer cell lines have shown that a quadruplex binding ligand,
3H-360A,

accumulates in the nuclei of these cells and preferentially binds to the terminal

regions of metaphase chromosomes of both normal and cancer cells[24]. Biochemical assays
have shown that the cationic porphyrin, TmPyP4, binds to and stabilizes a particular
conformation of G-quadruplex structure in the NHE III1 of c-myc promoter region thereby
directly repressing c-myc transcriptional activation[25]. The strongest evidence to date for Gquadruplex existence in vivo synthetic single chain antibody fragments specifically targeted
against a parallel intermolecular G-quadruplex assembled from the ciliated protozoan

Stylonichia lemnae telomeric sequence[26]. The presence of a strong signal in the macronucleus
by one of the antibody fragments confirmed the presence of quadruplex structures in vivo.
These exciting results demonstrate that quadruplex structures can also form in vivo and
ligands can be invariably employed to exploit these G-quadruplex structures as “druggable
targets”[27].

1.4.2 Telomeres
Telomeres are specialized non-coding structural units capping the ends of
chromosomes in eukaryotic cells of parasites and higher organisms

[17d, 28].

They are found to

play a vital role in maintaining the stability of chromosomes by preventing end-to-end fusion,
recombination, nuclear degradation and cellular senescence

[17d, 28a, 29].

Telomere length is

regarded as a potential biomarker of aging[30]; there is a growing body of evidence indicating
that shorter telomeres are associated with various diseases, including cancer, infectious
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diseases, psychological stress, and cardiovascular disease[28a,

31].

Telomere dysfunction limits

the proliferative capacity of human cells by activation of DNA damage responses, inducing
senescence or apoptosis[30]. In humans, telomere shortening occurs in the vast majority of
tissues during aging, and telomere shortening is accelerated in chronic diseases that increase
the rate of cell turnover[30]. The leading hypothesis for telomere attrition is due to
inflammation, exposure to infectious agents, and other types of oxidative stress, which damage
telomeres and impair their repair mechanisms[32]. Several lines of evidence support this
hypothesis, including observational findings that people exposed to infectious diseases have
shorter telomeres.

1.4.3 End-Replication Problem and Telomerase
The semi-conservative nature of DNA replication prohibits DNA polymerase from
replicating the 3‟-end of the lagging strand of the DNA (termed as the “end replication
problem”) due to the absence of a RNA primer with a free 3‟-OH group. Therefore, after each
round of cell division and DNA replication, the extreme 3‟-end of the telomeres shorten by
about 50-150 base pairs and after about 60-70 cycles of cell division, the telomeres reach a
critical length when the cell enters the senescence stage eventually leading to apoptosis and
finally results in cell death[17d, 31d]. However, the telomere length is maintained at a constant
level in tumor cell lines as well as in germ-line cells

[29].

This is due to the activation of an

enzyme called telomerase, which is absent for the normal function of most somatic cells that
usually have longer telomeres, whereas widely expressed in immortal cells. In fact, telomeres
are highly maintained in length in 80-85% of human tumor cells, which divide indefinitely by
the action of telomerase[21d]. Telomerase is a ribonucleoprotein reverse-transcriptase enzyme
consisting of an eleven bases long RNA template and a catalytic subunit (hTERT) with reverse
transcriptase activity. With the aid of accessory proteins, the enzyme extends the 3‟ ends of the
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DNA by consecutively adding the TTAGGG hexanucleotide repeats using the RNA template as a
primer[21d]. However, in order to continue the elongation process, it is highly imperative that
the primer maintain the single stranded conformation. Formation of any secondary structures,
such as G-quadruplexes, impedes the hybridization of template RNA subunit of telomerase
onto the primer during the elongation process and consequently resulting in the inhibition of
telomerase activity. Therefore, inducing or stabilizing the telomeric quadruplex conformation
might be one of the important methods of controlling and inhibiting the activity of telomerase.
Moreover, the telomerase holoenzyme itself has potential recognition sites that can be
exploited for the development of inhibitors. Antisense oligodeoxynucleotides[33], hammerhead
ribozymes[34], peptide nucleic acids[35], chimeric RNA modules[36], reverse transcriptase
inhibitors[37] and immunotherapy agents[38] are some of the agents that are shown to
potentially recognize different structural and functional units of telomerase holoenzyme, and
are actively studied as telomerase inhibitors. Since telomerase is necessary for the immortality
of many cancer types, it is thought to be a potentially highly selective and attractive drug target
for several anti-tumour strategies. Its action is detected in most primary human tumor
specimens and tumour-derived cell lines, such as those of the prostate, breast, colon, lung and
liver

[21c-e, 31c, 39].

Hence, inactivation of telomerase may play an important role in cancer

therapy. As aforementioned, telomerase activity can also be inhibited by stabilization of
quadruplex conformation of telomeres and, therefore, small molecules that stabilize these
quadruplex structures could act as telomerase inhibitors and can be employed as potential
therapeutic agents.

Human telomeric sequences are one of the most extensively studied motifs due to their
critical role in maintaining chromosomal integrity. Human telomeres consists of highly
conserved tandem repeats of guanine rich hexanucleotide d[TTAGGG] ranging from 5-15 kb,
while the extreme 3‟ terminus of this telomeric sequence is single stranded and composed of
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only about 100-200 bases that folds into a “t-loop” structure[40]. The hexanucleotide repeats of
d[TTAGGG] can fold into an array of quadruplex topologies in vitro under different
physiological conditions[5a]. Structural information of telomeric quadruplex DNA under in vivo
conditions is essential from drug design stand point of view. The first structure of the human
telomeric DNA sequence, AG3(T2AG3)3 by NMR in Na+ has shown that this sequence folds into
an intramolecular quadruplex termed as an antiparallel basket structure with a mixture of
diagonal and lateral TTA loops[41]. In the presence of K+ in a crystalline state, an intramolecular
parallel, propeller-type G-quadruplex conformation has been reported. Propeller-type Gquadruplexes have the loops running diagonally between the G-strands with the G-strands in
a parallel arrangement[42]. Because the structure in K+ solution is considered to be biologically
more relevant, due to the high intracellular K+ concentration, several attempts have been made
to elucidate the folding topology of human telomeric quadruplex in K+, and several structures
were found that are inconsistent with the crystal structure. The equilibrium of G-quadruplex
species in K+ solution can be altered by several additional factors. For example, platinum-based
cross-linking studies have shown that the basket-type structure coexists with other
quadruplexes in both Na+ and K+ solutions[43]. A subsequent

125I-radioprobing

study has

revealed that a chair-type conformation is the major species in K+ solution[44]. Recently,
sedimentation and fluorescence studies have revealed that the crystal structure of telomeric
DNA is unlikely to be the major species in K+ solution, and various forms are energetically
similar [45]. A mixture of chair-type and parallel/antiparallel hybrid structures may coexist for
telomeric DNA in K+ solution. Circular dichroism studies of several modified human telomeric
sequences with bromo-guanine substitutions revealed the formation of highly stable hybridtype conformations, and were later further confirmed by high resolution NMR studies

[46].

Recent structural studies by several groups also showed that the human telomeric quadruplex
folds into a mixture of “hybrid-type” mixed parallel/antiparallel quadruplex conformations
[47].

However, the NMR structures all have flanking sequences that confer additional
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stabilization, so they cannot be directly compared with the crystal structure. Recently, it was
reported that human telomeric DNA forms parallel-stranded intramolecular G-quadruplexes
in K+ solution under molecular crowding conditions

[48].

Moreover, various labs have

suggested a compact stacking structure for multimers of hybrid-type and parallel-type Gquadruplexes in human telomeric DNA. The “hybrid-type” structures of telomeric
quadruplexes under physiological K+ conditions maybe the predominant conformation in vivo.

1.4.4 Oncogenes
The c-myc gene belongs to the Myc gene family and functions as a gene-specific
transcription factor through its protein product, c-Myc, for a wide range of human cancers.
The c-Myc protein regulates almost 20% of all cellular genes and is also involved in cell cycle
regulation, apoptosis, metabolism, cellular differentiation, and cell adhesion[49]. As a result, the
aberrant over expression of c-myc is associated with a variety of malignant tumors including
those of breast, colon, cervix, and myeloid leukemia[50]. In particular, c-Myc has been
identified as one of the main activating factors for the human telomerase reverse transcriptase
(hTERT) catalytic domain of the telomerase enzyme[51]. The nuclear hypersensitivity
element III1 (NHE III1) upstream of the P1 promoter of c-myc is a G-rich strand containing a
27-base-pair sequence (Pu27, Table 1.1), which has the propensity to adopt a G-quadruplex
structure. The presence of a quadruplex within this promoter region was initially proposed
based on chemical probe studies, gel mobility measurements, and fluorescence resonance
energy transfer (FRET) spectroscopy[52]. In later studies, the topological structures of several c-

myc quadruplex sequences were determined by circular dichroism (CD), NMR, and
mutational experiments

[16a, 53].

The G-rich region of c-myc contains more than four

consecutive G-strands, resulting in the formation of a dynamic mixture of four parallel Gquadruplex loop isomers in the native Pu27 region. Furthermore, two different sequences
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derived from the Pu27 region have been analyzed by NMR[20d], revealed that both myc-2345
(Table 1.1) and myc-1245 (Table 1.1) fold into intramolecular propeller-type G-quadruplexes
in K+ solution. In this case, the core of three G-tetrads is formed by four G-stretches oriented in
the same direction, with all the guanines in an anti glycosidic conformation and the three
loops adopting double-chain-reversal structures, very similar to the crystalline state of
telomeric G-quadruplex conformation in K+. Similar structures have also been found in the

Pu24I (Table 1.1) and myc22-G14T/G23T (Table 1.1) sequences

[54].

A interesting structural

feature of Pu24I revealed by NMR studies show that a guanine base (G24) at the 3 end plugs
back into the G-tetrad core by participating in G-tetrad formation and displacing another
guanine (G10) of a continuous guanine tract in a loop. This configuration is maintained by a
stable diagonal loop, which contains a G•(A-G) triad stacking on and capping the G-tetrad
core. These new folding features result from the presence of five guanine tracts in the sequence
that are different from the four guanine tracts in the c-myc sequences studied previously.

bcl-2 is a proto-oncogene, and its oncogenic property arises from decreasing the rate of
cell death[55]. Its protein product, Bcl-2, is a mitochondrial membrane protein, which is present
in delicate balance with related proteins and is involved in the control of programmed cell
death, functioning as an apoptosis inhibitor

[56].

Over-expression of bcl-2 has been found in a

wide range of human cancers, including B-cell and T-cell lymphomas, breast, cervical,
prostate, and colorectal. In addition, it also functions in chemotherapy-induced apoptosis[55],
which indicates its potential role in drug resistance. The human bcl-2 gene contains a GC-rich
region upstream of the P1 promoter, which is critical for the regulation of bcl-2 gene
expression. It can form a mixture of three distinct intramolecular G-quadruplexes (5 G4,
MidG4, and 3 G4) resulting from the six runs of guanines, including one run of five guanines,
two runs of four guanines each, and three runs of three guanines each (Table 1.1). With more
than four consecutive G-tracts in the sequence, the G-quadruplex in bcl-2 has the ability to
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form either three or six different loop isomers

[57].

The central G-quadruplex (MidG4, Table

1.1), which is the most stable of the major species formed in the bcl-2 promoter region, is
likely to form a mixed parallel/antiparallel structure consisting of three tetrads connected by
loops and to give rise to three possible loop isomers. An NMR study of the shorter and mutated

bcl-2 quadruplex bcl2MidG4Pu23-G15T/G16T (Table 1.1) has shown that one of the
topologies for this mixed parallel/antiparallel intramolecular quadruplex has two lateral loops
and one propeller loop, similar to one of the Tel22 telomeric quadruplex topologies [20c, 58]. The
G-rich strand located in the bcl-2 P1 promoter plays a significant role in the regulation of bcl-

2 transcription

[59].

Although the effects of G-quadruplex ligands on bcl-2 expression remain

to be deciphered, some studies have shown that some G-quadruplex ligands can induce
apoptosis [60]. In particular, the ligand 12459 has been found to induce apoptosis characterized
by dysfunction of Bcl-2 [61]. These findings suggest the possible role of G-quadruplex formation
in the bcl-2 promoter during apoptosis.

Recently, two G-rich sequences (c-kit native and c-kit21, Table 1.1) in the promoter
region of the human c-kit gene have been identified, and biophysical studies have shown that
these sequences can form G-quadruplexes

[20e, 62].

In the c-kit native sequence, 87 base pairs

upstream of the transcription start site of the human c-kit gene, a single G-quadruplex
structure forms in K+ solution. An NMR study has shown that the c-kit87up (Table 1.1)
sequence forms a new intramolecular G-quadruplex[63]. Most strikingly, an isolated guanine
(G10) is involved in G-tetrad core formation, despite the presence of four three-guanine tracts.
There are four distinctive loops, including two single-residue and double-chain-reversal loops
(A5, C9), a two-residue loop (C11, T12), and a five-residue stem-loop (A16, G17, G18, A19,
G20). In view of the importance of predicting G-quadruplex topologies from sequence
information, these new folds in which G residues in non-G-tract regions can participate in
structural core formation are particularly worthy of attention. In the case of the c-kit21

13

sequence, a variety of quadruplex conformations have been identified. This sequence needs to
be mutated in order to form a single quadruplex species, probably with a parallel fold.

1.4.5 Other G-Quadruplex Families
Guanine-rich sequences of human vascular endothelial growth factor (VEGF) and the

neuroblastoma (Rb) oncogene promoter have also been shown to form G-quadruplexes by
chemical footprinting and CD studies [16c, 64]. The G-rich sequences in these regions are known
to exist in duplex form and ligands such as TMPyP4 and Telomestatin have been shown to
induce parallel quadruplex conformations. Putative quadruplex forming sequences have also
been discovered in hypoxia-inducible factor 1α (HIF-1α) promoter region, k-ras and ret
oncogenes

[65].

Other types of G-quadruplexes have also been found in the RNA region[66],

peptide nucleic acids (PNA)[67] and locked nucleic acids (LNA)[68].

There are now reasons to believe that G-quadruplex structures are not merely an in

vitro artifact. Both in vitro and in vivo data strongly support the physiological relevance of this
nucleic acid structure at the telomere, one of the signature guanine-rich regions of the
genome. While the precise role of this structure at chromosomal ends remains a matter of
conjecture, a number of scenarios have been put forward, taking into account the diverse
conformations of the G- quadruplex. The inability of telomerase to utilize the G-quadruplex
fold of telomere has led to the emergence of a novel avenue for cancer therapy, through Gquadruplex stabilizing agents. These agents can trap DNA in a quadruplex conformation and,
in this manner, may either inhibit telomere extension by telomerase or perturb telomerecapping mechanisms. This approach may be complicated by the structural heterogeneity of Gquadruplexes that arise from human telomeric DNA. In addition, questions remain regarding
the in vivo mechanism of action of existing G-quadruplex stabilizers. Nevertheless, given the
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clinical significance of the G-quadruplex, research activities on telomeric and genomic
quadruplexes will continue to grow. With a better understanding of the biological functions
and structural properties of G-quadruplexes, it is expected that a wealth of new drugs that are
less cytotoxic and that have higher selectivity will emerge in the near future.

1.5

TARGETING G-QUADRUPLEXES WITH SMALL MOLECULES
Studying small molecule interactions with quadruplex forming structures is a rapidly

developing area in the field of drug design and synthesis driven by the need for understanding
at the molecular level for the development of potential candidates into effective
chemotherapeutic agents. The basic principles that aid in the design and synthesis of small
molecules for duplex DNA recognition can also be employed for quadruplex recognition.
Compounds that intercalate between the base pairs of duplex DNA can be used as lead
candidates to develop small molecules that can interact with quadruplexes by either
intercalation or end-stacking. Several compounds to-date have been shown to bind and
stabilize the human telomeric quadruplex conformations. The quadruplex-small molecule
interactions, in most cases, occur via the external stacking of the ligand on the G-quartets of
either one or both ends of the quadruplex. These compounds are traditionally planar and have
aromatic moieties that can efficiently stack on the large aromatic surface area of the G-quartet
via π-π interactions. Some of the compounds designed by exploiting the structural properties
of G-quartets and have shown to inhibit telomerase activity are di- and tri-substituted
acridines such as BSU6039[69] and BRACO-19[60d, 70], cationic porphyrins such as TmPyP4[53, 71]
and Se2SAP[72], macrocycles such as PIPER[73], BOQ1[74] and MMQ3[75], carbazoles[76], metal
mediated compounds such as Pt-MPQ[77], Ni(II)-salphen[78] and Cu-ttpy[79], and neutral
molecules such as telomestatin[16d, 60b, 71b] and HXDV[80]. These compounds have been studied
in great detail, and in all cases end stacking is the observed primary mode of binding with
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telomeric quadruplex structure, whereas, some compounds such as TmPyP4 exhibit nonspecific binding such as external binding to the loops or the backbone of the quadruplex
structure.
Quadruplex grooves offer an attractive recognition site for interaction of small
molecules, but there has been very little success in designing molecules that target quadruplex
grooves. Small molecules that have been discovered to sequence-specifically interact with the
grooves of duplex DNA can be used as paradigms to develop compounds to target the grooves
of the quadruplex.

Spectroscopic studies have shown that DODC, a carbocyanine dye,

interacts with the grooves of a dimeric hairpin quadruplex DNA[81]. Recent NMR studies have
shown that distamycin, a classic duplex-DNA minor groove binder, also binds to an
intermolecular quadruplex conformation as an antiparallel dimer in the opposite grooves
making specific hydrogen bonding with the donor and acceptors along the grooves of the
quadruplex[82]. 1H-NMR studies have shown that diaryl amides can potentially recognize
grooves of a parallel quadruplex conformation formed in the promoter region of c-kit2
oncogene with high degree of selectivity over duplex DNA[83]. However, small molecules that
can target grooves of biologically relevant telomeric quadruplex conformation have not been
reported so far. Nonetheless, these results point out that quadruplex groove recognition is
indeed a viable strategy for drug design and needs much further attention.

1.6

RESEARCH GOALS
DB832, a bifuryl-phenyl diamidine, was recently reported to selectively recognizing

human telomeric G-quadruplex conformation with significant selectivity over duplex
sequences. Circular dichroism analysis revealed that DB832 can potentially recognize multiple
grooves of the telomeric quadruplex as a stacked agent. The first goal of this research described
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in Chapter 2 involved a multifaceted approach providing complementary lines of evidence to
comprehensively characterize the binding mode of DB832. An array of established
spectroscopic techniques, circular dichroism, NMR, thermal melting, fluorescence intercalator
displacement (G4-FID) assay, surface plasmon resonance, and isothermal calorimetry
techniques have been used to test this. DB832 serves as a paradigm to show that the grooves of
the human telomere can indeed be selectively targeted and can serve as a starting point for the
design of new molecules that may have therapeutic use as anti-cancer or anti-trypanosomal
agents.
With the abundance of various quadruplex forming structures in the human genome,
selectivity within different quadruplex conformations becomes an important task. Binding to
non-targeted quadruplex sequences results in compound loss and may have unintentional
effects on regulation of non-targeted genes. The second goal of this research was to evaluate
the selectivity of DB832 to various quadruplex forming sequences in the genome and is
presented in Chapter 3. CD studies show that DB832 is highly selective for different human
telomeric quadruplex conformations and potentially interacts as a stacked species in the
grooves. DB832 binding to non-telomeric sequences such as c-myc, bcl-2, TBA and
intermolecular quadruplex sequences are non-specific in nature, and most likely interact as
monomers by stacking at their terminal tetrads. NMR studies with the wild-type and modified
telomeric sequences further suggest that DB832 can bind to a selective quadruplex
conformation from a mixture of structures.
With the goal of gaining a better understanding of all the structural elements of DB832
contributing towards quadruplex recognition, a series of structurally similar aromatic
diamidines, designed and developed by the laboratory of Dr. David Boykin, with DB832 as the
prototype, were evaluated. Particular emphasis was directed towards compounds that
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maintained the core structure of DB832: the 5-5-6 ring systems. Systematic atom-wise and
group-wise modifications were undertaken on the 5-5-6 scaffold of DB832 that were
hypothesized to be important for the compound binding. Chapter 4 describes the
characterization of these ligands with telomeric quadruplex-DNA using an array of
biophysical techniques. These ligands form a novel class of quadruplex-interactive agents with
significant selectivity over duplex-DNA, and can be used as lead candidates to design
compounds with improved selectivity and affinity.
The goal of the work described in Chapter 5 was the characterization of different
classes of quadruplex-interactive agents with telomeric and oncogenic quadruplex forming
sequences using surface plasmon resonance. All the ligands exhibited significant selectivity for
quadruplex structures over duplex sequences. The synthetic ease of these ligands can facilitate
in carrying out more systematic substitutions, coupled with the opportunities to modulate the
side-chains, for better quadruplex recognition.
The goal of understanding groove-binding was also probed with a new duplex target
compound, DB1878, with a unique GC-containing duplex sequence, and is described in
Chapter 6. Detailed NMR studies show that DB1878 interacts as a cooperative antiparallel
dimer in the minor groove of –ATGA– containing sequences. However, the stacking of the
ligand in the minor groove is unique from all the ligands that have been reported as dimers so
far. The presence of guanine is of utmost importance for the dimer formation. Structural
details of the dimer complex could potentially aid in design and development of small
molecules that can better interact with the grooves of the guanine-rich quadruplex-DNA.
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(A)

(C)

(B)

(D)
B-Z Junctions

Figure 1.1: Some non-B DNA conformations commonly adopted by DNA. (A) cruciforms, (B)
triplexes, (C) slipped structures, and (D) Left-handed Z-DNA.

Cartoon representations directly obtained from Bacolla et al[84], without further permission.
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(A)

(B)

Hybrid-2
Hybrid-1

Antiparallel
Basket

Antiparallel
Chair

Parallel
Propeller
Figure 1.2: Organization of a G-Quadruplex (A), and some commonly observed intramolecular
quadruplex folds (B).
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Table 1.1: Quadruplex forming sequences most commonly found in the genome.
Region
Human
Telomere

c-myc

Variant

Sequence
TTAGGGTTAGGGTTAGGGTTAGGGTTA

Pu27
myc-2345
myc-1245
Pu24I
myc22-

T1GGGGAGGGT10GGGGAGGGTG20GGGAAGG
T1GAGGGTGGG10GAGGGTGGGG20AA
T1GGGGAGGGT10TTTTAGGGTG20GGGA
TG5AGGGT10GGIGAGGGTG20GGGAAGG
TGAGGGTGGGT14AGGGTGGGT23AA

G14T/G23T

bcl-2

Pu39
5‟-G4
3‟-G4
MidG4
MidG4G15T/G16T

c-kit

c-kit native
c-kit87up
c-kit21

A1GGGGCGGGC10GCGGGAGGAA20GGGGGCGGGA30GCGGGGCTG
A1GGGGCGGGC10GCGGGAGGAA20GGGGGC
C10GCGGGAGGAA20GGGGGCGGGA30GCGGGGCTG
CGGGC10GCGGGAGGAA20GGGGGCGGGA30GC
GGGCGCGGGAGGAAT15T16GGGCGGG

A1GGGAGGGCG10CTGGGAGGAG20GGGCTG
A1GGGAGGGCG10CTGGGAGGAG20GG
C1GGGCGGGCG10CGAGGGGAGG20GGAGGC
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2

EVALUATION OF DB832 AS A POTENTIAL GROOVE BINDER FOR HUMAN TELOMERIC
QUADRUPLEX DNA AS A STACKED SPECIES

2.1

INTRODUCTION
Contrary to popular belief that nucleic acids, particularly DNA, are relatively static

rigid units compared to other biomolecules

[1],

nucleic acids exhibit remarkable structural

plasticity with conformations ranging from simple linear strands to complex scaffolds such as
t-RNA, Holliday junctions and compaction in nucleosomes [2]. Such conformational transitions,
highly dictated by local sequence composition, can be substantially modulated with salt, pH,
degree of hydration and, most importantly, proteins and small-molecules, to influence diverse
cellular functions. Guanine-rich sequences have an intrinsic ability to form such
conformationally dynamic structures known as G-quadruplexes, comprised of planar arrays of
G-quartets connected through a network of Hoogsteen hydrogen bonds

[2c].

These G-quartets,

coupled with coordination with various metal ions and by combinatorial possibilities of loop
residues, can stack into a plethora of highly dynamic G-quadruplex architectures [3].
G-quadruplex motifs have been shown to form in several biologically active regions
including telomeres and oncogene promoter regions where there is a significant enrichment of
guanine-rich clusters

[4].

Furthermore, recent genome-wide studies suggest that as many as

376,000 potential quadruplexes could exist within the human genome and more than 40% of
human genes contain a putative G-quadruplex in their promoter regions
these structures were discovered more than half a century ago

[6],

[5].

Despite the fact

it is only during the past

decade or so they have garnered much recognition due to an overwhelming rise in the
evidences supporting their involvement in diverse biological process

[7].

G-quadruplex

formation and stabilization in the telomeric G-rich single-strand component has been shown
to significantly reduce telomerase activity

[7b, 7c, 8];

also ligand-mediated G-quadruplex
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stabilization in oncogene promoter regions can significantly down-regulate gene transcription
levels

[9].

Fundamental design strategies that have been successfully formulated to design

ligands for duplex recognition can also be extrapolated for quadruplex recognition. In fact,
CX3543, a promising candidate currently in phase II clinical trials, was designed from
fluoroquinolones that target duplex DNA

[10]

and exerts its antiproliferative activity through a

quadruplex-mediated chemical intervention [11]. It has now become more evident that these Gquadruplex structures have very unique chemical and biological properties, and potential
opportunities exist for regulation of biochemical processes through quadruplex-dependent
mechanisms.
Human telomeric DNA has certainly generated the greatest interest in the Gquadruplex field because of the natural existence of a potential quadruplex-forming guaninerich TTAGGG repeats at their 3‟ ends, and the mixture of G-quadruplex conformations it can
fold into [12]. The single-strand overhang is an essential substrate for the normal functioning of
telomerase enzyme; the formation of a G-quadruplex structure by the overhang essentially
disrupts the telomere elongation mechanism of the enzyme [4i, 7b, 8c, 13]. Enhanced expression of
telomerase is a key marker for and is essential for the survival of many types of cancer cells [14].
Small molecules that have been shown to induce and stabilize telomeric quadruplex
conformations are found to have telomerase inhibition activity

[15].

Therefore, stabilizing these

unique structures with small molecules is rapidly developing as an important anticancer
strategy to successfully design and develop potential lead candidates into effective
chemotherapeutic agents. Several compounds to-date have been shown to bind and stabilize
G-quadruplex conformations, and the most common recurring theme of quadruplex
recognition is via stacking of the ligands at one or both ends of the quadruplex

[3c, 16].

Most of

these ligands that bind by this mode are highly planar aromatic, macrocyclic scaffolds with
very little conformational flexibility

[16]

and, in some cases, these scaffolds are tethered with
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side chains to preferably interact with quadruplex grooves or the loops and enhance their
affinity with the target

[15a, 15e, 17].

Some of the strongest binding telomeric quadruplex end

stackers with highest telomerase inhibition and promising anticancer activity include
telomestatin, BRACO-19, and RHPS4 [18]. Essentially all of the known quadruplex-end stackers
are designed using duplex DNA intercalators as paradigms and, even though, some of the
ligands have significant selectivity for quadruplexes, the majority of them exhibit very little
selectivity among different quadruplex DNAs. From the target selectivity perspective, it is
important that the drug bind to relatively very few-to none of the non-target sequences to
circumvent any deleterious effects and also loss of valuable compound. Therefore, successfully
designing ligands that exhibit significant selectivity for quadruplex structures and effectively
inhibit telomerase is absolutely imperative.
The grooves of the quadruplexes offer an alternate recognition site for ligand
interactions with potentially higher selectivity than the traditional terminal stacking sites.
Moreover, the structural polymorphism exhibited by G-quadruplexes in the genome has in
itself posed significant challenges in designing ligands to distinguish between quadruplexes or
to induce interconversion between different conformers

[12a, 12d-f, 19].

Nevertheless, by

successfully exploiting the distinct structural differences in groove geometries among
quadruplex, coupled with diverse hydrogen-bonding possibilities, ligands can be successfully
engineered to discriminate quadruplex grooves from the grooves of other quadruplex and of
duplex DNA. However, there has been very little success so far in developing small molecules
that strongly and selectively target quadruplex grooves. Considering the wealth of quadruplex
structural information now available, groove-targeting is clearly an area that requires much
more consideration. Some of the ligands that have been reported so far to interact with
quadruplex grooves exhibit very little selectivity over duplex DNA and, moreover, the reported
groove-binding ligands have only been characterized with fairly simple tetrameric or dimeric
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G-quadruplex systems [20]. For instance, distamycin, a well-known DNA minor-groove binder,
was reported to bind as an antiparallel stacked dimer in the opposite grooves of truncated
telomeric sequence of Oxytricha, d(TGGGGT)

[20a].

This sequence is reported to fold into a

simple interstrand parallel conformation with four readily accessible equivalent grooves.
Additionally, distamycin molecules have been reported to stack on the terminal G-tetrads of
very similar G-quadruplex conformations

[20b],

and that the distamycin groove-recognition is

favored only at substantial ligand concentrations

[20a].

Similarly, virtual-screening and 1H-

NMR results from the same group have shown a series of compounds from a library
interacting with grooves of the aforementioned quadruplex conformation

[21].

In a very

important finding, cyanine dyes such as DODC were predicted to bind in the grooves of
human telomeric quadruplex conformation

[22].

Cyanine molecules are, however, well-known

for forming stacked aggregates in the grooves of DNA duplexes

[23]

and it maybe difficult to

develop as selective G-quadruplex agents. A recent exciting study has shown that diarylethynyl
amides can potentially recognize grooves of a parallel quadruplex conformation formed in the
promoter region of c-kit2 oncogene with high degree of selectivity over duplex DNA

[24].

The

terminal amide and amino groups of these ligands were hypothesized to form favorable
interactions with the G-quadruplex grooves and loops.
Small molecules that can strongly and selectively recognize quadruplex grooves in
biologically significant regions such as human telomeres have not been discovered or
characterized so far. We recently reported on a bifuryl-phenyl diamidine, DB832 (Figure 2.1C), capable of selectively recognizing human telomeric G-quadruplex conformation with
significant selectivity over duplex sequences

[25].

Circular dichroism analysis revealed that

DB832 can potentially recognize multiple grooves of the telomeric quadruplex as a stacked
agent. This highly encouraged us to pursue a high-resolution solution structure of DB832
complexed in the grooves of human telomeric quadruplex using multidimensional NMR.
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However, the unique quadruplex recognition mode of DB832 coupled with the conformational
plasticity of human telomeric quadruplex, and some of the inherent limitations associated with
NMR methods, presented major experimental hurdles that essentially constrained our structure
elucidation process. As a result, in this study, we formulated a multi-method approach that
would provide complementary lines of evidence to comprehensively characterize the groovebinding trait exhibited by DB832. An array of established spectroscopic techniques, circular
dichroism, NMR, thermal melting, fluorescence intercalator displacement (G4-FID) assay,
surface plasmon resonance, and isothermal calorimetry techniques have been used to test this.
In the process, we have also evaluated distamycin and F1190, two small molecules that were
recently reported as quadruplex groove-binders for simple quadruplex systems, for their
selectivity for human telomeric quadruplex sequences, and have found rather contradicting
evidence that proves otherwise. DB832 serves as a paradigm to show that the grooves of the
human telomere can indeed be targeted and it can also serve as the starting point for the
design of new molecules that may have therapeutic use as anti-cancer or anti-trypanosomal
agents. Nevertheless, the dearth of compounds representing the quadruplex groove-binding
class distinctly highlights the experimental challenges involved in successfully designing small
molecules with significant target selectivity and, therefore, makes it a much more challenging
and attractive field to pursue.

2.2

MATERIALS AND METHODS

2.2.1 Oligonucleotides, compounds and buffer
The unlabeled and 5‟-biotin labeled oligonucleotides Tel22, d[AGGG(TTAGGG)3];
Tel24,

d[TTGGG(TTAGGG)3A];

d[T(AGGGTGGGG)2AA];

U6U7,

d[AGBrGGTTAGBrGGTTAGGGTTAGBrGG];

Tel26,

d[AAAGGG(TTAGGG)3AA];

d[TTAGGGUUAGGG];

d[TGGGGT];

c-myc,
ODN9,

ODN4, d[AGGGTTAGGGTTAGBrGBrGBrTTAGGG];
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Dickerson, d[CGAATTCGTTTTCGAATTCG] were purchased from The Midland Certified
Reagent Company or Integrated DNA Technologies with HPLC purification and mass
spectrometry characterization. NMR analysis performed on these sequences further confirmed
the purity of these sequences. The concentration of oligonucleotides was determined from
absorbance at 260 nm using molar extinction coefficient obtained from nearest-neighbor
principle. F1190 was purchased from Life Chemicals. Thiazole Orange and TMPyP4 were
purchased from Mid-Century Chemicals. The synthesis of DB832 will be described elsewhere.
A 1 mM stock solution of each compound was prepared in double deionized water and in
deuterated water for NMR experiments. This stock solution was diluted to required
concentrations with appropriate buffer right before their usage.
2.2.2 Circular Dichroism Studies
All CD experiments were performed at 25 °C in 10 mM K2HPO4 buffer containing 80
mM KCl and 1 mM EDTA. CD spectra were recorded using a Jasco J-810 spectrophotometer
with a 1-cm pathlength quartz cell at a scan speed of 50 nm/min and response time of 1
second. Appropriate amount of compounds were sequentially titrated from the stock solution
into the DNA solution in the cuvette until the desired mole ratios of compound to quadruplex
were obtained. The spectra were averaged over four scans. A buffer baseline scan was collected
in the same cuvette and subtracted from the average scan of each ratio. Data were processed
and plotted using Kaleidagraph 4.0 software.
2.2.3 Thermal Melting Studies
Thermal denaturation studies were conducted on a Cary 300 BIO UV-visible
spectrophotometer in quartz cuvettes of 1 cm pathlength. Compound-DNA solutions were
prepared in low salt buffer containing 10 mM TRIS buffer (pH 7.4), 10 mM KCl and 1 mM
EDTA. The absorbance of the oligonucleotides was monitored at the recommended wavelength
of 295 nm for quadruplex sequences and 260 nm for duplex sequences as a function of
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temperature. Several duplex and hairpin DNA oligonucleotides without compound were used
as a control. Samples of compound to DNA ratios from 0:1 to 4:1 was prepared. Cuvettes were
mounted in a thermal block, and the solution temperatures were monitored by a thermistor in
a reference cuvette with a computer-controlled heating rate of 0.5 °C/min. Experiments were
generally conducted at quadruplex concentrations in the range of 2-3 µM in TRIS buffer
containing 10 mM KCl. Data were analyzed and plotted using Kaleidagraph 4.0 software.
2.2.4 Nuclear Magnetic Resonance Studies
Quadruplex DNA samples were prepared in degassed phosphate buffer containing 80
mM KCl, 10 mM K2HPO4 and 0.1 mM EDTA and reconstituted in 90% H2O:10% D2O. DSS was
employed as an internal reference. Intramolecular quadruplex concentrations were in the
range of 0.1 mM to 0.3 mM unless otherwise mentioned. The final DNA samples were adjusted
to pH 7.0 using 1M HCl or 1M KOH solutions. Finally, the NMR samples were heated past their
transition temperature and annealed to room temperature several times before collecting the
spectra. Experiments were performed on a Varian Unity 600 spectrometer. DB compounds
were titrated into the quadruplex DNA with compound to DNA ratios varying from 1 to 4.
Temperature-dependent 1H-spectra were recorded from 15ºC to 45ºC using jump-return and
WATERGATE methods for solvent suppression. All NMR data were processed and analyzed
with a combination of VNMR (Varian Inc.) and MNova (Mestrelab Research) software.
2.2.5 Quadruplex-Fluorescence Intercalator Displacement Assay (G4-FID)
All the experiments were performed using a Varian CARY Eclipse Fluorescence
Spectrophotometer in a 1 ml cuvette starting from 0.5 µM solution of pre-folded DNA mixed
with 1 µM of the fluorophore thiazole orange (an excess is required to be sure that all the
binding sites are occupied by the fluorophore) in 10 mM TRIS/50 mM KCl buffer at pH 7.5.
The addiction of ligand was followed after 3 minutes of equilibration time and after this the
fluorescence spectrum was recorded with excitation wavelength at 501 nm (thiazole orange
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maximum absorbance wavelength) and scanned from 520 nm to 700 nm. The 1/30%
fluorophore displacement value was then plotted as a function of the concentration of added
ligand.
2.2.6 Surface Plasmon Resonance Studies
Biosensor SPR experiments were performed with a four-channel BIAcore 2000 optical
biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips. All DNA samples, for
either duplex- or quadruplex-binding experiments, were used as single strands to prevent
dissociation in the SPR flow system. The chips were prepared for use by conditioning with a
series of 1 min injections of 1 M NaCl in 50 mM NaOH followed by extensive washing with
buffer. 5'-Biotinylated DNA samples (25-50 nM) in HBS buffer were immobilized on the flow
cell surface by non-covalent capture as previously described

[26].

Three flow cells were used to

immobilize DNA samples, and any one of the flow cell was left blank as a control. Interaction
analysis was performed by using steady-state methods with multiple injections of increasing
compound concentrations over the immobilized DNA surface at 25 ºC. Biosensor experiments
were conducted in filtered, degassed HEPES buffer (10 mM HEPES, 100 mM KCl, 3 mM EDTA,
0.005 v/v of 10% P20 BIACORE surfactant, pH 7.3) at 25 °C. Flow cell 1 was left blank as a
reference, while flow cells 2-4 were immobilized with DNA on a streptavidin-derivatized gold
chip (SA chip from BIAcore) by manual injection of DNA stock solutions (flow rate of 1
µL/min) until the desired value of DNA response was obtained (350-400 RU). Compound
solutions were prepared in with the running buffer by serial dilutions from stock solution.
Typically, a series of different ligand concentrations (100 nM to 50 µM) were injected onto the
chip (flow rate of 50 µL/min, 5-10 min) until a constant steady-state response was obtained
followed by a dissociation period (buffer, 10 min). After every cycle, the chip surface was
regenerated (20 s injection of 10 mM glycine solution, pH 2.0) followed by multiple buffer
injections.
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The instrument response (RU) in the steady-state region is proportional to the amount
of bound drug and was typically determined by linear averaging over a 10-20 s or longer time
span, depending on the length of the steady-state plateau. The predicted maximum response
per bound compound in the steady-state region (RUmax) was determined from the DNA
molecular weight, the amount of DNA on the flow cell, the compound molecular weight, and
the refractive index gradient ratio of the compound and DNA, as previously described

[27].

To

obtain the binding constants, the data were evaluated with different interaction models to
obtain an optimal fit using BIAevaluation (BIAcore Inc.) and Kaleidagraph (Synergy Software)
software for nonlinear least-squares optimization of the binding parameters:
One site:

r = (K1Cfree)/(1 + K1Cfree)

Two site:

r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2)

Three site:

r = (K1Cfree + 2K1K2Cfree2 + 3K1K2K3Cfree3)/(1 + K1Cfree + K1K2Cfree2 +
K1K2K3Cfree3)

where K1, K2 and K3 are equilibrium constants for three types of binding sites and Cfree
is the concentration of the compound in equilibrium with the complex and is fixed by the
concentration in the flow solution.
2.2.7 Isothermal Calorimetry
ITC experiments were performed with a MicroCal VP-ITC (MicroCal Inc.,
Northampton, MA, USA). Phosphate buffer containing 10 mM K2HPO4, 3 mM EDTA, and 80
mM KCl and pH adjusted to 7.4 was used for the ITC experiments. The compound was injected
into the DNA in the sample cell in 5 µL increments. The observed heat for each injection was
determined by integration of the injection peak areas with respect with time. Blank titrations
were conducted by injecting the compound into the sample cell containing only buffer under
the same conditions. The corrected interaction heat was determined by subtracting the blank
heat from that for the compound/DNA titration.
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2.3

RESULTS AND DISCUSSION

2.3.1 DB832 Binds to the Human Telomeric DNA as a Stacked Species in Multiple Grooves
Circular dichroism has emerged as an important non-invasive technique for
determination of the conformation of biomolecules and also provides insights about the
binding modes of small molecules with DNA using pattern recognition

[28].

Binding of ligands

to DNA can be easily identified by the changes exhibited in the CD pattern by monitoring the
compound and DNA wavelengths. When an achiral ligand, which has no CD by itself in
solution, binds to a chiral macromolecule, an induced CD (ICD) signal is observed in the
wavelength region corresponding to the bound achiral ligand

[29].

This ICD signal can be a

weak positive or negative, as in the case of duplex DNA intercalators, or can be a large positive
signal, as in the case of duplex DNA groove binders

[26b, 30].

Compounds that are known to

interact with quadruplex structures have demonstrated preferential stacking at the terminal Gtetrads. Quadruplex end stackers, similar to duplex DNA intercalators, also exhibit a weak
positive or negative ICD signal upon complex formation. In some cases, compounds are shown
to effectively stack at the ends even without exhibiting any significant ICD signals

[31].

Groove

binding with quadruplexes has been a rarely observed phenomenon. As a result, a clear CD
pattern that can used to identify possible groove binding agents has not been established until
now. Shafer et al., using docking method, identified a carbocyanine dye, DODC (Figure 2.1-B),
as a potential groove binder, and studied its interaction with an intermolecular dimeric hairpin
quadruplex using CD

[22].

This was the first ever reported binding study of a quadruplex

interacting agent using CD. DODC binding to the quadruplex resulted in an induced CD signal
in the wavelength region corresponding to the absorbance of the bound DODC. The large
positive and negative ICD signal was hypothesized to be a consequence of the dye molecules
stacking in the grooves of the quadruplex (Figure 2.3-A, adopted from the above reference).
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CD experiments were carried out with DODC with other very similar quadruplex
systems to confirm that a similar ICD pattern is exhibited for groove binding. Figure 2.3-B
shows the CD spectra of DODC also with a dimeric hairpin quadruplex (Materials and
Methods, Section 2.2.1), recently reported to exist as a mixture of parallel and antiparallel
conformers. DODC exhibits an exciton-type splitting upon complex formation suggesting that
compounds that can form stacked species possibly in the grooves of the quadruplex have an
exciton-type splitting in the region corresponding to the absorbance of the bound ligand.
DODC also exhibited a very similar ICD pattern upon complex formation with the wild-type
human telomeric sequence, Tel22. Therefore, the large ICD pattern exhibited by small
molecules upon complex formation is characteristic of the ligands stacking in the grooves of
quadruplex systems. RHPS4 (Figure 2.1-A), a well-known small molecule shown to stack at the
ends of human telomeric quadruplex DNA by NMR, was evaluated by CD to see if a ICD
pattern exists for this class of compounds. As expected, RHPS4 did not exhibit any ICD upon
complex formation (Figure 2.3-C) further suggesting that end-stacking compounds have very
weak to almost no ICD with quadruplexes.

DB832 was recently reported to bind to the human telomeric quadruplex DNA, Tel22
d[AG3(T2AG3)3], possibly in the grooves of the quadruplex conformation as exemplified by a
large positive and negative induced CD signals (Figure 2.5-A)

[25].

The large magnitude of the

induced CD was hypothesized due to the stacking of DB832 in different grooves of the
telomeric quadruplex structure. Using the induced CD pattern exhibited by DB832 as a model
for quadruplex groove recognition, CD studies of DB832 were carried out with Tel24,
d[TTG3(T2AG3)3A], to investigate if a pattern similar exists (Figure 2.5-B). NMR studies have
shown that Tel24 sequence forms a mixed parallel/antiparallel hybrid type structure in K+
(Figure 2.2-A)

[32].

When DB832 is titrated into Tel24, a large exciton-type ICD signal, very

similar to Tel22, is observed in the wavelength region corresponding to the absorbance of
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bound DB832. This suggests that the DB832 is also binding as a stacked species possibly in the
grooves of this quadruplex system. Moreover, the DNA wavelength region does not exhibit
much change upon compound binding suggesting that DB832 is preferentially binding to the
pre-formed hybrid conformations.

Based on the CD studies of Tel22 and Tel24, however, it is rather difficult to definitively
establish the groove binding aspect of DB832. Therefore, if such a system exists, where the
grooves of the quadruplex systems are rendered sterically inaccessible, small molecules that
selectively bind in the grooves can be completely prevented from interacting in the grooves.
Structural features of G-quartets reveal that the aromatic proton, H8, of the guanine bases is
directly pointed into the grooves of the quadruplex. If those protons could be replaced by a
bulky substituent, small molecules can be directly inhibited from interacting in the grooves.
Bromo-guanines turn out to be the best possible candidate to test such a hypothesis. Sugiyama
and coworkers have successfully employed these modified guanine bases and shown that stable
quadruplex architectures could be maintained with this modification

[12a, 33].

The bromine

substitution on the C8 position of guanine further locks the syn glycosidic conformation of
guanine nucleotides further adding to the stability of the fold

[34].

Sugiyama and coworkers

recently showed that ODN9, d(AG2GGTTAG8GGTTAGGGTTAG20GG), folds in a mixed
parallel/antiparallel hybrid conformation, which is likely the structure the unmodified human
telomere adopts in solution in the presence of K+

[34].

The three bromoguanine substitutions

correspond to the guanines in the terminal tetrad at the 5‟-end of the hybrid fold. These bulky
bromine substituents selectively inhibit binding in all the three accessible grooves of the
quadruplex (Figure 2.2-C), thereby, effectively hindering the interaction of any groove binding
molecules. The fourth groove in the hybrid quadruplex conformation is inaccessible due to a
diagonally running loop connecting two adjacent strands.

39

CD studies of DB832 were conducted with the ODN9 sequence to further test the
groove binding mode. CD spectra of DB832 titrated into ODN9 shown in figure 2.5-C. Most
interestingly, DB832 does not exhibit the characteristic exciton-type splitting, that is observed
with unmodified telomeric sequences, with the ODN9 sequence. A weak ICD signal at
significantly high ratios of DB832 is observed, suggesting that the interaction of DB832 with
ODN9 is primarily at the ends. Since DB832 does not exhibit any exciton-type splitting with
this hybrid quadruplex structure when the grooves are rendered inaccessible by bromoguanine substitution, it provides evidence that the mode of binding of this compound to the
human telomere is groove binding as a stacked species.

Another modified human telomeric sequence with bromine atoms at different positions
was

also

tested

to

confirm

d(AGGGTTAGGGTTAG14G15G16TTAGGG),

the
was

groove
also

binding
shown

of

to

fold

DB832.
into

ODN4,
a

mixed

parallel/antiparallel hybrid conformation, similar to the unmodified human telomeric
sequence

[34].

However, in this case, the three bromine substitutions were located in a single

quadruplex groove (Figure 2.2-D). Therefore, small molecules that interact in the grooves
should still be able to bind in the remainder of the two accessible grooves. CD studies of DB832
were conducted with ODN4 sequence (Figure 2.5-D). Interestingly, exciton-type ICD signal is
still observed with this sequence upon titration of DB832. However, the magnitude of the ICD
is comparatively smaller than what is observed with the unmodified telomeric sequences. The
ICD signal generated upon complex formation is due to the formation of stacked species of
DB832 in the remaining two grooves of the hybrid fold, resulting in decreased intensity.

The 27-nt G-rich sequence in the NHE-III promoter element of the c-myc oncogene has
been shown to fold into a parallel quadruplex architecture

[35].

The connecting loop bases

between the guanine stretches can form different loop isomers while maintaining the same
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parallel scaffold in different variants of c-myc. Moreover, the connecting bases form a doublechain reversal loop and completely block all the grooves of the quadruplex. This parallel
quadruplex fold is also an excellent system to test for small molecules that interact primarily in
the grooves of the quadruplex. The loop bases should act as a natural steric blockage for
groove interacting ligands. To test this idea, CD titrations of DB832 were carried out with a
dual mutant c-myc variant, d[T(AGGGTGGGG)2AA], that was shown by NMR to form a stable
parallel conformation [35b]. Figure 2.6-C shows the CD spectra of DB832 with c-myc sequence.
The absence of any exciton-type ICD signal indicates that the compound is not able to form
stacked species due to the steric blockage of the grooves. This also suggests the preferential
affinity of DB832 for the hybrid-type quadruplex scaffolds and the exciton-type splitting
observed with the telomeric sequences is as a result of stacking molecules in the grooves.

The combined CD results of Tel22, Tel24, ODN9, ODN4 and c-myc strongly suggest
the groove binding mode of DB832 with the human telomeric quadruplex sequence.

2.3.2 DB832 is the First Reported Quadruplex Groove Binder for Biologically Relevant
Telomeric Quadruplex Sequences
Distamycin-A (Figure 2.1-D) is a well known small molecule that has high affinity for
AT-rich duplex sequences

[36].

Small molecules that are excellent duplex binders are often

tested for their affinity for quadruplex systems. Distamycin-A was shown to interact with
simple quadruplex systems, such as d[TG4T]. The interaction of distamycin with the
aforementioned sequence and very similar quadruplex systems has been shown primarily by
stacking at the terminal tetrads by NMR [20b]. However, a recent high resolution NMR study has
shown that distamycin can also stack in the grooves of the same quadruplex system, but at
significantly higher concentrations

[20a].

The ligand binds as an antiparallel dimer in the two
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diametrically opposite grooves of the quadruplex with a 4:1 stoichiometry. However, there
have not been any studies related to distamycin binding in the grooves of biologically relevant
quadruplex systems. Considerable resources are still being devoted to test the quadruplex
interacting potential of distamycin to non-targeted simple model systems.

To test the groove binding potential of distamycin with biologically relevant quadruplex
conformations, such as the human telomeric system, CD studies of distamycin were conducted
with Tel22 sequence (Figure 2.6-A). Interestingly, the CD spectrum of distamycin does not
show any exciton-type ICD signals proposed for ligands forming stacked species in the grooves
of the quadruplex. The interaction of distamycin at low CD concentrations might be by
stacking at the ends of this quadruplex system, supporting the NMR studies with simple
quadruplex systems at low concentrations. Moreover, thermal melting studies (data not
shown) of distamycin with various telomeric systems showed a negligible change in the
stability of the quadruplex. Therefore, the validity of distamycin, as a groove binder, for
biologically relevant quadruplex systems is a matter of question.

Virtual screening and docking studies of a library of small molecules have shown that a
subset of ligands also selectively target the grooves of the simple quadruplex systems

[21].

However, their affinities for duplex systems have not been reported so far. These compounds
were proposed by NMR to bind in the grooves of the d[TG4T] system with optimum
hydrophobic and van der Waals interactions along the grooves of the quadruplex. To further
test the selectivity of these ligands, F1190 (Figure 2.1-E), the most potent compound from the
series, was chosen to evaluate its interaction potential with a relevant quadruplex system, such
as Tel22. CD spectra of F1190 with Tel22 (Figure 2.6-B) exhibited virtually no ICD signal even
at high ratios of the ligand. Absence of the ICD suggests that this compound might not be
interacting in the grooves of the quadruplex system.
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Apart from these two reported molecules as groove binders for simple quadruplex
models, no other small molecule has been reported to selectively target the grooves of human
telomeric quadruplex DNA. Therefore, DB832 is the first heterocyclic diamidine that is shown
to selectively bind as stacked species in the grooves of the telomeric DNA with preferential
binding for the hybrid-type conformation.

2.3.3 DB832 Induces the Formation of Hybrid Conformation in Telomeric Quadruplex DNA
To further confirm the groove binding mode of DB832, Fluorescence Intercalator
Displacement Assay (FID) and competition CD experiments were performed (by Caterina
Musetti from Dr. Wilson‟s group). FID assay is based on the displacement by small molecules
of a fluorescent probe from DNA [37]. It allows the ranking of a set of putative ligands based on
their ability to displace the probe from the specific DNA region where the probe interacts. Also
based on the affinity of a ligand, a general idea about the binding site of the ligand can be
obtained. The choice of what molecule to use as probe was based on recent studies with
Thiazole Orange (TO)

[38].

This dye was used as a displacement probe because its excitation

wavelength (501 nm) is higher than most compounds and therefore does not interfere with the
assay. Furthermore, TO, shown to bind as an end-stacker, has a binding affinity in the order of

ca. 3 x 106 M-1 for human telomeric DNA [39], making it an ideal probe to study. Figure 2.7-A
shows the graph of the displacement assay of DB832 and a well known quadruplex end
stacker, TMPyP4. Distamycin was also tested as a control molecule based on CD results. DB832
has a binding affinity of ca. 1.4 x 106 M-1 with Tel22 quadruplex sequence (discussed later in
the SPR results). From the graph, it is evident that DB832 is not able to displace TO even at the
highest concentrations. This is most likely not due to binding constant differences but due to
the fact that DB832 preferentially interacts with the grooves of the human telomeric sequence.
In fact, the same assay, performed with c-myc, indicates that the compound is able to displace
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30% of the TO at low concentrations (4.5 µM). Since c-myc is known to fold in a parallel
conformation with no accessible grooves and based also on results obtained by CD studies, this
assay reinforces the hypothesis that DB832 interacts with the human telomeric grooves.
TMPyP4, which has a strong affinity for the ends of the human telomeric quadruplex, displaces
TO completely even at modest concentrations. Distamycin, which was earlier shown by CD not
to interact with telomeric quadruplex DNA, also does not displace TO even at high
concentrations.

To test the results of FID assay, a competition CD experiment was performed with Tel22
and DB832 with TO as a probe (Figure 2.7-B). TO has been shown to preferentially bind to the
antiparallel conformation of human telomeric DNA

[37, 39].

CD spectra (Figure 2.7-B) of Tel22

reveal the presence of 260 nm and 290 nm peaks in the DNA absorbance region, characteristic
of a hybrid-type quadruplex conformation. Upon titration of TO, there is a decrease in the
intensity of 260 nm peak and a subsequent increase of the 290 nm peak, indicative of an
increased antiparallel characteristic of the sequence upon complex formation. TO, being a
quadruplex end stacker, do not exhibit any ICD signals upon complex formation either. When
DB832 is titrated upon saturation with TO, significant changes are observed in the DNA
wavelength region (Figure 2.7-C). The peak at 290 nm decreases in the magnitude slowly
whereas the 260 nm peak remains the same. However, when the compound exhibits the
induced CD signal formation, a drastic reduction in the 290 nm peak is observed with a
concomitant change in the 260 nm peak. Upon complete saturation, the DNA region exhibits
peaks at both 260 nm and 290 nm, very similar to the starting conformation - the hybrid
conformation - of the DNA but of lesser magnitude. Therefore, DB832 was able to induce a
conformational switch from an antiparallel fold, induced by TO, back to the hybrid fold.
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2.3.4 DB832 Exhibits High Selectivity for Human Telomeric Quadruplex DNA over Duplex
DNA
With the abundance of duplex DNA in genome, targeting relatively very few nonduplex structures such as quadruplexes becomes a complex task. Non-selective binding to
secondary sites might result in deleterious effects and cytotoxicity, therefore, structure and
sequence selectivity is of utmost importance to achieve desired results. In order to determine
the selectivity of DB compounds for human telomeric quadruplex sequence over duplex DNA,
thermal melting studies were performed with telomeric quadruplex DNA. Figure 2.4 shows the
UV melting profile of DB832 with a duplex sequence and two human telomeric quadruplex
forming sequences, Tel24 and Tel26 (Materials and Methods). DB832, showed a ∆Tm of ~12
°C and an impressive 20 °C for Tel24 and Tel26 quadruplex sequences respectively at 6:1
ratios indicating signification stabilization of the quadruplex conformation. From the UV
profile it is highly apparent that DB832 has a very low stabilizing potential for duplex (∆Tm ~
3 °C). The quadruplex stabilization potential observed for DB832 rank among the strongest for
quadruplex-interacting small molecules reported so far. It is highly apparent that the DB832 is
significantly stabilizing the quadruplex conformation, while maintaining a low degree of
selectivity for duplex sequences. Therefore, DB832 makes an ideal candidate for further study
as a highly selective quadruplex interacting agent.

2.3.5 Multiple Binding Modes Observed in NMR
Telomeric quadruplex sequences in K+ exists as a mixture of conformations [3a, 12f], with
the hybrid structure predominant. The NMR structure of Tel24 reveals that this sequence folds
into a mixed parallel/antiparallel hybrid-1 type structure [32]. To test the groove binding mode
exhibited by DB832 from CD, 1H-NMR titration studies were conducted with Tel24. Imino
protons of guanines are excellent probes to determine if a G-rich sequence folds into a
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quadruplex conformation

[40].

These imino protons resonate between 10.0 to 12.5 ppm in a

quadruplex structure and are readily observable in a water sample. Moreover, the presence of
multiple quadruplex conformations can also be readily addressed by monitoring the imino
protons. Binding of a small molecule to a quadruplex structure affects the chemical
environment of imino protons which can also be identified from simple titration experiments.
Figure 2.8 shows the guanine imino proton NMR spectra of DB832 with the Tel24 sequence
up to ratios 2:1 at 25 °C. At higher compound to quadruplex ratios, especially at NMR
concentrations, solubilities of the compound and the complex become an issue. Considerable
aggregation is observed resulting in significant line broadening and rendering it difficult to
obtain spectra for analysis. In the absence of any compound (Fig 2.8, 0:1 ratio), the spectra
show distinct number of imino protons corresponding to the total number of guanines in the
Tel24 sequence. This shows that the sequence forms primarily a single structure in K+, and in
this case it is the hybrid-1 type structure. Titration of DB832 into the DNA solution resulted in
significant changes in the imino proton spectra and spectral broadening and shifts revealed
that the ligands were in intermediate exchange on the NMR timescale. A number of imino
resonances broaden in a site-specific fashion, consistent with the local chemical environment
of various residues being perturbed by ligand binding. Distinct chemical shift changes can be
readily observed for most of the imino protons. Imino protons of G3, G9, G17 and G21, which
constitute the 5‟ terminal tetrad of the quadruplex, are the most perturbed even at the lowest
compound to quadruplex ratio. This suggests the inherent sensitivity of this technique even for
the smallest changes produced, at relatively low ratios, upon complex formation. The 5‟ Gtetrad imino protons broadened considerably and disappeared completely at high ratios.
The high perturbation of the imino protons at the top end is consistent with the
stacking of the ligand on the 5‟ G-quartet. NMR studies of distamycin, Hoechst-33258, and
ethidium with several quadruplex forming sequences has revealed similar perturbations of the
imino protons of the top tetrad of the quadruplex indicating stacking on the top end of the
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quadruplex

[40].

Small molecules that have excellent duplex-DNA groove binding properties,

such as Hoechst-33258 and distamycin, can also preferentially bind as end-stackers with
quadruplex systems. Therefore, it is equally conceivable for the currently studied ligands to
exhibit a similar end-stacking as the initial mode of binding. Interestingly, broadening occurs
for the aromatic residues of the 5‟ G-tetrads (G3, G9, G17 and G21 of 5‟-tetrad) and A20·T1
base pair (spectra not shown), providing support for a mixed intercalation-exterior stacking
mode of binding (i.e., between the 5‟-tetrad and the capping A20·T1 base pair of the loops).
Therefore NMR results show the stacking of DB832 on the top quartet at low ratios. In most of
the cases, imino protons of G11and G23, that constitutes the bottom tetrad, exhibited very little
change. This is probably due to the presence of a stable capping A24·T13 base pair at the 3‟
terminal, offering significant protection from solvent exchange. Also, relatively unchanged
imino proton chemical shifts of the bottom tetrad indicates that 3‟ end of the Tel24 quadruplex
structure is least likely the binding site for DB832. Imino protons of G4 and G22 that
correspond to the adjacent guanine of the middle tetrad exhibit small downfield shifts
accompanied by slow broadening; however, imino protons of G10 and G16 of the same tetrad
exhibit very little changes. G4 and G22 are located in a groove that has optimal dimensions for
compounds to form stacked species. Therefore, after the initial end-stacking mode at the 5‟
terminal, there is a very likely possibility that DB832 is targeting the “medium” groove
encompassed by G3, G5, G23, G21 plane. The groove adjacent to the medium groove,
comprised by the plane of G15, G17, G21, and G23 residue is classified as the narrowest
groove. Therefore, it is highly unlikely for DB832 to efficiently form stacked species in the
narrow groove. Absence of any major changes in imino protons of guanines (G16 and G15)
further confirms this.
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Figure 2.9 shows the aromatic proton spectra of Tel24 titrated with DB832. Similar to
the imino protons, aromatic protons of the bases can also be used as probes to verify the
interaction of ligands [41]. The aromatic protons of the guanine residues, involved in the tetrad
formation, point directly into the grooves of the quadruplex. Ligands that can bind in the
grooves of the quadruplex can perturb the local environment of these protons and, therefore,
these protons can be used to monitor the drug-quadruplex interaction. Titration of DB832 into
the DNA solution resulted in significant changes in the aromatic proton spectra and spectral
broadening and shifts revealed that the ligands were in intermediate exchange on the NMR
timescale. A number of aromatic resonances broaden in a site-specific fashion, again consistent
with the local chemical environment of various residues being perturbed by ligand binding.
Interestingly, broadening occurs for the aromatic residues of the 5‟-end G-tetrad: G3, G9 and
G21, providing support for a mixed intercalation-exterior stacking mode of binding (i.e.,
between the exterior tetrads and the capping A20·T1 base pairs of the loops). Surprisingly,
G17 undergoes significant downfield shifts followed by broadening. Aromatic protons of
A20·T1 base-pair undergo significant perturbations (broad, downfield shifts) upon ligand
binding indicating a preferential stacking at the 5‟-terminal tetrad. The guanine aromatic
protons of the 3‟-end tetrad undergo very small changes, except for G5, suggesting the 3‟-end
might be an optimal binding site for stacking of DB832. This was also observed with the imino
protons of the same residues. However, the aromatic protons of A24·T13, that forms a stable
base-pair at the 3‟-end undergoes broad downfield shifts. Therefore, the ligand might be
exhibiting a weak stacking at the 3‟-terminal tetrad. The stacking of the ligand might be
occurring by a conformational rearrangement of the two base-pairs to accommodate the
ligands in an efficient manner. Aromatic protons of G4 and G22 that constitute the middle
tetrad, and G5 of the bottom tetrad, undergo small upfield broadening. Whether this change is
due to the binding of the ligands in the grooves is not clear. SPR and ITC studies (discussed
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later in Section 2.3.6) show a weak secondary binding by the ligand which is hypothesized to
be groove binding. Therefore, it is a possibility that such weak interactions might not be easily
detectable using traditional NMR methods.

2.3.6 DB832 Binds to the Human Telomere Cooperatively with High Stoichiometry
Well over half a century ago, George Scatchard, a renowned physical chemist, noted
that the following questions 'How many? How tightly? Where? Why?' must be answered in
order to understand the fundamentals of ligand binding to DNA

[42].

There is not one single

experimental technique that can provide the answers to all these questions and, thus, a
multifaceted approach has to be employed to elucidate drug-DNA interactions. Effective drug
design requires sufficiently clear, thermodynamic, kinetic and structural details of the drugDNA interactions, a picture that can only be unraveled by combining the information from
different methodologies. With regards to DB832, sufficient information is available to answer

Where? How tightly? and, to some extent, Why? the ligand is selective for quadruplex DNA.
However, the question of How many? has always been the most challenging to answer.

To decipher the number of DB832 molecules that are bound to a quadruplex unit, a
combination of CD, ITC and SPR techniques were used. Titration curves from CD experiments
were plotted for the CD signal at the maximum absorbance wavelength of bound DB832 as a
function of molar ratio for different telomeric quadruplex sequences (Figure 2.10). From the
plot, it is clear that DB832 binds to the quadruplex system with a high stoichiometry. Due to
the high stoichiometry of the system, it is difficult to fit the data in order to obtain the exact
number of bound molecules. However, a straightforward analysis of the plot reveals about 5-6
DB832 molecules are bound per quadruplex unit. Closer inspection of the titration curves for
different telomeric sequences also show a clear breakpoint at different added ratios of DB832.

49

The first break occurs at an added ratio of around 3:1 for all the telomeric sequences.
However, the second break varies for different quadruplex sequences, but is generally
occurring around 6:1 compounds /quadruplex ratio. The two breakpoints exhibited by the
compound upon complex formation suggest multiple binding events exhibited by the
compound. This was also highly evident from NMR studies (Section 2.3.5). The initial binding
observed until 3:1 ratios, characterized by weak ICD signal, is due to the stacking of the ligand
at the terminal tetrads of the quadruplex, as also suggested by NMR results. The latter binding
observed at higher ratios until around 6:1, characterized by strong excition-type splitting, is
due to the recognition of quadruplex grooves as stacked species. The sigmoidal shape of the
curve also indicates that the binding of DB832 to the quadruplex sequences occurs with
positive cooperativity. Small molecules, such as porphyrins, can aggregate on the surface of
quadruplex-DNA, resulting in false high stoichiometries, due to the non-specific binding.
However, in the case of DB832, a clear saturation of the ICD signal is observed at higher molar
ratios (Figure 2.10, ratios above 10 are not shown) suggesting that the high stoichiometry is
not due to the aggregation or non-specific interactions, and the binding of DB832 to the
telomeric quadruplex DNA is indeed distinct.

To further test the binding stoichiometry of DB832, ITC experiments were conducted
with telomeric quadruplex DNA, Tel24, with different DNA concentrations (Figures 2.12-A,
B). Plots of the observed net binding heat/mol versus molar ratio were obtained by subtracting
the integrated peak areas for the blank titration (DB832 into buffer) from the areas in the
DB832-DNA interaction titration. Figure 2.12-A shows the ITC plot of DB832 titrated into 10
µM quadruplex DNA. From the plot it is clear that DB832 is indeed binding with high
stoichiometry and with multiple binding modes as characterized by distinct breaks in the
titration curve at different ratios. Surprisingly, the compound exhibits some non-specific
binding at ratios higher ratios (> 6:1), but the heat observed at those ratios are very small. ITC
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titrations were also conducted with a higher DNA concentration (20 µM Figure 2.12-B) to
understand the thermodynamics at lower drug-DNA ratios. From the titration curve it is again
clear that the ligand is binding with distinct binding modes with the telomeric DNA. An initial
strong binding (up to ratio 2:1) is followed by a weaker secondary binding (ratios above 2:1).
The initial strong binding, as suggested by CD and NMR, is probably due to the stacking of
DB832 at either one or both ends of the quadruplex. The latter weaker binding is due to the
recognition of multiple grooves of the quadruplex as stacked species. Due to the high
stoichiometry, it was difficult to obtain complete thermodynamic profile for DB832 binding to
the DNA. Nevertheless, based on the CD and ITC data analysis, results suggest that
approximately 6 molecules of DB832 are bound per quadruplex unit.

SPR was used to quantitatively evaluate the interactions between DB832 and a series of
telomeric quadruplex DNA in order to gain insight into their affinities (Figure 2.11: A-F). From
the sensorgrams, the large response obtained suggests that DB832 is binding to all the
telomeric sequences, and exhibit fast association and dissociation kinetics. Sensorgrams of
Tel24 and Tel26, Figures 2.11-B and C respectively, are shown for high concentrations of
DB832 (up to 50 µM) to show the behavior exhibited by the ligand, characterized by high
response values. Responses obtained at such high ligand concentrations are generally due to
non-specific binding, and are not included during evaluation of binding affinities. From the
steady-state binding plots, fit to a two-site model for low ligand concentrations (up to 1 µM),
we can readily notice that the primary binding constant (K1) for different sequences fall in the
range of 1 x 106 to 4 x 106 M-1, and is followed by a weak binding constant (K2) that is 10fold weaker in all cases. Although the primary binding constant obtained for DB832 is not
high, it does fall in the range of values that is generally observed for compounds that interact
at the ends of the quadruplex

[25].

The secondary, 10-fold weaker, binding observed is most

likely the binding event occurring due to the interaction of DB832 in the grooves of the
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quadruplex as stacked species. Thermodynamic studies of distamycin-A interacting with a
parallel quadruplex conformation were also characterized with binding affinities in the same
range (~4 x 105 M-1)

[20a].

Therefore, this might be a general interaction affinity that is

observed for compounds that bind in the grooves of the quadruplexes. Therefore, as
aforementioned, small molecules that are excellent duplex-DNA groove binders, such as
Hoechst-33258 and distamycin, initially interact at the ends of the quadruplex conformations
due to their weak affinity for quadruplex grooves. This again highlights the difficulty in
designing compounds that are very specific to the quadruplex grooves; however, ligands that
are shown to target grooves of quadruplexes can be used as paradigms to develop more potent
ligands with enhanced affinities.

2.4

CONCLUSION
Quadruplex grooves offer an attractive target to design new classes of compounds that

can bind strongly and selectively. Since groove dimensions vary significantly according to the
type of quadruplex, groove-binding also offers the opportunity for obtaining increased
selectivity for a particular quadruplex structure. Selectivity of a compound for its target
quadruplex structure is important in order to reduce cytotoxicity from duplex-binding as well
as prevent drug loss from binding to non-targeted quadruplex sites.

DB832 is a heterocyclic diamidine that recognizes multiple sites of the human
telomeric DNA, showing virtually no binding to duplex DNA. This is the first reported small
molecule that is shown to recognize grooves of the wild-type telomeric quadruplex
conformation. Although, the initial binding mode observed with DB832 is end-stacking, the
latter binding which is the recognition of the grooves as a stacked species is a much more
interesting phenomenon. The unique binding mode of DB832 as well as its selectivity for its
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DNA target may allow it to serve as the starting point for the design of a new class of highly
selective groove-binding molecules. Potentially, the individual monomer units could be
covalently linked, dramatically increasing the affinity and selectivity of the compound for
human telomeric DNA, leading to enhanced telomerase inhibition and anti-protozoan activity
with decreased cytotoxic side effects.
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(A)

(B)

(C)

(D)

(E)

Figure 2.1: Chemical structures of RHPS4 (A), DODC (B), DB832 (C), Distamycin (D) and
F1190 (E).
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(A)

(B)

(C)

(D)

Figure 2.2: Folding patterns of different quadruplex-forming motifs: Tel24 [32] (A), c-myc [40]
(B), ODN9 [34] (C), and ODN4 [12a] (D) used in this study. The bulky bromine atoms are
represented as green ball and stick.

All the quadruplex cartoons are directly obtained from their published journals without
further permission.
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Figure 2.3: (A) Induced CD spectra of DODC with intermolecular quadruplex forming
sequences and a duplex sequence as reported by Shafer et al. (B) CD spectra of DODC with a
dimeric quadruplex sequence, U6U7 in K+, and (C) CD spectra of Tel22 in K+ with RHPS4, a
well-known human telomeric quadruplex end-stacking agent.

The exciton-type splitting observed in (A-dashed lines, dotted lines) is proposed for the
formation of stacked species by the DODC dye possibly in the grooves of the quadruplex. A
similar excition-type is observed for DODC with a dimer quadruplex. A weak or an absence of
exciton-type splitting is characteristic of compounds that are known to stack at the ends of the
quadruplex, as shown by RHPS4 (C). Buffer conditions: Phosphate buffer containing 100 mM
K+ at 25 °C.
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Figure 2.4: UV melting profiles of the hairpin duplex, d(CGCGAATTCGTCTCCGAATTCGCG), monitored at 260 nm (A) modified
human telomere sequences, Tel24 (B), and Tel26 (C) monitored at 295 nm in the absence and presence of DB832 in phosphate
buffer containing 100 mM K+.

DB832:DNA ratio for duplex sequence was 2:1, while, DB832:DNA ratio for quadruplex sequences was 2:1 and 6:1. DB832
increases the melting temperature of the Tel24 by approximately 12 °C, and that of Tel26 by an impressive 20 °C at 6:1 ratios,
while it has a negligible effect on the melting temperature of the duplex sequence. DNA/quadruplex concentration for Tm and CD
experiments is ~3-5 µM unless otherwise mentioned.
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Figure 2.5: CD spectra of DB832 titrated into (A) Tel22 (B) Tel24, (C) ODN9, and (D) ODN4
quadruplex forming sequences.

DB832 was titrated into DNA solutions until saturation point is reached in the ICD region.
Tel22 and Tel24, which has multiple accessible grooves, can facilitate the formation of stacked
DB832 molecules in their grooves. ODN9, with all the grooves blocked by the bulky bromine
atoms exhibit no exciton-type splitting, confirming the groove binding mode of DB832 as
stacked species. The small induced CD observed with ODN9 is possibly due to the stacking of
DB832 at the terminal tetrads. ODN4, with one the grooves completely blocked by bromine
atoms, exhibit an exciton-type splitting but of lesser magnitude. The decrease in the magnitude
of ICD signal might be due to the blockage of one of the grooves preventing the formation of
stacked species in that groove. Buffer conditions: Phosphate buffer containing 100 mM K+ at
25 °C.
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Figure 2.6: CD spectra of Distamycin with Tel22 (A), F1190 with Tel22 (B), and DB832 with
c-myc (C) in K+.

Distamycin has been proposed to be the first small molecule to bind in the grooves of
quadruplex systems. However, this has been proven only with simple quadruplex systems at
high NMR concentrations. CD studies of distamycin with biologically relevant quadruplex
systems such as human telomeric sequences do not show any ICD signal, refuting the groove
binding mode of this molecule. F1190 was also shown to interact with the grooves of simple
quadruplex systems by docking and preliminary NMR studies. However, when F1190 was
tested with full length human telomeric sequence, no ICD signal is observed, invalidating the
proposed quadruplex groove binding, c-myc quadruplex sequence is shown to fold into an all
parallel topology in which the grooves are completely blocked by the connecting loop bases.
Groove targeting ligands, such as DB832, should not be able to form stacked species in the
grooves of such systems. As expected, no ICD signal is observed even at high ratios of DB832
with c-myc, confirming the groove binding mode of the compound.

59

Displacement Assay
1.2

(B)

(A)
40
20

0.8

CD (mdeg)

% Displacement

1

0.6
DB832-Tel22
0.4

TmPyP4

-40

Distamycin
0

1

2
3
conc (uM)

4

5

0

-20

DB832-cmyc

0.2
0 -1

Tel22 + TO + DB832

60

6

7

-60

250

300
350
400
wavelength (nm)

20

HT
2:1
4:1
6:1
+832 4:1
+832 8:1
+832 12:1
+832 16:1
+832 20:1
+832 24:1
+832 28:1
+832 32:1

(C)

15
CD (mdeg)

450

HT
2:1
4:1
6:1
+832 4:1
+832 8:1
+832 12:1
+832 16:1
+832 20:1
+832 24:1
500
+832 28:1
+832 32:1

10

5

0
240

250

260

270

280

290

300

310

320

wavelength (nm)

Figure 2.7: Fluorescence Displacement assay (A) and competition CD experiment (B)
performed with Tel22 sequence using TO as the fluorescent probe. (C) Close-up of the DNA
absorbance region highlighted in blue in (B).
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Figure 2.8: Imino proton spectra of Tel24 (hybrid-1) with DB832 at 25 °C in 10 mM K2HPO4/80 mM KCl, pH 7.0.

DB832 is titrated in the increments of 0.2 molar equivalents into Tel24 to a final ratio of 2:1 DB832/Tel24. Proton assignments of
Tel24 were courteously provided by Dr. Anh T. Phan.
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Figure 2.9: Aromatic proton spectra of Tel24 with DB832 at 25 °C in 10 mM K2HPO4/80 mM KCl, pH 7.0.

DB832 is titrated in the increments of 0.2 molar equivalents into Tel24 to a final ratio of 2:1 DB832/Tel24. Proton assignments of
Tel24 were courteously provided by Dr. Anh T. Phan.
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Figure 2.10: Plot of the ICD signal at wavelength corresponding to the maximum absorbance
of the bound DB832 (434 nm) as a function of DB832 added molar ratio with different
telomeric quadruplex sequences.

From the plot, it is clear that a multiple binding mode is exhibited by DB832. The end-stacking
as observed from NMR and CD occurs at the initial ratio, and the subsequent formation of
stacked complexes in the grooves occurs at latter ratios (> 2:1 or 3:1)
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Figure 2.11: SPR sensorgrams for binding of DB832 analogs with human telomeric quadruplex sequences.

(A) Tel22, (B) Tel24, and (C) Tel26 in 10 mM phosphate buffer containing 100 mM K+ at 25 °C. The quadruplex curves range in
ligand concentration from 10 nM for the bottom curve to 10 µM for the top curve. Steady-state binding plots fit to a two-site model
(Materials and Methods) and their binding parameters (inset) are listed in D-F. The concentration values are for unbound
compound concentration in the flow solution. DB832 exhibits an initial strong binding by stacking at the ends, followed by a
weaker stacking in the grooves of these quadruplex systems.
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Figure 2.12: Isothermal titration calorimetry plot of DB832 (400 µM) titrated into a 10 µM (A) and 20 µM (B) Tel24 quadruplex
sequence in TRIS buffer containing 100 mM K+.

Plot of heat versus molar ratio (bottom) was obtained by subtracting the integrated peak areas for the blank, buffer titration from
the DNA interaction titration. From the ITC plots, it can be clearly seen that multiple binding events are occurring as suggested by
CD, NMR and SPR. The binding stoichiometry of DB832 with Tel24 sequence is clearly in the range of 5-6 molecules per
quadruplex unit. Accurate thermodynamic and binding parameters could not be obtained due to the high stoichiometry.
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3

SELECTIVE RECOGNITION OF MIXED PARALLEL/ANTIPARALLEL HYBRID QUADRUPLEX
DNA BY DB832 AS A STACKED SPECIES

3.1

INTRODUCTION
G-quadruplex DNA is comprised of a series of stacked guanine tetrads held together in

a coplanar cyclic array by Hoogsteen and Watson-Crick hydrogen bonds. The quadruplex
structure is stabilized through hydrogen bonds, π-π stacking interactions of the stacked tetrads
as well as by coordination with cations located between or within the tetrads. G-Quadruplex
DNA is highly polymorphic and can form different structures depending on sequence, length,
concentration, nature of cations present, presence of crowding agents and other factors.
Potential quadruplex-forming sequences are common in the genome. Telomeric DNA
immunoglobulin switch region sequences
regions of some oncogenes

[4],

[2],

the fragile-X repeat sequence

[3],

[1],

promoter

the insulin gene[5], and other genomic sequences have been

shown to form quadruplex structures in vitro

[1b, 4a, 6].

The extensive variation among

quadruplex structures, combined with the fact that some small molecules can induce or lock a
particular conformation, may allow the design of compounds that can target particular
quadruplex structure with a high degree of selectivity. Selectivity of a compound for
quadruplex-DNA over duplex-DNA is also important because nonselective duplex-binding is
associated with cytotoxicity and can also result in significant loss of valuable drug. Moreover,
selectivity for a certain quadruplex structure over other non-targeted quadruplexes is also a
very important consideration in design of quadruplex-interactive agents. Binding to nontargeted quadruplex sequences results in compound loss and may have unintentional effects
on regulation of non-targeted genes. Thus, there is a need for new classes of compounds that
can selectively discriminate between different quadruplex conformations in order to achieve
full therapeutic response and minimal side effects.
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Telomeres are guanine-rich regions of non-coding DNA located at the ends of
eukaryotic chromosomes. They serve a variety of functions, from protecting the ends of
chromosomes from erosion and end-end fusion leading to recombination
organisms they play a significant role in gene expression

[8].

[7].

In some

Telomeric DNA sequences have

been shown to fold into four-stranded G-quadruplex structures in vitro under physiological
conditions [9]. Recent studies suggest that telomeres may also form G-quadruplex structures in

vivo

[10].

Human telomeric sequence is one of the most extensively studied motifs due to its

critical role in maintaining chromosomal integrity, and also its potential implication as a
critical target for anticancer therapy

[11].

The hexanucleotide repeats of TTAGGG can fold into

an array of quadruplex topologies in vitro under different physiological conditions. Structural
information of telomeric quadruplex DNA under in vivo conditions is imperative from the
drug design standpoint of view.

The earliest solution structure of the human telomeric DNA sequence, d[AG3(T2AG3)3]
solved by NMR in Na+ shows that this sequence folds into an intramolecular quadruplex
conformation termed as an antiparallel basket topology

[6h]

(Figure 3.1-E). The term

“antiparallel” refers to the directionality of a strand with respect to its adjacent connecting
strand. Therefore, in the antiparallel topology, the adjacent connecting strands are antiparallel
to each other, and the connecting loop bases adopt a “basket-type” conformation. However,
since the intracellular K+ concentration is much higher than Na+, several attempts have been
made to elucidate the folding topology of human telomeric quadruplex in K+. The first human
telomeric quadruplex structure in K+ by crystallography studies have shown that this sequence
folds into a parallel, propeller-type topology

[12]

(Figure 3.1-D). In a parallel topology, all the

G-tracts run parallel to each other, while the connecting residues form a double-chainreversal loop, resulting in a propeller-type structure. Recent NMR structural studies in K+ by
several groups have showed that the human telomeric quadruplex folds into a mixture of
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mixed parallel/antiparallel quadruplex conformations termed hybrid-1 and hybrid-2
structures [13] (Figure 3.1-B, C). Interestingly, a third hybrid structure was also recently found
by NMR for the human telomeric sequence

[14],

adding to the repertoire of conformations this

sequence can fold into. These “hybrid-type” structures of human telomeric quadruplexes
under physiological K+ concentrations maybe the predominant conformation in vivo.

With the evidence for in vivo existence of telomeric quadruplexes becoming more
compelling

[15],

their possible function or functions must be addressed. Small molecules that

can bind to and stabilize the quadruplex conformation of telomeres perturb their functions [16].
Telomerase is a reverse-transcriptase enzyme that is expressed in rapidly dividing cells,
including cancer cells and eukaryotic parasites

[17].

The enzyme exerts its action by adding

TTAGGG repeats to the end of the telomere, preventing telomere shortening and allowing the
cells to replicate indefinitely, a hallmark of cancer cells. The development of quadruplexinteractive small molecules that can inhibit telomerase is therefore a current area of interest in
anticancer and antiparasitic drug design. Small molecules that can selectively bind to the
various human telomeric quadruplex conformations or induce a conformational switch from
one conformer to the other have significant potential therapeutic impact.

Apart from the telomeres, potential quadruplex forming G-rich sequences are also
highly prevalent throughout the genome, particularly in promoter sequences of oncogenes
6c, 6f, 18].

[4a,

The 27-nt G-rich sequence in the NHE-III promoter element of c-myc oncogene has

been shown to exist as multiple quadruplex species [19]. Structural studies on shorter sequences
from within the 27-nt G-rich sequence have been shown to form a single, very stable
intramolecular parallel-stranded quadruplex conformation in K+ solution, with the G-tracts
joined through propeller loops, and with all guanines involved in the G-tetrads adopting an

anti conformation [6f, 18a] (Figure 3.1-D). The parallel propeller-type conformation adopted by
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c-myc has structural features very similar to the conformation of human telomeric quadruplex
solved by crystallography (Figure 3.1-D). The 39-nt G-rich strand in the promoter region of

bcl-2 oncogene has also been shown to form three distinct intramolecular G-quadruplexes in
K+ solution
the

[4c, 6b].

formation

Detailed NMR studies of a dual mutant, 23-nt bcl-2 (G15T/G16T), showed
of

a

unique

parallel/antiparallel G-strands

[6a]

intramolecular

G-quadruplex

structure

with

mixed

(Figure 3.1-C). The bcl-2 quadruplex scaffold contains

three G-tetrads with the G-tracts connected by a single-nucleotide double-chain-reversal side
loop and two lateral loops, respectively. The first three-nucleotide CGC loop in the bcl-2
promoter sequence forms a lateral loop, as opposed to a double-chain-reversal side loop
observed in a similar sequence in the c-myc promoter, and appears to largely determine the
overall folding of the bcl-2 quadruplex conformation. The overall fold of bcl-2 resembles the
hybrid-2 fold adopted by the human telomere (Figure 3.1-C), however, subtle differences in
the connecting loops bases makes the two hybrid-2 folds very distinct. Small molecules that
can bind and stabilize these quadruplex conformations or, more importantly, discriminate
between two very similar structures such as the hybrid-2 folds can have significant therapeutic
impact.

In Chapter 2, DB832 (Figure 3.1-A), a heterocyclic diamidine, was shown to selectively
bind to human telomeric quadruplex conformation with high affinity over duplex DNA. The
multitude of conformations that G-rich sequences could fold into led to elucidate the
structure-specific selectivity of DB832 for the different quadruplex architectures throughout
the genome. Circular Dichroism (CD) and NMR techniques were used to probe these
interactions. The selectivity within the different quadruplex folds exhibited by human
telomeric sequences was also investigated. CD studies show that DB832 is highly selective for
different human telomeric quadruplex conformations and potentially interacts as a stacked
species in the grooves. DB832 binding to non-telomeric sequences such as c-myc, bcl-2, TBA
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and intermolecular quadruplex sequences are non-specific in nature, and most likely interact
as monomers by stacking at their terminal tetrads. NMR studies with the wild-type and
modified telomeric sequences further suggest that DB832 can bind to a selective quadruplex
conformation from a mixture of structures.

3.2

MATERIALS AND METHODS

3.2.1 Sample Preparation
The oligonucleotides Tel22, d[AG3(T2AG3)3];

Tel26, d[A3(G3T2A)3G3A2]; wtTel26,

d[T2G3(T2AG3)3A]; TBA, d[G2T2G2TGTG2T2G2]; Aptamer, d[(G2T4)3G2]; Tetrahymena d[T2G4]4;
Oxytricha,

d[G4(T4G4)3];

bcl-2,

d[G3CGCG3AG2A2T2G3CG3];

c-myc27,

d[TG4AG3TG4AG3TG4AAG2]; U6U7, d[TAGGGUUAGGGT]; intramolecular d[TG4T]; AATT,
d[GCGAATTCGC]; mixed duplex d[CGAGATCAAAAGATCTCG], and

GC, d[GC]7 were

purchased with HPLC purification from Midland Certified Reagent Company or Integrated
DNA Technologies, Inc. The G-quadruplex DNA samples were dissolved in buffer to the
desired concentrations, heated to 85 0C and cooled slowly to insure the folding of the
quadruplexes prior to each experiment. The concentration of each DNA sample was
determined spectrophotometrically at 260 nm using the nearest neighbor extinction coefficient
at 80 °C and extrapolated to 25 °C. A stock solution containing 1 mM of each compound was
prepared in double distilled water and diluted to working concentrations immediately before
use. The synthesis of DB832 will be described elsewhere.
3.2.2 Thermal Denaturation Studies
Thermal denaturation studies were conducted on a Cary Varian 300 BIO UV-visible
spectrophotometer in quartz cells with a 1 cm pathlength. A phosphate buffer containing 80
mM KCl, 10 mM K2HPO4, and 0.1 mM EDTA was used. A thermistor fixed into a reference
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cuvette was used to monitor the temperature. The absorbance of the quadruplex sequences was
monitored at 295 nm, while the duplex sequence was monitored at 260 nm. Melting curves
were obtained for each DNA sequence in the presence and absence of DB832. For each
oligomer the DNA concentration was 3 x 10-6 M and the DB832: DNA ratio was 2:1. Data
manipulation and plotting were performed using the program Kaleidagraph version 3.6.
3.2.3 Circular Dichroism (CD) Studies
CD measurements were performed at 25 °C in a 10 mM HEPES buffer (pH 7.4)
containing 3 mM EDTA and 50 mM KCl, or NaCl. For CD measurements obtained in the
presence of 50 mM LiCl, a 10 mM TRIS buffer containing 3 mM EDTA acid and pH adjusted to
7.4 were used. CD spectra were recorded using a Jasco J-810 spectrapolarimeter in a 1-cm cell
using a scanning speed of 50 nm/min with a response time of 1 s. The spectra were averaged
over four scans. A buffer baseline scan was collected in the same cuvette and subtracted from
the average scan for each sample. Appropriate amounts of stock solution of compound were
added sequentially to increase the molar ratio. Data manipulation and plotting was performed
using the program Kaleidagraph version 3.6.
3.2.4 Nuclear Magnetic Resonance Studies
Tel22, TG4T, and U6U7 samples were prepared in phosphate buffer containing 50 mM
KCl, 10 mM K2HPO4 and 0.1 mM EDTA. Tel26, wtTel26 and bcl-2 samples were prepared in
phosphate buffer containing 80 mM KCl, 10 mM K2HPO4 and 0.1 mM EDTA and 0.01 mM
DSS as an internal reference. Quadruplex DNA concentrations were 0.1-0.2 mM for 1D
experiments and 0.5 mM for 2D experiments in 90% H2O:10% D2O (Cambridge Isotope
Laboratories, Inc.). The final DNA samples were adjusted to pH 7.0 using 1M HCl or 1M KOH
solutions and were heated past their transition temperature and annealed to room temperature
several times before collecting the spectra. Experiments were performed on a Varian Unity
600 spectrometer equipped with a triple resonance broadband probe. DB832 was titrated with
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quadruplex DNA with DB832:DNA ratios varying from 0.5 to 2 for U6U7 sequence and ratios
from 1 to 4 for Tel22, Tel26, wtTel26, bcl-2 and TG4T sequences. Temperature-dependent 1D
spectra were recorded at 35 ºC using jump-return and WATERGATE methods for solvent
suppression

[20].

Homonuclear TOCSY on U6U7 was performed at 35 ºC using WATERGATE

solvent suppression method with a mixing time of 60 ms [21]. All NMR data were processed and
analyzed with a combination of VNMR (Varian Inc.), SPARKY (UCSF) and MestreC (Mestrelab
Research) software.
3.3

RESULTS AND DISCUSSION

3.3.1 DB832 is Highly Selective for Quadruplex DNA over Duplex DNA
In order to determine the selectivity of DB832 for human telomeric DNA over duplex
DNA, melting curves were obtained for the intramolecular human telomeric sequence Tel22,
as well as a random hairpin duplex d(CGAGATCAAAAGATCTCG) (loop underlined) that has a
similar Tm value. The melting temperature of the telomeric DNA in the absence of DB832 is
53.6 C (Figure 3.2-B). Upon addition of DB832 at 2:1, the melting temperature of the DNA
increases by approximately 9 C, indicating that the compound is highly stabilizing the
quadruplex conformation of the DNA. This is comparable to the ∆Tm for a wide range of small
molecules known to stabilize the human telomeric quadruplex conformation under similar
conditions [22]. In contrast, when DB832 is added to the duplex sequence at the same ratio and
conditions, there is an insignificant change in Tm (Figure 3.2-A). This indicates that DB832
binds much more strongly to quadruplex than to duplex DNAs, making it ideal for further
study as a highly selective G-quadruplex interactive compound. CD spectra were also obtained
with two duplex sequences: an AT-rich sequence, d(GCGAATTCGC), and a GC-rich sequence,
d(GC)7 (Figure 3.2 C, D respectively). AT-rich duplexes have been shown to have narrower
grooves than GC-rich sequences

[23].

The wider grooves of GC can mimic the different groove
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dimensions of telomeric quadruplex. In both cases, only a small induced signal was observed
upon titration of DB832, and the small with no exciton-type splitting suggests that binding as
an extensively stacked species is not occurring.

3.3.2 Effect of Salt on DB832 Binding to Human Telomeric Quadruplex DNA
The CD spectrum for the human telomeric sequence has previously been shown to
differ in the presence of sodium ions versus potassium ions

[24].

This suggests that this DNA

sequence exhibits a different conformation in the presence of each of these counterions.
Differing NMR and crystal structures which were obtained in the presence of sodium ions and
potassium ions, respectively, support this idea

[12, 14, 25].

The NMR structure of d[AG3(T2AG3)3]

in the presence of sodium is an antiparallel basket-like structure

[6h].

The crystal structure of

this sequence obtained in the presence of potassium ions consists of a parallel, propeller-like
structure
potassium
[27].

[12].
[26].

Other structures have been proposed to exist in solution in the presence of
Lithium has been shown to have a destabilizing effect on quadruplex structure

To investigate the effect of DNA structure on the binding of DB832, CD titrations were

performed (by Dr. Elizabeth White in Dr. Wilson‟s laboratory) with Tel22 under different salt
conditions to determine if DB832 would bind as stacked species to different conformations of
this DNA sequence. Figures 3.3 A-C shows the CD spectra for Tel22 titrated with DB832 in the
presence of 50 mM potassium, 50 mM sodium, and 50 mM lithium, respectively. Regardless of
the cation present, upon addition of DB832 exciton splitting occurs in the induced wavelength
region of the CD spectra and peaks occur in the DNA region at 265 and 295 nm. The final CD
spectra in different salt conditions had very similar parallel/antiparallel characteristics (Figure
3.3 D-F). This suggests that regardless of the starting conformation of the DNA, DB832 induces
the formation of a specific conformation of DNA to form an optimum binding site for stacked
species.
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The large exciton-type ICD signal observed in Figure 3.3 can be compared to that
obtained with a demonstrated end-stacking compound, RHPS4 (Chapter 2, Figure 2.3-C), and
a cyanine dye (Chapter 2, Figure 2.3-A) that is of the groove-binding type. Therefore, DB832
is binding as a stacked species in the grooves of the telomeric quadruplex conformation
regardless of the type of the cation present.

3.3.3 DB832 Binds Selectively as Stacked Species to the Hybrid Conformation of the Human
Telomere
Formation of hybrid quadruplex conformations is highly dependent on the flanking
bases of the G-rich sequences

[28].

To investigate the effect of flanking bases on the binding of

DB832, CD titrations were performed with Tel22, Tel26 and wtTel26 conformations to
determine if DB832 would bind as a stacked species to different conformations of this DNA
sequence. Tel26, composed of d(AAA3GGGTTA9GGGTTAGGGTTA21GGGAA), adopts a hybrid-1
intramolecular G-quadruplex (Figure 3.1 B) consisting of three G-tetrads linked with mixed
parallel/antiparallel G-strands in K+ solution

[28b].

The three TTA loop segments sequentially

adopt diagonal, lateral, and lateral loop conformations. The three highlighted adenines form a
stable triple capping structure on top of the 5‟ terminal tetrad of the motif further stabilizing
this conformation. wtTel26, composed of d(TTAGGGTT8A9GGGTTAGGGTTAGGGT25T); adopts
a hybrid-2 intramolecular G-quadruplex (Figure 3.1 C) consisting of three G-tetrads linked
with mixed parallel/antiparallel G-strands in K+ solution

[13c];

however, this hybrid-type

structure is different from the hybrid-1 structure in loop arrangement. The three TTA loop
segments sequentially adopt lateral, lateral, and diagonal orientations. The three highlighted
residues form a very well defined T•A•T triple platform at the 3‟ terminal tetrad of the motif.
Tel22, composed of d(AGGGTTAGGGTTAGGGTTAGGG) as previously described, exists as
multiple conformers in K+.
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CD studies were performed to evaluate the effect of flanking bases on the binding of
DB832. The CD spectrum of Tel26 sequence (Figure 3.4 B) has peaks at both 260 and 295 nm,
suggesting the DNA has a hybrid structure, which is consistent with the NMR data. Upon
addition of DB832, the CD signal at both peaks initially increases slightly (up to a 2:1
compound:DNA ratio), then decreases, resulting in a final conformation similar in shape to the
initial conformation, indicating that DB832 does not cause significant rearrangement of the
DNA conformation upon binding. This behavior is also commonly observed with the titration
of DB832 into the wild type human telomeric sequence, Tel22 (Figure 3.4 A). In the
wavelength region of DB832 absorbance induced exciton splitting is observed, indicating that
the compound is binding to the Tel26 sequence as a stacked species.

The CD spectrum of wtTel26 sequence (Figure 3.4 C) also exhibits peaks at both 260
and 295 nm, suggesting that this DNA is folding into a hybrid structure. However, based on
CD, it cannot be firmly established the particular type of the hybrid conformation the sequence
folds into since, as aforementioned, this sequence folds into a hybrid-2 conformation. Upon
titrating DB832, the CD signal at both peaks also exhibit a behavior similar to Tel26,
indicating that DB832 does not affect the DNA conformation upon binding. Also, DB832
exhibits a similar ICD signal indicating the same preferential binding towards this sequence.
However, a significantly larger concentration of DB832 (~ 6:1 ratio) is required to observe the
induced exciton splitting in this case. This may be due to the requirement of additional DB832
molecules probably to induce a conformational switch from hybrid-2 to hybrid-1. However, a
conformational switch between two very similar hybrid structures with very similar energy
profiles is rather difficult to confirm based only on CD pattern analysis.

A CD titration was also performed with the human telomere in potassium, in a buffer
containing polyethylene glycol (PEG 400). PEG is a crowding agent that reduces accessible
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volume. It has been used in in vitro experiments to mimic crowded intracellular conditions
where biomacromolecules can take up as much as 40% of the cellular volume

[29].

PEG has

been shown in vitro to induce conformational changes in quadruplex DNA by driving the DNA
to a conformation with reduced excluded volume

[30].

Oxytricha telomeric DNA has been

shown to transition from an antiparallel to a parallel conformation upon addition of PEG

[31].

The human telomeric sequence has been shown to adopt a parallel conformation in the
presence of PEG 400, even in the presence of potassium

[30a]

(Figure 3.1-D). The crystal

structure also confirms the parallel topology adopted by the human telomeric sequence,
further suggesting that the crystal packing effect closely mimics the molecular crowding
conditions. When PEG 400 is added to human telomeric DNA in the presence of potassium
(Figure 3.4 D), the CD spectrum has a dominant peak at 260 nm, consistent with the presence
of a parallel structure, as expected. When DB832 is added, the CD signal does not change in
either the DNA region or the induced region, further confirming the selectivity for the
quadruplex conformation formed by the human telomere in the presence of potassium and in
the absence of PEG.

3.3.4 Selectivity of DB832 to Diverse Quadruplex-Forming Sequences
To investigate the selectivity of DB832 for the different quadruplex forming sequences,
CD studies of DB832 were performed with telomeric DNA sequences from different organisms
that are shown to fold into a variety of structures, including antiparallel chair and basket
quadruplexes, and also an intermolecular quadruplex sequence (Figure 3.1). Quadruplex
forming sequences from oncogene promoter regions of c-myc and bcl-2, and G-rich aptamers
capable of forming stable G-quadruplexes were also evaluated to gain insight into selectivity of
DB832.
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The tetrahymena telomeric sequence, d[T2G4]4, has also been shown by NMR to form a
mixed parallel/antiparallel quadruplex structure with loops oriented lateral/lateral/diagonal
from 5‟ to 3‟

[6i]

(Figure 3.1-C). Before the addition of DB832, the spectrum in the DNA

wavelength region has peaks at both 260 and 295 nm, consistent with the formation of a
mixed parallel/antiparallel structure (Figure 3.5-A). Upon addition of DB832, the peak at 260
nm shifts to a higher wavelength and has a large decrease in magnitude. The presence of a
shoulder peak at 269 nm suggests that the final structure is still a mixed hybrid conformation.
An ICD signal is seen in the wavelength region of DB832 absorbance. However, it is much
smaller in magnitude than the signal seen when DB832 is titrated with either Tel22 or Tel26.
DB832 may be inducing a conformation change of the tetrahymena telomere from a 5‟lateral/lateral/diagonal-3‟ hybrid to a 5‟-diagonal/lateral/lateral-3‟ hybrid quadruplex. The
small ICD signal seen with this sequence may be due to DB832 binding as an end-stacking
species to the rearranged conformation.

The dual mutant bcl2-G15T/G16T, d(G3CGCG3AG2A2T2G3CG3), in the promoter
region of the bcl-2 proto-oncogene sequence has been shown to fold into a stable mixed
parallel/antiparallel hybrid-2 quadruplex conformation

[32]

(Figure 3.1-C). The loops of the

bcl2-G15T/G16T sequence are oriented lateral/lateral/diagonal from 5‟ to 3‟. Before the
addition of DB832, the spectrum in the DNA wavelength region has peaks at both 260 and
295 nm (Figure 3.5-C) suggesting the DNA has a mixed parallel/antiparallel structure, which
is consistent with the NMR structure and previously published CD data

[33].

The addition of

DB832 does not significantly change the shape of the spectra in the DNA region, indicating
that the compound does not significantly change the conformation of the DNA upon binding.
In the wavelength region of DB832 absorbance, a very weak induced CD signal is observed
and the absence of exciton-type splitting indicates that the compound is likely binding as a
weak, end-stacked monomer. Proton NMR studies of the bcl-2 sequence with DB832 are
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shown in Figure 3.8-A. Significant line broadening is observed for all the guanine imino
protons upon titration of DB832, suggesting the binding of DB832 to this sequence is nonspecific in nature. The 5'-lateral/lateral/diagonal-3' loop orientation of this sequence is clearly
not the favored conformation for DB832 binding.

Oxytricha telomeric sequence, d[G4(T4G4)3], is shown to fold into an antiparallel-basket
quadruplex conformation in Na+

[34]

parallel/antiparallel conformer in K+

(Figure 3.1-E); whereas, it exists as a

[35].

mixed

CD studies of this sequence, in the absence of

DB832, reveal a major peak at 290 nm and a very small shoulder at 260 nm, suggesting a
more antiparallel character of this sequence (Figure 3.5-B). Surprisingly, a weak exciton-type
ICD signal is observed suggesting that DB832 might be binding as a stacked species to this
sequence. The magnitude of the ICD signal observed can be classified as weak when compared
to the ICD of DB832 with Tel22. Upon titration, DB832 does not induce any change in the
DNA conformation of this sequence as indicated by the absence of any changes in peak shapes
in the DNA absorbance region, which suggests that the preformed mixed parallel/antiparallel
quadruplex conformation is the preferred fold for the DB832. Tel22, which is shown to fold
into an antiparallel basket conformation in Na+, undergoes major conformational changes
upon titration of DB832 and results in a final structure that has both parallel/antiparallel
characteristics as observed in K+. The fact that DB832 does not induce conformational switch
in the oxytricha telomeric sequence, unlike Tel22 in Na+, but still exhibits a weak exciton-type
ICD signal, highlights the subtle differences that the ligands can identify between very similar
conformers. In this case the antiparallel-basket makes it important to thoroughly understand
the smallest differences that exist in a DNA microenvironment in order to develop promising
therapeutic candidates.
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Even though the above discussed three sequences form mixed parallel/antiparallel
hybrid quadruplex structures, they are not identical to the hybrid conformation formed by the
human telomeric sequences Tel22 and Tel26. The three loops of the Tel22 and Tel26
sequences are oriented diagonal/lateral/lateral as read from the 5‟ to 3‟ direction. The loops of
the tetrahymena, bcl2, and oxytricha sequences are oriented lateral/lateral/diagonal from 5‟
to 3‟. These three sequences also have a different pattern of glycosidic orientation of the sugars
than Tel22 and Tel26. The relative difference in magnitude of the CD signals at 260 nm vs.
295 nm for tetrahymena, bcl-2 and oxytricha, as compared to Tel22 and Tel26, may be
indicative of this difference in structure. If this is the case, the fact that the addition of DB832
to tetrahymena results in a smaller signal at 260 nm, as compared to 295 nm, suggests that
DB832

may

be

inducing

a

conformation

change

of

tetrahymena

from

a

5‟-

lateral/lateral/diagonal-3‟ hybrid to a 5‟-diagonal/lateral/lateral-3‟ hybrid quadruplex. The
small amount of exciton splitting seen with this sequence may be due to DB832 binding as a
stacked species to the rearranged conformation.

Aptamers have proven to be therapeutically significant due to their high stability, the
ease of synthesis and several clinical applications [36]. In fact, a G-rich aptamer, AS1411, which
is shown to fold into diverse quadruplex conformers, is currently in clinical trials as a potential
anticancer agent

[37].

Small molecules that can selectively target aptamers can also have

potential therapeutic applications. Thrombin Binding Aptamer, d(G2T2G2TGTG2T2G2), forms
an antiparallel basket-type quadruplex as determined by NMR

[6g]

(Figure 3.1-E). The G-rich

oligonucleotide, d[(G2T4)3G2], has been characterized as an antiparallel chair-type quadruplex
by 1-D NMR

[38]

(Figure 3.1-F). CD studies were performed to determine the interaction of

DB832 with the TBA and G-rich oligonucleotide. When DB832 is titrated into this DNA no
exciton splitting similar to that with human telomeric DNA occurs, and the small ICD signal is
observed with TBA is characteristic of an end-stacking mode (Figure 3.6 A). Before the

83

addition of DB832, the spectrum in the DNA wavelength region of TBA has a maximum at 295
nm, with a minimum at 260 nm, confirming the presence of the antiparallel-chair
conformation. The addition of DB832 increases the signal at 260 nm and decreases the signal
at 295 nm, indicating a conformation change in the DNA as the compound binds. CD of the Grich oligonucleotide, d[(G2T4)3G2], confirms a predominant antiparallel-chair topology of this
sequence (Figure 3.6 B). The addition of DB832 does not cause a significant change in the
shape of the spectra in the DNA region, indicating that DB832 does not significantly rearrange
the conformation of the DNA. No induced exciton splitting is observed in the wavelength
region of DB832 absorbance, indicating that binding is occurring as a monomer and not a
stacked species.

The

G-rich

strand

of

the

promoter

region

of

the

c-myc

oncogene,

d[TG4AG3TG4AG3TG4AAG2], forms a parallel propeller-type quadruplex in solution [39] (Figure
3.1-D). Before the addition of DB832, the spectrum in the DNA wavelength region has a
maximum at 260 nm, consistent with a parallel conformation of DNA (Figure 3.6 C). The
addition of DB832 causes a decrease in signal at 260 nm, but still results in a positive peak at
that wavelength, indicating that DB832 does not significantly rearrange the conformation of
the DNA. No induced exciton splitting is observed in the wavelength region of DB832
absorbance, indicating that binding is occurring as a monomer and not a stacked species.
d(TG4T) forms a simple four-stranded intermolecular quadruplex with easily accessible
grooves and exposed terminal tetrads

[40]

(Figure 3.1-G). The addition of DB832 does not

change the CD spectrum of this DNA, suggesting that this compound does not bind to
intermolecular quadruplexes (Figure 3.6 D). Intermolecular G-quadruplexes may have less
biological significance than intramolecular G-quadruplexes, which can be formed at the 3'
overhang of telomeric DNA, but are likely to play a role in vivo in phenomena such as
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recombination and end to end pairing. Binding to intermolecular quadruplexes may result in
undesirable genomic effects including end-end fusion of chromosomes.

The absence of any significant exciton-type ICD signals when DB832 is titrated into
these DNA sequences suggests that DB832 binds as a stacked species in the grooves of mixed
parallel/antiparallel hybrid quadruplexes with a high degree of selectivity.

3.3.5 DB832 Induces the Formation of a Single Quadruplex Structure
To test the idea that DB832 is inducing the formation of a single mixed
parallel/antiparallel quadruplex structure in the human telomere and is selective for hybrid
type conformations,

1H-NMR

studies were performed on several telomeric quadruplex

sequences. Tel22 exists as a mixture of conformations in K+ solution as previously shown by
NMR studies; whereas, Tel26 and wtTel26 are shown to fold predominantly into hybrid-1 and
hybrid-2 conformations respectively (discussed in Section 3.3.3). The imino proton spectra of
Tel22 show the presence of more than one conformer in solution judging by the number of
imino proton signals (Figure 3.7 Top, ratio 0). When DB832 is added, significant changes in
the imino proton region can be readily observed, with spectral broadening and shifts indicative
of an intermediate exchange of ligands on NMR timescale. At higher DB832 ratios, the
intensity of many imino protons is significantly reduced and a new set of signals is observed,
suggesting selectivity for a particular quadruplex conformation from an ensemble.

The imino proton spectra of Tel26 show the presence of a distinct number of imino
protons (Figure 3.7 Middle, ratio 0) corresponding to the total number of guanines in that
sequence. This is consistent with an intramolecular monomeric quadruplex formation, hybrid1. Upon titration of DB832, a very similar spectral broadening and shifts, as in the case of
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Tel22, are observed revealing an intermediate exchange of ligands on NMR timescale. A
number of imino resonances broaden in a site-specific fashion consistent with the local
chemical environment of different residues being perturbed upon ligand binding. This
indicates that the compound is selectively binding to the hybrid-1 conformation, as seen from
CD studies (Section 3.3.3). A similar effect is also observed with the wtTel26 (Figure 3.7Bottom) upon ligand binding, indicating preferential binding to the preformed hybrid
conformation.

The sequence d[TG4T] is shown to fold into a simple intermolecular quadruplex
topology by NMR and confirmed by CD studies (Section 3.3.4) (Figure 3.1-G). Current CD
results have shown that DB832 does not induce a change in quadruplex conformation even at
high ratios of the ligand, and does not have any ICD signals. 1H NMR studies of TG4T were
performed with DB832, as shown in Figure 3.8-B. In the absence of any ligand (Figure 3.8-B,
ratio 0), the imino proton spectra confirms the parallel topology adopted by this sequence.
Upon titration of DB832, significant upfield shifts are observed for certain imino resonances
indicative of the ligand stacking on the terminal tetrads. This is consistent with the current CD
studies, which also suggest end-stacking as the only possible binding mode. This is also a
commonly observed phenomenon between distamycin and TG4T sequence, where the ligand
initially stacks at the ends followed by stacking in the grooves [41].

The sequence, U6U7, d(TAGGGUUTAGGGT), has been shown to exist in solution as an
ensemble of parallel and antiparallel dimeric hairpin quadruplexes

[42]

(Figure 3.1-H). This

sequence is suitable as a model system for studying interactions with DB832, since the CD
spectra of DB832 titrated into this DNA exhibits the same patterns in both the induced
wavelength region and the DNA region as observed with the intramolecular sequence
d[AG3(T2AG3)3] (CD spectra not shown). The imino proton spectra of DB832 titrated into
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U6U7 is shown in Figure 3.9-A. As the molar ratio of DB832 is increased, the NMR peaks
become sharper, suggesting that the compound is selectively binding to a single DNA
conformation and stabilizing the structure. This is further supported by TOCSY spectra of the
U6U7 sequence with DB832 at a 2:1 ratio (Figure 3.9-B). The four peaks correspond to the
two uracil H5-H6 interaction peaks from the parallel and antiparallel conformations. In the
absence of DB832, all the peaks are of similar intensity indicating equilibrium of two different
conformations. However, upon DB832 titration, there is a significant decrease in the intensity
of the two most upfield peaks suggesting that the compound is preferably binding to a
particular conformation from the mixture.

3.4

CONCLUSION
Many DNA-targeted anti-cancer drugs act by intercalating between base pairs of

duplex DNA, which causes a disruption in transcription and replication and leads to cell death.
A difficulty with these types of small molecules is that they typically exhibit non-selective
binding to many sites. Drugs in use today against cancer and eukaryotic parasites have
significant toxicity to the host and can cause deleterious side-effects and death. Telomeres and
some oncogenes have been shown to form quadruplex structures in vitro, and may serve as
structure-specific targets for anticancer as well as antiparasitic therapeutics. The unique
structural features of quadruplexes offer a way to target DNA in a structure-specific manner,
leading to increased selectivity for quadruplex over duplex DNA, as well as selectivity for a
particular quadruplex structure over other quadruplexes. DB832 is a heterocyclic diamidine
that binds to human telomeric DNA as a groove-specific, stacked species. It is highly selective
for quadruplex binding, showing virtually no binding to duplex DNA. Regardless of the
starting conformation of the human telomeric DNA, DB832 is capable of inducing the
formation of a mixed parallel/antiparallel hybrid quadruplex structure, and can even induce
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formation of this structure in the absence of salt. DB832 also binds very selectively as a stacked
species to the 5‟-diagonal/lateral/lateral-3‟ hybrid quadruplex structure which is preformed
or induced by DB832 in human telomere and modified human telomeric DNA sequences.
Table 3.1 summaries the interaction of DB832 with different quadruplex conformations in this
study. The unique binding mode of DB832 as well as its selectivity for its DNA target may
allow it to serve as the starting point for the design of unique compounds with high affinity
and selectivity for human telomeric DNA, leading to improved therapeutics for treating cancer
and parasitic infections with decreased side effects.
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(A)

(B)

(C)

Hybrid-1: Tel22 Tel26

Hybrid-2: Tel22

bcl-2

wtTel26

(D)

Intramolecular Parallel:
(E)

Antiparallel Basket
Tel22, TBA

(F)

Antiparallel Chair
Tel22, G4(T4G4)3

c-myc

Tel22
(G)

Intermolecular Parallel
TG4T

(H)

Dimeric Quadruplex
U6U7

Figure 3.1: (A) Chemical structure of DB832. (B-H) Major folding topologies of quadruplex
forming sequences used in this study.

References for the different quadruplex folds are provided within the main text.
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Figure 3.2: UV melting profiles of the hairpin duplex, d(CGAGATCAAAAGATCTCG),
monitored at 260 nm (A) and the human telomere sequence, Tel22, monitored at 295 nm (B)
in the absence and presence of DB832 in phosphate buffer containing 100 mM K+. (C) CD
spectra of DB832 titrated into d[(GC)7] in HEPES buffer containing 50 mM KCl.
Compound:DNA ratios ranged from 1:1 to 5:1. (D) CD spectra of DB832 titrated into
d(GCGAATTCGC) in HEPES buffer containing 50 mM KCl.

Thermal melting compound:DNA ratios ranged from 1:1 to 5:1. DB832:DNA ratio was 2:1 for
both DNAs. DB832 increases the melting temperature of the Tel22 by approximately 9 °C,
while it has a negligible effect on the melting temperature of the duplex sequence.
DNA/quadruplex concentration for Tm and CD experiments is ~3-5 µM unless otherwise
mentioned.

90

150 (A)

KCl

150 (B)

NaCl

150

50

50

50

0

-50

CD

100

CD

100

CD

100

0

-100

-100
250 300 350 400 450 500 550
Wavelength

4 10 8

250 300 350 400 450 500 550
Wavelength

250

300 350 400 450
wavelength (nm)

500

(F)

(E)

(D)

0

-50

-50

-100
-150

(C) LiCl

CD [molar ellipticity]

3 10 8
2 10 8
1 10 8
0

-1 10 8
-2 10 8
-3 10 8
240

260

280 300 320
wavelength (nm)

340

240

260

280 300 320
wavelength (nm)

340

240

260

280 300 320
wavelength (nm)

340

Figure 3.3: CD spectra of DB832 titrated into Tel22 in HEPES buffer containing 50 mM KCl (A), NaCl (B), or LiCl (C). (D-F) Closeup of the wavelength region of DNA absorbance for the spectra shown in A-C respectively.

In each case (top panels), the spectra show ICD signals, suggesting that DB832 is binding as a stacked species to human telomeric
DNA under each of these conditions. The arrows (bottom panels) indicate increasing DB832 concentration. Although the initial
spectra of the free DNA are quite different in each of these salts, upon addition of DB832, the CD spectra all exhibit peaks near both
265 and 295 nm. This suggests that regardless of the starting DNA conformation, DB832 induces the same final quadruplex
conformation, which has both parallel and antiparallel characteristics.
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Figure 3.4: CD spectra of DB832 titrated into (A) Tel22, (B) Tel26, (C) wtTel26, and (D) Tel22
(with PEG 400).

Buffer conditions: HEPES buffer containing 50 mM KCl, 25 °C. DB832 was titrated into DNA
solutions until saturation point is reached in the ICD region. Quadruplex concentration is ~ 35 µM unless otherwise mentioned. Exciton splitting is observed for Tel22, Tel26 and wtTel26
in the induced region, indicating that DB832 binds as a stacked species to the mixed
parallel/antiparallel hybrid structure formed by these sequences. Tel22, with PEG 400,
predominantly folds into a parallel conformation. Absence of any exciton-type ICD signal
under these conditions suggests that the parallel conformation is not a preferred fold for
DB832.
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Figure 3.5: CD spectra of DB832 titrated into (A) Tetrahymena telomeric sequence, d(T2G4)4,
(B) Oxytricha, d[G4(T4G4)3], and (C) bcl-2, d(G3CGCG3AG2A2T2G3CG3) quadruplex sequences.

Buffer conditions: HEPES buffer containing 50 mM KCl, 25 °C. DB832 was titrated into DNA
solutions until saturation point is reached in the ICD region. Quadruplex concentration is ~ 35 µM unless otherwise mentioned. DB832 does not exhibit any exciton-type splitting with the
bcl-2 sequence, and only exhibits small ICD signal at high concentrations with the
Tetrahymena telomere. The large change in the CD signal in the DNA region of Tetrahymena
suggests that the DNA undergoes a major conformation change upon the addition of DB832.
Oxytricha exists as a mixture of quadruplex conformations in K+. DB832 might be selectively
binding to a single conformation from this ensemble, but exhibits a low ICD signal when
compared to Tel22.
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solutions until saturation point is reached in the ICD region. Quadruplex concentration is ~ 35 µM unless otherwise mentioned.
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Figure 3.7: Imino proton spectra of DB832 with Tel22 (top), Tel26 (middle), and wtTel26
(bottom) at 25 °C in 10 mM K2HPO4/80 mM KCl, pH 7.0.

As the molar ratio of DB832 is increased, distinct chemical shifts for some guanine imino
protons are observed for all the sequences indicating that the compound is binding to these
quadruplex conformations. These results show that DB832 is selective for the
diagonal/lateral/lateral-type hybrid quadruplex structure.

95

G3

G4

G5 G6

Figure 3.8: NMR imino proton titrations of (A) bcl-2 promoter sequence and (B) TG4T with
DB832.

As the molar ratio of DB832 is increased, the guanine imino peaks of bcl-2 undergoes
significant broadening, indicating nonspecific binding. TG4T exhibits significant upfield shifts
for some imino protons. This is consistent with the stacking of the compound at the terminal
tetrads of this sequence: a commonly recurring theme with most of the small molecules
interacting with this conformation. Imino proton assignments are for d[TAGGGGTT]4
intermolecular quadruplex obtained from [41].
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Figure 3.9: NMR imino proton titration of U6U7, d(TAGGGUUAGGGT) dimeric hairpin
quadruplex with DB832 (A). (B) TOCSY spectra of uracil H5-H6 cross-peaks for 0.5 mM
U6U7 at 0:1 (top), and 2:1 (bottom) DB832 molar ratios at 308K.

Buffer conditions: 80 mM KCl/10 mM K2HPO4, 0.1 mM EDTA, pH 7.0 at 35 °C. As the molar
ratio of DB832 is increased, the peaks exhibit upfield shifting and become sharper, (A). At a
ratio of 2:1, only six peaks are seen, indicating that the compound is binding to a single DNA
conformation for each DNA sequence. In the absence of the compound, U6U7 exists as a
mixture of conformations (shown in inset). Upon DB832 titration, the intensity of upfield
peaks significantly decreases (B, 2:1), suggesting that the compound is binding to a single
hybrid quadruplex conformation from a mixture.
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Table 3.1: DNA sequences selected for CD studies with DB832.

a

DNA

Sequence

Conformationa

Tel22

d[AG3(T2AG3)3]

Mixture

Tel26

d[A3(G3T2A)3G3A2]

Hybrid-1

Yes

wtTel26

d[T2G3(T2AG3)3A]

Hybrid-2

Yes

c-myc27

d[TG4AG3TG4AG3TG4AAG2]

Intra-Parallel

No

Oxytricha

d[G4(T4G4)3]

No

Tetrahymena

d[T2G4]4

bcl-2

d[G3CGCG3AG2A2T2G3CG3]

Mixed
parallel/antiparallel
Mixed
parallel/antiparallel
Mixed
parallel/antiparallel

Thrombin
d[G2T2G2TGTG2T2G2]
Binding Aptamer

Antiparallel-chair

No

G-rich
oligonucleotide

d[(G2T4)3G2]

Antiparallel-basket

No

TG4T

d[TG4T]

Inter-Parallel

No

AATT

d[GCGAATTCGC]

Duplex

No

(GC)7

d[CGAGATCAAAAGATCTCG]

Duplex

No

Mixed duplex

d[GC]7

Hairpin

No

Quadruplex conformations reported are determined in K+.

Exciton
Splitting
Yes

No
No
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4
4.1

HETEROCYCLIC DIAMIDINES AS POTENTIAL G-QUADRUPLEX TARGETING AGENTS
INTRODUCTION
DNA is an important drug target in anticancer therapies and development of successful

anticancer agents is highly dependent on the discovery and understanding of the DNA duplex
and its associated processes. Unfortunately, many of the currently available drugs that target
DNA are cytotoxic and nonspecific. As such, extensive efforts have been directed toward the
discovery of new agents with improved selectivity and less cytotoxicity

[1].

Apart from the

typical right-handed double helix, DNA can adopt other biologically relevant structures, such
as G-quadruplexes

[2].

The unique structural characteristics of G-quadruplexes and their

polymorphism can contribute to their varied biological roles. The major roles of the Gquadruplexes may be their ability to “turn-on” or “turn-off” some physiological events by the
transcriptional regulation of genes or telomere length. The particular geometry of the Gquadruplex structure is thought to allow specific recognition by small molecules through
various binding modes in a manner corresponding to that of duplex-DNA binders. The Gquadruplex architecture is recognized as a significant drug target for cancer and other diseases
and extensive efforts have been directed toward the discovery of promising lead compounds
capable of stabilizing G-quadruplexes

[3].

Despite the emergence of a wide array of

quadruplex-interactive small molecules, the interaction of most of these small molecules with
G-quadruplexes in vitro have been shown to be primarily through by end-stacking mode. The
intercalation mode between the tetrads of quadruplexes is considered to be highly improbable,
not only because the G-quadruplex is an extremely stable and rigid structure, but also because
distortion of quadruplex integrity requires a very high energy cost. Electrostatic interactions
between cationic ligands and the anionic backbone can also be important for improving their
binding affinity. Most importantly, quadruplex groove-binding has been shown to be a viable
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strategy to develop a completely new spectrum of small molecules

[4].

Moreover, opportunities

do exist to combine any of these binding modes to get enhanced degrees of binding specificity.
DNA duplex binders constitute an important class of small molecules that have
exhibited great success in antiparasitic and anticancer therapy [5]. The minor groove of double
helical B-DNA has been a site of greatest interest for developing new drugs since it is the site of
non-covalent high sequence specific interactions for a large number of small molecules. The
DNA-binding properties of these agents have been examined in great detail and have provided
insights into the structural and functional features that contribute to binding selectivity.
Polyamides and diamidines have garnered the most attention as the most successful duplex
groove-binding agents

[5e, 6].

Much of the facts that are established about DNA minor groove

binders are based on detailed studies of polyamides such as distamycin and netropsin (Figure
4.1: A, B). These compounds are characterized by repeating pyrrole units connected by amide
bonds and ending with one or more positively charged nitrogen atoms. They are capable of
interacting with the DNA minor groove based on their curved shape, which matches well with
the topology of double-stranded DNA. Distamycin and netropsin are potent inhibitors of
Topoisomerase I, II and DNA helicases

[1f, 7].

Diamidines such as DAPI, berenil, and

pentamidine (Figure 4.1: C-E) were proved to be therapeutically successful agents against
several protozoan diseases [8]. DAPI binds to the minor groove with the phenyl and indole rings
parallel to the groove walls, covering the four basepair sequence, AATT [9]. The amidine groups
at the termini of the molecule seemed to contribute significantly to the complex stability
between the dications and the DNA through H-bonding and electrostatic interactions. A
weaker intercalation mode at GC sites is also commonly observed for DAPI [10]. Berenil, a diaryl
diamidine, is widely used for the treatment of trypanosomal infections in animals

[8d, 8e].

Its

biological activity has been related to a selective inhibition of kinetoplasts, specialized DNAcontaining regions of the mitochondrion

[11].

This compound is also characterized by a high
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affinity for the AT-rich sequences [12]. Pentamidine, also an aromatic diamidine, is particularly
effective in the treatment of P. carinii pneumonia (PCP) in patients with AIDS [13]. Footprinting
analysis indicates a strong preference of pentamidine for the AT-rich region of the DNA minor
groove containing at least five consecutive AT base pairs

[14].

Although, the mechanism of

pentamidine action against P. carinii is unknown, there is considerable evidence that direct
interaction with the pathogenic genome is important for its activity

[15].

Although pentamidine

is one of the drugs of choice used for the treatment of PCP, this compound is associated with
serious toxicities, and has prompted the search for new and safer agents to combat this fatal
infection, which afflicts the majority of AIDS patients. Although a wide number of pentamidine
analogs have been developed, there is still an ongoing need for more potent and less toxic
derivatives of pentamidine

[1b, 16].

The replacement of the linker in either berenil or

pentamidine with a furan ring system resulted in furamidine (DB75) (Figure 4.1: F) shown to
be less toxic and more effective against PCP in immunosupressed rat models

[17].

In addition,

DB75 is active against diverse highly infectious parasites such as Giardia lamblia, Plasmodium

falcifarum, and Trypanosoma rhodesience

[17b, 18].

Interestingly, replacement of a phenyl ring

with a benzimidazole system resulted in DB293 (Figure 4.1: G), the first unfused aromatic
dication capable of forming stacked dimer in the DNA minor groove of GC-containing
sequence [19]. In particular, a 13-bp sequence including two contiguous ATGA motifs provided
a highly preferential recognition site for this compound

[20].

This is particularly important

considering the dearth of small molecules that can selectively recognize sequences containing
guanine residues, and the possible potential of these ligands to recognize guanine-rich
quadruplex forming sequences as well.
Owing to the success as potent antiparasitic and anticancer duplex-interactive agents, it
is not highly inconceivable to use polyamides and heterocyclic diamidines also as potential
anticancer quadruplex-interactive agents. However, polyamides that can interact with
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quadruplex systems have not been reported so far. In fact, Distamycin-A (Dist-A) is the only
polyamide that was shown to recognize simple quadruplex systems

[21].

Dist-A was shown to

bind with a 4:1 stoichiometry as an asymmetric dimer in the opposite grooves of [d(TG 4T)]4
sequence

[22].

An end-stacking interaction mode has however, been shown to be most

important in more complex quadruplex systems

[21].

The lack of selectivity of distamycin for

quadruplex systems over duplex systems and the lack of evidence supporting targeting
biologically significant quadruplex systems, such as those formed in telomeres and protooncogenes, suggests that polyamides are not good paradigms for quadruplex-interactive
agents.
In a recent exciting finding from our laboratory, DB832 (Figure 4.1: H), a heterocyclic
diamidine, was shown to strongly and selectively interact with quadruplex forming sequences
of telomeric DNA. Even though the compound encompassed all those structural elements that
are explicitly used to characterize duplex minor-groove binders, DB832 exhibited a very high
degree of selectivity for telomeric quadruplex-DNA and virtually zero affinity for a wide range
of duplex-DNAs. Moreover, DB832 exhibited a unique CD signature that has been reported for
small molecules that can form stacked complexes with quadruplex-DNA

[23].

DB832 was

shown in Chapter 2 to selectively interact with hybrid-type telomeric quadruplexes as stacked
species and most likely stacked in the multiple accessible grooves. The oxygen atoms of the two
furan ring systems were hypothesized to potentially participate in H-bonding interactions with
the G-NH2 groups positioned in the quadruplex grooves, and the amidine moieties of DB832 to
potentially recognize the N3 atoms of guanine, creating additional quadruplex recognition
sites. To gain a better understanding of all the structural elements of DB832 contributing
towards quadruplex groove recognition, Dr. David Boykin and coworkers from Georgia State
University developed a series of structurally similar aromatic diamidines (Figure 4.2) using
DB832 as the prototype. Particular emphasis was directed towards compounds that maintained
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the core structure of DB832: the 5-5-6 ring systems. Systematic atom-wise and group-wise
modifications were undertaken on the 5-5-6 ring systems of DB832 that were hypothesized to
be important for the compound binding. Switching the order of components in DB1093, for
example, significantly changes the molecular shape. Converting one or two furans to
thiophenes (DB1463, DB1438 and DB1450) makes subtle shape changes but also can affect
stacking. The furan-thiophene change has been shown to have a significant effect in duplex
groove binding systems

[24].

Ortho or meta nitrogen substitution on the phenyl ring (DB934

and DB1693) or on the central furan ring (DB1999) of DB832 modifies stacking ability and
can have potential to participate in hydrogen-bonding interaction in the grooves of Gquadruplex. Insertion of a methyl group to the terminal furan (DB1949) provides changes in
stacking ability but also a steric restraint to that region of the molecule. A freely rotatable triple
bond addition between the phenyl and the furan (DB1694) is expected to further weaken
duplex interactions and potentially enhance quadruplex binding. Finally, the role of the
amidine groups can be probed by converting them to imidazolines in DB832 (DB1972) as well
as in a thiophene (DB2037). The imidazoline substitution will provide planarity to the central
system and maintain a doubly charged state at physiological pH. To help understand the
quadruplex interactions of the new compounds, two central molecules, which have been
reported in literature, were used as reference compounds. One, RHPS4 is known to bind to the
human telomeric quadruplex conformation at the terminal G-tetrads of the human telomeric
sequence [25]. The other, distamycin-A, was recently assigned as a G-quadruplex groove binder
after its NMR evaluation with a parallel four-stranded intermolecular quadruplex [22].
An array of biophysical techniques was used to characterize the binding of these
ligands to the telomeric quadruplex-DNA and also duplex-DNA. Thermal melting results
showed these compounds bind to quadruplex-DNA with significant selectivity over duplex
sequences. Interestingly, NMR and CD results indicated a mixed binding mode with an initial
strong binding, through stacking at either one or both ends of the terminal G-quartets,
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followed by a weaker binding, through groove-recognition. Surface plasmon resonance studies
on selective compounds show that the compounds exhibited binding affinities that are
commonly observed for most of the quadruplex end-stacking compounds: in the order of 106 107 M-1. The binding affinities for the subsequent binding phenomena, proposed to be grooverecognition, could not be accurately determined with the available simple binding models, but
were generally found to be over 10-fold weaker. Nevertheless, we have identified a series of
heterocyclic diamidines, derived from duplex groove binders, which can potentially recognize
quadruplex architecture and can be used as lead candidates to design compounds with
improved selectivity and affinity.
4.2

MATERIALS AND METHODS

4.2.1 Sample Preparation
The biotin-free and 5′-biotin labeled DNA sequences Tel22, d[AGGG(TTAGGG)3];
Tel24,

d[TTGGG(TTAGGG)3A];

Dickerson,

d[CGAATTCGT4CGAATTCG];

GC20,

[(CG)4TTTT(CG)4]; were purchased with HPLC purification and mass spectrometry
characterization from Integrated DNA Technologies (Coralville, IA) and from Midland
Certified Reagent Company. NMR analysis performed on these sequences further confirmed
the purity of these sequences. The concentration of oligonucleotides was determined from
absorbance at 260 nm using molar extinction coefficient obtained from nearest-neighbor
principle. The syntheses of DB compounds were performed by Dr. David Boykin‟s group at
Georgia State University and will be reported elsewhere. Appropriate stock solution of each
compound was prepared in double deionized water and in deuterated water for NMR
experiments. This stock solution was diluted to required concentrations with appropriate
buffer right before their usage.
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4.2.2 Circular Dichroism Experiments
All CD experiments were performed at 25 °C in 10 mM K2HPO4 buffer containing 80
mM KCl and 1 mM EDTA. CD spectra were recorded using a Jasco J-810 spectrophotometer
with a 1-cm pathlength quartz cell at a scan speed of 50 nm/min and response time of 1
second. Appropriate amount of compounds were sequentially titrated from the stock solution
into the DNA solution in the cuvette until the desired mole ratios of compound to quadruplex
were obtained. The spectra were averaged over four scans. A buffer baseline scan was collected
in the same cuvette and subtracted from the average scan of each ratio. Data were processed
and plotted using Kaleidagraph 4.0 software.
4.2.3 Thermal Melting Studies
Thermal denaturation studies were conducted on a Cary 300 BIO UV-visible
spectrophotometer in quartz cuvettes of 1 cm pathlength. Compound-DNA solutions were
prepared in low salt buffer containing 10 mM TRIS buffer (pH 7.4), 10 mM KCl and 1 mM
EDTA. The absorbance of the oligonucleotides was monitored at the recommended wavelength
of 295 nm for quadruplex sequences and 260 nm for duplex sequences as a function of
temperature, and DNA without compound was used as a control. Samples of compound to
DNA ratios ranging from 0:1 to 4:1 were prepared. Cuvettes were mounted in a thermal block,
and the solution temperatures were monitored by a thermistor in a reference cuvette with a
computer-controlled heating rate of 0.5 °C/min. Experiments were generally conducted at
quadruplex concentrations in the range of 2-3 µM in TRIS buffer containing 10 mM KCl. Data
were analyzed and plotted using Kaleidagraph 4.0 software.
4.2.4 Surface Plasmon Resonance Studies
Biosensor SPR experiments were performed with a four-channel BIAcore 2000 optical
biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips (BIAcore SA with linked
streptavidin). All DNA samples, for either duplex- or quadruplex-binding experiments, were
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used as single strands to prevent dissociation in the SPR flow system. The chips were prepared
for use by conditioning with a series of 1 min injections of 1 M NaCl in 50 mM NaOH
followed by extensive washing with buffer. 5'-Biotinylated DNA samples (25-50 nM) in HBS
buffer were immobilized on the flow cell surface by non-covalent capture as previously
described

[26].

Three flow cells were used to immobilize DNA samples, and the first flow cell

was left blank as a control. Interaction analysis was performed by using steady-state methods
with multiple injections of increasing compound concentrations over the immobilized DNA
surface at 25 ºC. Biosensor experiments were conducted in filtered, degassed HEPES buffer (10
mM HEPES, 100 mM KCl, 3 mM EDTA, 0.005 v/v of 10% P20 BIACORE surfactant, pH 7.3) at
25 °C. Flow cell 1 was left blank as a reference, while flow cells 2-4 were immobilized with
DNA on a streptavidin-derivatized gold chip (SA chip from BIAcore) by manual injection of
DNA stock solutions (flow rate of 1 µL/min) until the desired value of DNA response was
obtained (350-400 RU). Compound solutions were prepared with the running buffer by serial
dilutions from stock solution. Typically, a series of different ligand concentrations (1 nM to 10
µM from 20 mM H2O stock) were injected onto the chip (flow rate of 50 µL/min, 5-10 min)
until a constant steady-state response was obtained followed by a dissociation period (buffer,
10 min). After every cycle, the chip surface was regenerated (20 s injection of 10 mM glycine
solution, pH 2.0) followed by multiple buffer injections.

The instrument response (RU) in the steady-state region is proportional to the amount
of bound drug and was typically determined by linear averaging over a 10-20 s or longer time
span, depending on the length of the steady-state plateau. The predicted maximum response
per bound compound in the steady-state region (RUmax) was determined from the DNA
molecular weight, the amount of DNA on the flow cell, the compound molecular weight, and
the refractive index gradient ratio of the compound and DNA, as previously described

[27].

In

most of the cases, the observed RU values at high concentrations were greater than RUmax,
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pointing to more than one binding site in these DNA sequences. The number of binding sites
was estimated fitting plots of RU versus Cfree. These methods can also be used to determine an
empirical RUmax value. The RUmax value is required to convert the observed response (RU) to
the standard binding parameter r (moles of drug bound per moles of DNA hairpin)
r = RU/RUmax
which is useful for comparison of a compound binding to different DNAs to obtain the binding
constants, the data were evaluated with different interaction models to obtain an optimal fit
using BIAevaluation (BIAcore Inc.) and Kaleidagraph (Synergy Software) software for
nonlinear least-squares optimization of the binding parameters:
One site:

r = (K1Cfree)/(1 + K1Cfree)

Two site:

r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2)

Three site:

r = (K1Cfree + 2K1K2Cfree2 + 3K1K2K3Cfree3)/(1 + K1Cfree + K1K2Cfree2 +
K1K2K3Cfree3)

where K1, K2 and K3 are equilibrium constants for three types of binding sites and Cfree is the
concentration of the compound in equilibrium with the complex and is fixed by the
concentration in the flow solution.
4.2.5 Nuclear Magnetic Resonance Studies
Quadruplex DNA samples were prepared in degassed phosphate buffer, containing 80
mM KCl, 10 mM K2HPO4 and 0.1 mM EDTA, and reconstituted in 90% H2O:10% D2O. 0.01
mM DSS was employed as an internal reference. DNA concentrations were in the range of 0.1
mM to 0.3 mM unless otherwise mentioned. The final DNA samples were adjusted to pH 7.0
using 1M HCl or 1M KOH solutions. Finally, the NMR samples were heated past their
transition temperature and annealed to room temperature several times before collecting the
spectra. Experiments were performed on a Varian Unity 600 spectrometer. DB compounds
were titrated into the quadruplex DNA with compound to DNA ratios varying from 1 to 3.
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Temperature-dependent 1H-spectra were recorded from 15 ºC to 45 ºC using jump-return and
WATERGATE methods for solvent suppression

[28].

All NMR data were processed and analyzed

with a combination of VNMR (Varian Inc.), NMRPipe (NIH) and MNova (Mestrelab Research)
software.

4.3

RESULTS AND DISCUSSION

4.3.1 Compounds are Highly Selective for Quadruplex-DNA over Duplex-DNA
With the abundance of duplex DNA in the genome, targeting relatively few non-duplex
structures such as quadruplexes becomes a complex task. Non-selective binding to secondary
sites might result in deleterious effects and cytotoxicity, therefore, structure and sequence
selectivity is of utmost importance to achieve desired results. In order to determine the
selectivity of DB compounds for human telomeric quadruplex sequence over duplex DNA
sequences, thermal melting studies were performed with telomeric quadruplex DNA (Tel22:
Materials and Methods, 4.2.1) and two different duplex sequences (AATT, GC20: Materials
and Methods, 4.2.1). The AT-rich duplex sequence was chosen since small molecules show a
preferential binding towards sequences with a narrow minor groove, and a GC-rich duplex
sequence was chosen to mimic the wider grooves of quadruplex DNA and, also, DB293, as
aforementioned, has been shown to cooperatively bind as a stacked dimer in GC- containing
sequences. This would also eliminate any bias towards any particular groove width for the
tested compounds. Melting curves were obtained for quadruplex sequences up to ratios as high
as 6:1 compound per quadruplex and ratios as high as 4:1 for duplex sequences. The ∆Tm
values for quadruplex (2:1, 4:1 ratios) and duplex sequences (2:1 ratio) are reported in Table
4.1; ratios higher than the listed range resulted in the signification complex aggregation and
produced inconsistent melting curves. This high stoichiometry was used because, as
aforementioned, the recently solved NMR structure of distamycin bound to an intermolecular
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quadruplex structure shows that up to four distamycin molecules are bound in the opposite
grooves of the quadruplex. Therefore, it is a likely possibility that relatively small-sized
molecules that mimic distamycin can bind to quadruplex DNA with a high stoichiometry. The
melting temperature of Tel22 in 100 mM K+ is 48.8 °C. DB832, the paradigm compound,
showed a ∆Tm of 19.1 °C at 2:1 and an impressive 26.1 °C at 4:1 ratios indicating signification
stabilization of the quadruplex conformation. Also, with the two duplex sequences, Dickerson
and GC20, DB832 shows very little increase in the Tm (3 °C and 3.7 °C respectively at 2:1
ratio) suggesting high selectivity over duplex DNA. Interestingly, DB1093, a more linear
structural isomer of DB832, showed almost no change in ∆Tm at 2:1 ratio and a small increase
(5 °C) at 4:1 ratio highlighting the importance of the neighboring furan ring systems for
effective recognition of quadruplex architecture. DB1093 also exhibited very little change in
∆Tm for duplex sequences (Table 4.1) suggesting that the compound is too linear to interact
with duplex DNA minor groove. The substitution of the two furan rings with thiophenes,
DB1450, results in very similar quadruplex stabilization (2:1-17.6 °C, 4:1-24.2 °C) as DB832
but, unfortunately, this modification decreases the specificity, with a ΔTm of almost 9 °C, for
the duplex sequences. Affinity for duplex sequences decreases by an impressive 6°C, relative to
DB1450, when the terminal furan is replaced by a thiophene (DB1438), while maintaining
strong quadruplex stabilization potential (4:1-25.5 °C). Interestingly, the substitution of the
central furan by a thiophene, DB1463, significantly increases the binding to AATT sequence
(8.5 °C), but not the GC20 sequence (3.4 °C), suggesting the effect of compound curvature on
recognizing different groove dimensions. However, the quadruplex stabilization for DB1463 is
not very different (2:1-17.3 °C, 4:1-23.1 °C) from what was observed for DB832. The addition
of a freely rotatable triple bond between the phenyl and furan ring systems, DB1694, also
significantly decreases the affinity for duplex sequences (AATT-1.0 °C, GC20-2.1 °C) while
maintaining good stabilization properties with quadruplex DNA. This has been previously
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observed in the case of diaryl amides where the addition of the acetylene group has increased
quadruplex recognition potential

[29].

The nitrogen substitution on the phenyl ring of DB832

exhibited enhanced stabilization of the quadruplex arrangement when it is placed in the meta
position (DB1693) but slightly decreased affinity when it is in ortho (DB934). The conversion
of amidine groups to imidazolines (DB1972 and DB2037) yields a more planar arrangement
while still maintaining a dicationic charge system. These modifications provide an increased
stacking surface available for ligand interaction with the terminal tetrads, and might have
higher quadruplex recognition potential. The imidazoline analogs, however, exhibited
generally lower ∆Tm than amidine counterparts. The oxazole derivative of DB832, DB1999,
and the addition of a methyl group on terminal furan, DB1949, also had high quadruplex
stabilization properties while and very little affinity for duplex sequences under low salt
conditions. The reference compound, distamycin, recently proposed as a G-quadruplex groove
binder with the four-stranded d(TG4T) at NMR concentrations, did not show any ΔTm with the
human telomere quadruplex sequence. As it is well known, however, that the polyamide is a
strong binder to AT sequences in duplex DNA, distamycin is the only compound of this group
that has reverse selectivity for duplex over quadruplex. Finally, RHPS4, a well-studied
quadruplex stabilizing compound that has been reported to bind by π-π interactions with the
external tetrad, shows melting values lower than to DB832 in terms of stabilization properties
and selectivity for quadruplex over duplex DNA. The quadruplex stabilization potential
observed for some of the DB compounds ranks among the strongest for quadruplex-interacting
small molecules reported so far. It is highly apparent that the ligands are significantly
stabilizing the quadruplex conformation, while maintaining a low degree of selectivity for
duplex sequences. Therefore, these compounds make ideal candidates for further study as
highly selective quadruplex interacting agents.
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4.3.2 DB Compounds Bind to the Human Telomeric DNA with Multiple Binding Modes
Circular dichroism (CD) studies were performed to evaluate how modifications on the
DB832 system influence the DNA conformation in the complex and the ligand interaction
mode with the human telomere. Circular dichroism has emerged as an important non-invasive
technique for determination of the conformation of biomolecules and also provides insights
about the binding modes of small molecules with DNA using pattern recognition

[30].

When an

achiral ligand, which has no CD by itself in solution, binds to a chiral macromolecule such as
DNA, an induced CD signal is observed in the wavelength region corresponding to the bound
achiral ligand

[31].

This induced CD (ICD) signal can be a small positive or negative, as in the

case of duplex intercalators, or can be a large positive signal, as in the case of duplex groove
binders

[32].

A combination of both positive and negative CD signals, coupled with different

ICD signal shapes indicates formation of stacked complexes, as was previously shown with
DODC with quadruplex systems

[33]

(Chapter 2, Figure 2.3-A). Recent CD studies have shown

that DB832 binds to the human telomeric quadruplex DNA possibly in the grooves of the
quadruplex conformation with large positive (435 nm) and negative (390 and 418 nm) ICD
signals at the wavelength region corresponding to the absorbance of bound DB832

[23].

Moreover modifications in the DNA region driven by the compound indicate stabilization of a
quadruplex conformation.

Using the ICD pattern exhibited by DB832 as a model for quadruplex multiple-site
recognition (Figure 4.3-A), CD studies were conducted for the compounds in Figure 4.2 with
Tel24 to investigate if a pattern similar to DB832 exists. Figures 4.3-4.5 show CD spectra of
the DB compounds with the Tel24 sequence. The addition of a methyl group on the terminal
furan (DB1949, Figure 4.3-B) and the substitution of a central furan with an oxazole
(DB1999, Figure 4.3-C) yielded ICD patterns similar to DB832. These modifications
apparently did not significantly affect the interaction mode with Tel24. The only difference
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that emerges by comparing the spectra is the magnitude of the signal at the ICD signal
saturation ratio. However, DB1093, the linear isomer of DB832, exhibits a different pattern
with Tel24 sequence (Figure 4.3-D). The positive band below 350 nm and negative ICD signal
above 350 nm with relatively low intensity is characteristic of ligands intercalating with
duplex-DNA or end-stacking with quadruplex-DNA. Therefore, DB1093 might be an endstacking molecule with quadruplex systems with relatively low ∆Tm (Section 4.3.1, Table 4.1).

Tm studies of thiophene containing diamidines (DB1438, DB1450 and DB1463:
Section 4.3.1) showed that all the compounds have quadruplex stabilization potential with
varying degrees of duplex selectivity. Sulfur is not as electronegative as oxygen and therefore
has weaker hydrogen bonding interactions than oxygen. The two monosubstituted thiophene
analogs, DB1438 (Figure 4.4-B) and DB1463 (Figure 4.4-C) exhibit a smaller magnitude of
ICD signals relative to DB832, which may be due to decreased stacking interactions due to a
small change in the curvature of the compounds. However, the disubstituted DB1450 has a
very similar exciton splitting as DB832 suggesting a very similar binding mode.

DB1972 and DB2037 have structural characteristics that make them unique: the
presence of two imidazoline rings instead of the two amidine groups. These rings affect the
equilibrium structure of the compound because the imidazoline relative to an amidine reduces
the torsional angle with the neighbor ring. This feature provides a more planar shape to the
molecule. This kind of shape suggests a more favorable end stacking interaction with the
external tetrads of the quadruplex. The ICD shape looks different from all the other
compounds spectra and it shows small positive and negative peaks (Figure 4.5: A, B).
Interestingly, both the compounds exhibit very similar saturation ratios indicating very similar
interaction modes and possibly with a very similar stoichiometry. DB934, with ortho nitrogen
substitution on the phenyl ring, exhibited virtually no ICD even at very high ratios (Figure 4.5-
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C), and, DB1693, with meta nitrogen substitution, exhibited a weak excition-type splitting
(Figure 4.5-D). The fact that substitution of a single atom makes a large change in compound
ICD signal shows that recognition of the quadruplex as a stacked species is extremely sensitive
to the compound structure. Tm studies with these two compounds (Section 4.3.1) have shown
that these compounds also have great quadruplex stabilization potential, suggesting an endstacking mode of interaction. Most of the compounds in this study had a very little effect on the
quadruplex conformation as can be seen from the CD signals corresponding to DNA regions
(Figure 4.3-4.5). NMR studies have shown that the sequence, Tel24, folds into a mixed
parallel/antiparallel hybrid-1 conformation in K+

[34].

The very small effect on DNA

conformation upon ligand binding indicates that the DB compounds are preferentially binding
to an already preformed hybrid structure.

Interestingly, closer inspection of the ICD signal exhibited by most of the compounds
reveals a pattern emerging upon complex formation. Figure 4.6 shows a plot of ICD signal at
the wavelength corresponding to the maximum CD signal of different compounds versus mole
ratio of the complex. A very weak ICD signal is observed for all of the compounds until the
ratio 3:1, followed by a dramatic increase in ICD above ratios 3:1 for DB832, DB1949 and
DB1450 (Figure 4.6). Other compounds have weaker ICD signals that are less than the
original DNA CD signal. A weak induced CD signal with duplex DNA is generally observed for
intercalation-type mechanisms

[32f].

However, with quadruplexes, intercalation is not

commonly observed due to the high energetic cost required to replace the coordinating cations
along the quadruplex helical axis and also due to the conformational restraints posed by the
terminal diamidine units of the DB compounds [35]. Therefore, intercalation has been ruled out
as the possible binding mode for the compounds. The observed weak ICD signal at low ratios is
consistent with the interaction of the ligands at either one or both the ends of the quadruplex.
NMR studies (discussed later in Section 4.3.3) further confirm the primary end stacking mode
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observed for most of the compounds at low ratios. Also, the aromatic moieties of these ligands
can favorably stack on the G-tetrads to form optimal π-π interactions. At ratios higher than
3:1, some compounds appear to be forming stacked complexes probably in different grooves of
the quadruplexes, characterized by exciton-type ICD signals. To summarize, the CD results, at
ratios until 3:1 compound per quadruplex, ligands exhibit initial mode of binding by stacking
on either one or both ends of the quadruplex structure, whereas, at ratios higher than 3:1,
DB832, DB1949 and DB1450, form stacked species probably in the grooves of the quadruplex.

4.3.3 Multiple Binding Modes Observed in NMR
Telomeric quadruplex sequences in K+ exists as a mixture of conformations, with the
hybrid conformation as a predominant structure

[34, 36].

An NMR structure of Tel24 show that

this sequence folds into a mixed parallel/antiparallel hybrid-1 type structure [34, 37]. To test the
idea that multiple binding mode are exhibited by some of the compounds from CD, 1H-NMR
titration studies were conducted with Tel24. Imino protons of guanines are excellent probes to
determine if a G-rich sequence folds into a quadruplex conformation

[38].

These imino protons

resonate between 10.0 to 12.5 ppm in a quadruplex structure and are readily observable in
water sample. Moreover, the presence of multiple quadruplex conformations can also be
readily answered by monitoring the imino protons. Binding of a small molecule to a
quadruplex structure affects the chemical environment of imino protons which can also be
identified from simple titration experiments. Figures 4.7-4.8 show the guanine imino proton
NMR spectra of different DB compounds with the Tel24 sequence at 25 °C. At higher
compound to quadruplex ratios, particularly at NMR concentrations, solubilities of the
compound and complex become an issue. Considerable aggregation is observed at high
compound concentrations resulting in significant line broadening and rendering it difficult to
obtain spectra for analysis. In the absence of any ligands (Figures 4.7-4.8, 0:1 ratio), the
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spectra show distinct numbers of imino protons corresponding to the total number of guanines
in the Tel24 sequence. This shows that the sequence forms primarily a single structure in K+,
and in this case it is the hybrid-1 type structure. Titration of the compounds with Tel24
resulted in significant changes in the imino proton spectra and spectral broadening and shifts
revealed that the ligands were in intermediate exchange on the NMR timescale. A number of
imino resonances broaden in a site-specific fashion, consistent with the local chemical
environment of various residues being perturbed differentially by ligand binding. Distinct
chemical shift changes can be readily observed for most of the imino protons. Imino protons of
G3, G9, G17 and G21, that constitute the 5‟ terminal tetrad of the quadruplex, are the most
perturbed even at the lowest compound to quadruplex ratio. This suggests the inherent
sensitivity of this technique even for the smallest changes produced, at relatively low ratios,
upon complex formation.

The 5‟ G-tetrad imino protons broadened considerably and disappeared completely at
high ratios. The high perturbation of the imino protons at the top end is consistent with the
stacking of the ligand on the 5‟ G-quartet. NMR studies of distamycin, Hoechst-33258, and
ethidium with several quadruplex forming sequences has revealed similar perturbations of the
imino protons of the top tetrad of the quadruplex and can stack on the top end of the
quadruplex indicating stacking on the top end of the quadruplex

[38-39].

Small molecules that

have excellent duplex-DNA groove binding properties, such as Hoechst-33258 and
distamycin, can preferentially bind as end-stackers with quadruplex systems. Therefore, it is
equally conceivable for the currently studied ligands to exhibit a similar end-stacking as the
primary mode of binding. Interestingly, broadening occurs for the aromatic residues of the 5‟
G-tetrads (G3, G9, G17 and G21 of 5‟-tetrad) and A20·T1 base pair (spectra not shown),
providing support for a mixed intercalation-exterior stacking mode of binding (i.e., between
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the 5‟-tetrad and the capping A20·T1 base pair of the loops). Therefore the results agree with
the stacking of the ligands on the top quartet at low ratios as suggested from CD studies
(Section 4.3.2). In most of the cases imino protons of G11and G23, that constitutes the bottom
tetrad, exhibited very little change. This is probably due to the presence of a stable capping
A24·T13 base pair at the 3‟ terminal, offering significant protection from solvent exchange.
Also, relatively unchanged imino proton chemical shifts of the bottom tetrad indicates that 3‟
end of the Tel24 quadruplex structure is not likely the binding site for these compounds. In all
the cases, imino protons of G4 and G22 that correspond to the adjacent guanine of the middle
tetrad exhibit small downfield shifts accompanied by slow broadening; however, imino protons
of G10 and G16 of the same tetrad exhibit very little changes. G4 and G22 are located in a
groove that has optimal dimensions for compounds to form stacked species. Therefore, after
the initial end-stacking mode at the 5‟ terminal, there is a very likely possibility that the ligands
are targeting the “medium” groove encompassed by the G3, G5, G23, G21 plane. The groove
adjacent to the medium groove is classified as the narrowest. Therefore, it is highly unlikely
that the compounds can efficiently form stacked species in the narrow groove. Absence of any
major changes in imino protons of guanines (G16 and G15) further confirms this. Therefore
NMR results are consistent with the recognition of multiple sites by DB compounds at high
ratios, thereby, agreeing with the CD results.

4.3.4 Surface Plasmon Resonance Study Reveals Multiple Binding Events
Surface plasmon resonance (SPR) has developed into an effective tool to measure the
affinity and study the kinetics of most biomolecular interactions

[26].

A recent literature survey

has shown that more and more quadruplex-small molecule interactions are being evaluated
using SPR techniques due to the high quality results obtained using SPR methodology

[40].

In

order to obtain qualitative binding affinities of the compounds in Figure 4.1 with the telomeric
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quadruplex sequence, a series of steady-state SPR experiments were conducted (Materials and
Methods, 4.2.4). Figures 4.9 and 4.10 show sensorgrams for several compounds with Tel22
sequence. From the sensorgrams, the large response obtained suggests that the compounds are
binding to the Tel22 sequence, and both the compounds exhibit fast association and
dissociation kinetics. Table 4.2 lists the binding constants obtained using a two-site model by
plotting the steady-state RU values as a function of free ligand concentration for different
compounds. From the table, we can readily notice that the primary binding constant (K1) of
different compounds fall in the range of 8 x 105 to 3 x 106 M-1, and is followed by a weak
binding constant (K2) that is 10-100 fold weaker in most cases. Although the primary binding
constants obtained for different compounds are not high, it does fall in the range of binding
constants that is generally observed for compounds that interact at the ends of the
quadruplex[23].

As discussed earlier, NMR and CD results have shown that the recognition of
quadruplex conformation by the DB compounds occur by more than one type of binding
mechanism. The initial binding observed at low ratios from NMR and CD is due to the endstacking of the ligands, whereas, binding events occurring at high ratios is possibly due to
groove recognition. Excellent results can be obtained using the SPR technique at low ligand
concentrations and so the first binding event was easily detectable. As the concentration range
is increased to follow the second binding, the free compound adsorbs on the chip surface
resulting in curves that are difficult to fit. This can be readily observed in the sensorgrams of
DB1450 (Figure 4.8, top right) and DB1463 (Figure 4.8, top middle), and their corresponding
fitting. The cooperative binding that gives the large ICD signal could not be accurately detected
by this method for most compounds. The K1 and K2 binding constants obtained from SPR were
determined by fitting only the initial parts of the binding curve with a two-site model. The
entire binding curve could not be fitted with either of the models due to the complex shape of
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the curve. The binding affinities obtained by fitting the initial part of the binding curve might
be due to the binding of one or more ligands to the ends of the quadruplex structure at low
ratios.

4.4

CONCLUSION
The current studies suggest that the binding mode of these compounds is very sensitive

to the subtle changes in compound. Here, we have identified a small subset of heterocyclic
diamidines that can recognize quadruplex DNA conformation with high selectivity and the
recognition of telomeric quadruplex DNA may occur by more than one type of binding
mechanism. Although end stacking is what was found to be the most common binding
mechanism for these compounds, the secondary binding that we believe is occurring, by
stacking in the grooves of the quadruplex, is a much more interesting phenomenon. It is this
groove binding phenomenon that we are more actively pursuing, since targeting grooves of the
quadruplex with small molecules has become an important strategy and has posed great
challenges in recent years for drug design and development. Stacked species are of particular
interest for recognition of quadruplexes since studies with duplex DNAs show that compounds
which bind as stacked dimers have increased binding affinity and selectivity over similar
compounds that bind as monomers. Similar stacking in the grooves of quadruplex DNA
structures would appear to be a favorable way to selectively recognize quadruplexes with
optimum interactions, perhaps employing an induced fit component between the stacked
heterocycles and the guanine bases of the quadruplex tetrads. Potentially, the individual
monomer units could be covalently linked, dramatically increasing the affinity and selectivity
of the compound for human telomeric DNA, leading to enhanced telomerase inhibition with
decreased cytotoxic side effects.
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Figure 4.1: Chemical structures of representative Duplex-DNA minor groove binders. (A)
Distamycin, (B) Netropsin, (C) DAPI, (D) Berenil, (E) Pentamidine, (F) DB75, and (G) DB293.
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Figure 4.2: Chemical structures of 5-5-6 and related ring systems used in this study.
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(A) DB1450

(B) DB1463

Figure 4.7: Imino proton spectra of Tel24 with (A) DB1450 and (B) DB1463 at 25 °C in 10
mM K2HPO4/80 mM KCl, pH 7.0.

Inset shows the hybrid-1fold of Tel24 reported in Luu et al
were provided by Dr. Anh T. Phan

[34].

Proton assignments of Tel24
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Figure 4.8: Imino proton spectra of Tel24 with (A) DB1438 and (B) DB2037 at 25 °C in 10
mM K2HPO4/80 mM KCl, pH 7.0.

Inset shows the hybrid-1 fold of Tel24 reported in Luu et al
were provided by Dr. Anh T. Phan

[34].
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Figure 4.9: SPR sensorgrams for binding of representative thiophene analogs with Tel22 quadruplex sequence. DB1450 (top left),
DB1463 (top middle) and DB1438 (top right) to Tel22 in 10 mM TRIS buffer containing 100 mM K+ at 25 °C.

The quadruplex curves range in ligand concentration from 10 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The steady-state curves were fitted only for low
compound concentrations, since at higher concentrations, non-specific binding is occurring. The concentration values are for
unbound compound concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 4.10: SPR sensorgrams for binding of DB832 analogs with Tel22 quadruplex sequence. DB934 (top left), DB1693 (top
middle) and DB1694 (top right) to Tel22 in 10 mM TRIS buffer containing 100 mM K+ at 25 °C.

The quadruplex curves range in ligand concentration from 10 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Table 4.1: Thermal melting resultsa at different ratios (listed in bracket) for Tel22b and two
duplex sequences (Dickerson and GC20) with 5-5-6 and related ring systems at 100 mM K+.
Compound

Tel22 (2:1)

Tel22 (4:1)

AATT (2:1)

(GC)20 (2:1)

DB832

19.1

26.1

3.0

3.7

DB1093

0.00

5.00

5.0

2.5

DB1438

18.2

25.5

2.1

2.5

DB1450

17.6

24.2

8.1

9.1

DB1463

17.3

23.1

8.5

3.4

DB934

16.8

22.6

2.0

2.3

DB1693

22.5

27.2

5.1

2.1

DB1694

16.5

23.8

1.0

2.3

DB1949

ND

11.5

2.3

ND

DB1972c

ND

13.0

4.0

ND

DB2037c

ND

20.0

7.6

ND

DB1999c

ND

9.50

2.5

4.8

Distamycinc

ND

0.00

7.0

ND

RHPS4c

ND

9.30

3.0

ND

a

∆Tm values (complex – free DNA, in °C) are estimated as the mid-points of the melting
transition.
b Ligand

free single-strand concentration in this study is 2-3 µM.

c

Performed by Caterina Musetti in our laboratory. The ∆Tm values listed are at 50 mM K+
concentration.
ND: Not determined
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Table 4.2: Equilibrium binding constantsa determined by SPR for representative DB compounds
with Tel22.
Compound

K1

K2

DB1450

1.40

0.10

DB1463

1.15

0.08

DB1438

2.35

0.03

DB1693

2.89

0.34

DB1694

1.30

0.23

DB934

0.81

0.08

DB832b

3.79

0.23

a

Binding Constants (K x 106 M-1) determined with a two-site model (See Figure 4.9 and 4.10
for fitting)
b

Binding Constant with Tel24 sequence (Chapter 2, Figure 2.11)
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5

EVALUATION OF AZACYANINES, NAPHTHALENE DIIMIDES AND DIARYL UREAS AS NEW
SCAFFOLDS FOR G-QUADRUPLEX RECOGNITION: SURFACE PLASMON RESONANCE
STUDIES

5.1

INTRODUCTION
Stabilization of quadruplex architecture by small molecules is emerging as a potential

anticancer approach since it is thought to interfere with oncogenic expression and telomeric
maintenance in cancer cells. Interestingly, several classes of small molecules have been
developed that efficiently target G-quadruplex DNA. Most of the quadruplex-interactive small
molecules discovered to this time are planar, aromatic, heterocyclic scaffolds that are generally
derived from duplex DNA intercalators. The planar units of these molecules are
conformationally constrained and, as a result, primarily interact with quadruplex units by
stacking on either one or both ends of the terminal G-tetrads. Because of the structural
similarity to duplex DNA intercalators, many of these quadruplex-binding molecules exhibit
limited selectivity for quadruplex over duplex structures. Binding to non-targeted duplex
sequences can result in significant loss of valuable compound with potential non-selective
cytotoxicity. Since potential quadruplex-forming sequences are common throughout the
genome, selectivity for a particular quadruplex structure over other quadruplex motifs is also a
concern in the design of quadruplex-binding compounds. Binding to non-targeted quadruplex
sequences might also have deleterious effect on regulation of non-targeted genes. Increasing
selectivity of small molecules for their targets is therefore an important focus of research.
Several classes of small molecules that interact with selective quadruplex forming
motifs via end-stacking have been extensively investigated [1]. Porphyrins and acridines are two
important classes of small molecules that have been thoroughly investigated and have shown
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potential to lead to clinical agents

[1b, 2].

Porphyrins are a class of heterocyclic macrocycles

composed of pyrrole subunits linked through methine bridges. Porphyrins are known to bind
to and stabilize different types of G-quadruplexes and, in some cases, to facilitate Gquadruplex formation

[2b, 3].

TMPyP4 (Figure 5.1) is a commercially-available cationic

porphyrin that has been widely studied and shown to bind to quadruplex DNA sequences

[4].

TMPyP4 binds to human telomeric DNA by stacking externally on each of the terminal
quartets, with the positively charged groups oriented toward the sugar-phosphate DNA
backbone

[2b].

However, several other secondary binding modes have also been reported for

TMPyP4 [5], but the external end-stacking is established as the most common interaction mode.
The stabilization of quadruplex conformations of telomeric DNA by TMPyP4 has shown to
prevent recognition of the telomere by telomerase and resulting in effective inhibition of the
enzyme

[3b, 6].

TMPyP4 also binds to and stabilizes the G-rich strand of the intramolecular c-

myc sequence, with each molecule stacked externally on the G-tetrad surface

[3d].

Moreover,

binding of TMPyP4 to c-myc also induces a switch from a parallel conformation of c-myc to an
antiparallel conformation; this conformational switch has been shown to directly repress the
transcriptional activity and effectively inhibit tumor growth in vivo

[2a, 7].

Therefore, TMPyP4

has a potential to be developed as an effective chemotherapeutic agent, but its associated
toxicity is also a major concern [8].
In spite of being a great quadruplex-stabilizer and an effective telomerase inhibitor,
TMPyP4 has several drawbacks that would prevent it from being used therapeutically

[9].

TMPyP4 has an enhanced selectivity for duplex sequences and can efficiently stack in the
grooves of AT-rich sequences

[10].

An exquisite specificity is imperative to target the relatively

few quadruplex structures in the presence of an excess of double-stranded DNA in the genome
to attain the maximum effectiveness. Also, the broad spectra of porphyrin molecules are
known to produce photo-induced cytotoxicity due to their unique chemical structure, resulting
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in indiscriminant cell damage

[11].

TMPyP4 also binds preferentially to intermolecular

quadruplexes over the biologically relevant intramolecular quadruplexes. This intermolecular
binding has been demonstrated through the TMPyP4-induced formation of anaphase bridges
in sea urchins

[3b].

The porphyrin core of TMPyP4 is smaller (~10 Å) than the size of the G-

quartet (~13 Å) which results in the molecule binding with an offset from the center of the
terminal G-quartet

[2b, 4].

TMPyP4 only overlaps with two out of four of the guanines in the

terminal G-quartets. The binding of TMPyP4 to the quadruplex could potentially be improved
if it were modified to increase the contact surface between the compound and the G-quartets,
in order to maximize stacking interactions.

The acridine scaffold is of great interest since its DNA affinity and intercalative
properties make it an important pharmacophore for the design of antitumor drugs targeting
DNA

[1a, 1b, 2d, 12].

The global substitution on the heterocycle is crucial for a specific biological

activity and also selectivity for tumor cells. To increase the strength of DNA binding in an
effort to design more potent molecules, different strategies have been used either by adding
cationic substituents or by preparing dimeric molecules in which two intercalating structures
are linked together

[1b, 13].

Tri-substituted acridine, BRACO19 (Figure 5.1), and a pentacyclic

acridine, RHPS4 (Figure 5.1), selectively bind to the single-strand overhang of telomeric DNA,
induce the formation of G-quadruplex structures and inhibit cell growth and telomerase
activity at sub-cytotoxic doses

[14].

Both RHPS4 and BRACO19 cause chromosomal end-to-end

fusions and anaphase bridges, which are mitotic defects that typically result in nearly
immediate cellular senescence or apoptosis [15]. Furthermore, it has been discovered that RHPS4
also has the ability to act synergistically with several common cancer drugs such as Taxol,
Doxorubicin, and others [16]. However, some antagonism has also occurred with drugs such as
Cisplatin that have targets similar to RHPS4

[17].

In vivo studies with BRACO19 also reveal it

has positive combinatorial affects with Taxol in promoting cancer-cell senescence [18].
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However, pharmacokinetic studies have shown that BRACO-19 and its associated
compounds pose stability problems during the preparation of dosage forms, their storage and
after application

[19].

This limits its therapeutic applications, since any new drug candidate

should be submitted to thorough stability investigations prior to in vitro and in vivo tests. Cell
permeability studies with Caco-2 cells, a standard model for intestinal drug absorption,
indicate that BRACO-19 might not be suitable for oral administration

[20];

this was also

supported by tumor xenografts in mice that did not respond to an oral treatment with
BRACO19 [21]. The drawbacks associated with BRACO19 are partially attributed to its chemical
structure. It contains two basic pyrrolidine rings that are very likely to be protonated under
physiological conditions; that is, the molecule is positively charged. This results in good water
solubility but strongly decreases the interaction with hydrophobic structures like cell
membranes and significantly reduces the cellular uptake potential of BRACO19 [20].
Telomestatin (Figure 5.1), a natural product macrocycle with a larger ring system than
TMPyP4, has been shown to bind strongly to and stabilize intramolecular basket-type Gquadruplex structures

[3c, 22].

Studies have shown that Telomestatin binds to the ends of the

basket conformation of the intramolecular human telomeric sequence

[2c].

Telomestatin is also

able to induce and stabilize G-quadruplexes in the absence of added monovalent cations,
which is a unique characteristic among small molecules

[22].

Telomestatin is the strongest

telomerase inhibitor ever reported of any G-quadruplex interactive small molecule, with an
IC50 of ca. 0.005 µM [3c] as compared to TmPyP4, with an IC50 of ca 0.6 µM [3b]. Telomestatin is
also highly selective for quadruplex DNA over duplex DNA

[2c],

likely due to the close match

between its size, shape and macrocycle structure to that of the G-quartet. Nevertheless, being a
natural product, Telomestatin is very difficult to obtain, especially in quantities needed for
widespread therapeutic use. The complex ring system is difficult to synthesize, and at present
would be cost-prohibitive to produce commercially. Also, since Telomestatin is an uncharged

142

molecule, it has low solubility in water, which is not only undesirable from a therapeutic
standpoint, but also makes it difficult to study [23].
Approaches to platinum-based anti-cancer targeting have included conjugation of
known minor-groove DNA binding ligands and intercalators into discrete platinum complexes
as well as noncovalent dinuclear and trinuclear complexes

[24].

Platinum (II) complexes have

also been shown to interact with the human telomeric G-quadruplex

[25].

Terpyridine-

platinum (Pt-TPY) complexes selectively trap the adenine residues in the loops of the
antiparallel quadruplex conformation of the wild-type human telomeric DNA, and their
interaction being driven by the aromatic surface of the ligand
hybrid

(Pt-MPQ)

(Figure

5.1)

interacts

with

[26].

G-quadruplex

Platinum-quinacridine
DNA

via

a

dual

noncovalent/covalent binding mode, targeting preferentially the guanines constitutive of
external G-tetrads

[26-27].

However, the lack of specificity for a particular DNA sequence, an

inherent drawback observed in platinum chemistry, makes it very difficult to design platinumbased quadruplex-selective drugs [28].

The unique physicochemical properties of these ligands and its relation to the observed
cytotoxicity render important challenges in modifying these small molecules in an effective
way to circumvent any deleterious effects. Alternatively, new inroads can be made towards the
design and development of new classes of small molecules that can interact with target
sequences with enhanced selectivity and exhibit very little side effects. The compounds
mentioned above have the potential to be less harmful than current chemotherapies which
often affect all rapidly proliferating cells rather than just tumor cells. Even if none of these
small molecules prove to be directly applicable to clinical medicine, the insight these
compounds have provided into the function of telomerase and telomere structure will be
indispensable to the future of cancer therapeutics.
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The success of the agents described above to selectively target G-quadruplexes has led
to the design of different classes of potential quadruplex-interacting small molecules. The
interaction of several classes has been evaluated with several quadruplex forming motifs
(Figure 5.2) from the genome using surface plasmon resonance (SPR)-biosensor studies. The
selectivity of these different classes of ligands has also been evaluated with various duplex
forming sequences.

On the basis of modeling and comparative analysis of the binding of Coralyne, a
crescent-shaped molecule known to intercalate duplex and triplex DNA [29], and slightly larger
than typical DNA intercalators, a series of azacyanines (Figure 5.3) were designed and
synthesized by Dr. Nick Hud‟s group at Georgia Institute of Technology. The fused ring systems
of azacyanines were hypothesized to be marginally too large to intercalate a Watson-Crick
duplex but effectively stack at the terminal G-quartets. The synthesis of azacyanines has been
reported

[30],

and the relatively ease of synthesis of these molecules makes them ideal

candidates to study as quadruplex-interactive agents.

Naphthalene imides and diimides (ND) are a different class of compounds that are
shown to bind to duplex DNA

[31].

Several show in vivo anti-cancer activity and two

(Amonafide and Elinafide) have been evaluated in anti-cancer clinical trials in humans

[32].

A

series of disubstituted NDs have been previously reported as quadruplex-interactive ligands
but showed only low affinity

[1g].

Nevertheless, the planarity of the ND moiety would be an

interesting starting point for the development of more complex ligands and possibly possess
higher affinities for quadruplex motifs. The introduction of different side chains along the ND
core would produce a greater ligand diversity that may discriminate between different types of
G-quadruplexes and also with much higher selectivity over non-targeted sequences. Using this
design principle, Dr. Stephen Neidle‟s group at University of London developed a series of tri
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and tetra-substituted analogs of NDs (Figure 5.4), in hopes of improving binding and
selectivity. The recent advancements in efficient synthesis routes for this class of ligands also
makes them ideal candidates to study as quadruplex-interactive agents [33].

Substituted urea analogs with the diaryl functionality are another class of compounds
that is present in numerous clinically-approved therapeutic agents

[34].

The diaryl urea

skeleton is represented in many kinase inhibitors, for example, multi-targeted tyrosine kinase
inhibitors and inhibitors of insulin-like growth factor I receptor signaling

[35].

The diaryl

scaffold represents planar, non-polycyclic systems that deviate from the normal quadruplexinteracting ligands, which are exemplified by planar but polycyclic and fused-ring systems.
Structure-based design indicated that incorporation of additional phenyl-carbamoyl groups to
the 1, 3-diphenyl scaffold allows all four guanine bases of a G-tetrad to be targeted, with
addition of cationic side chains to enhance G-quadruplex potency, selectivity and aid solubility
of these ligands [36]. Using the simple and efficient “click-chemistry” approach [37], Dr. Stephen
Neidle‟s group designed a series of 1, 3-diphenyl derivatives with different ring systems and
varying side-chain lengths. These compounds were also evaluated for their quadruplex
recognition potential by using the very powerful biosensor-SPR methods.
5.2

MATERIALS AND METHODS

5.2.1 Sample Preparation
The 5′-biotin labeled oligonucleotide sequences Tel22, d[AGGG(TTAGGG)3]; Tel24,
d[TTGGG(TTAGGG)3A];
d[(AGGG)2CGCTGGGAGGAGGG];
d[(CGGG)2CGCGAGGGAGGGG];
d[CGAATTCGTTTTCGAATTCG];

Tel26,

c-kit1,

d[AAAGGG(TTAGGG)3AA];

bcl-2,

d[GGGCGCGGGAGGAATTGGGCGGG];

c-myc,
GC20,

d[(AGGGTGGGG)2A];
[CGCGCGCGTTTTCGCGCGCG];

c-kit2,

Dickerson,
(AT) 7,

d[CC(AT)7AGCCCCCGC(TA)7TGG] were purchased with HPLC purification and mass
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spectrometry characterization from Integrated DNA Technologies (Coralville, IA). Azacyanines
were synthesized by Dr. Nick Hud‟s group at Georgia Institute of Technology and are reported
in [30]. Naphthalene Diimides (NDs) and Diaryl Ureas were synthesized by Dr. Stephen Neidle‟s
group at University of London and are reported

[38].

Stock solutions containing 1 mM of each

compound were prepared in double distilled water and diluted to working concentrations
immediately before use with buffer.
5.2.2 Immobilization of DNA and Biosensor SPR Experiments
Biosensor SPR experiments were performed with a four-channel BIAcore 2000 optical
biosensor system (BIAcore, Inc.) and streptavidin-coated sensor chips. All DNA samples, for
either duplex- or quadruplex-binding experiments, were used as single strands to prevent
dissociation in the SPR flow system. The chips were prepared for use by conditioning with a
series of 1 min injections of 1 M NaCl in 50 mM NaOH followed by extensive washing with
buffer. 5'-Biotinylated DNA samples (25-50 nM) in HBS buffer were immobilized on the flow
cell surface by non-covalent capture as previously described

[39].

Three flow cells were used to

immobilize DNA samples, and any one of the flow cell was left blank as a control. Interaction
analysis was performed by using steady-state methods with multiple injections of increasing
compound concentrations over the immobilized DNA surface at 25 ºC. Biosensor experiments
were conducted in filtered, degassed HEPES buffer (10 mM HEPES, 100 mM KCl, 3 mM EDTA,
0.005 v/v of 10% P20 BIACORE surfactant, pH 7.3) at 25 °C. Flow cell 1 was left blank as a
reference, while flow cells 2-4 were immobilized with DNA on a streptavidin-derivatized gold
chip (SA chip from BIAcore) by manual injection of DNA stock solutions (flow rate of 1
µL/min) until the desired value of DNA response was obtained (350-400 RU). Compound
solutions were prepared in with the running buffer by serial dilutions from stock solution.
Typically, a series of different ligand concentrations (1 nM to 10 µM from 20 mM H2O stock)
were injected onto the chip (flow rate of 50 µL/min, 5-10 min) until a constant steady-state
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response was obtained followed by a dissociation period (buffer, 10 min). After every cycle, the
chip surface was regenerated (20 s injection of 10 mM glycine solution, pH 2.0) followed by
multiple buffer injections.

The instrument response (RU) in the steady-state region is proportional to the amount
of bound drug and was typically determined by linear averaging over a 10-20 s or longer time
span, depending on the length of the steady-state plateau. The predicted maximum response
per bound compound in the steady-state region (RUmax) was determined from the DNA
molecular weight, the amount of DNA on the flow cell, the compound molecular weight, and
the refractive index gradient ratio of the compound and DNA, as previously described

[40].

In

most of the cases, the observed RU values at high concentrations were greater than RUmax,
pointing to more than one binding site in these DNA sequences. The number of binding sites
was estimated by fitting plots of RU versus Cfree. These methods can also be used to determine
an empirical RUmax value. The RUmax value is required to convert the observed response
(RU) to the standard binding parameter r (moles of drug bound per moles of DNA hairpin)

r = RU/RUmax

which is useful for comparison of a compound binding to different DNAs. To obtain the
binding constants, the data were evaluated with different interaction models to obtain an
optimal fit using BIAevaluation (BIAcore Inc.) and Kaleidagraph (Synergy Software) software
for nonlinear least-squares optimization of the binding parameters:
One site:

r = (K1Cfree)/(1 + K1Cfree)

Two site:

r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2)

Three site:

r = (K1Cfree + 2K1K2Cfree2 + 3K1K2K3Cfree3)/(1 + K1Cfree + K1K2Cfree2 +
K1K2K3Cfree3)
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where K1, K2 and K3 are equilibrium constants for three types of binding sites and Cfree
is the concentration of the compound in equilibrium with the complex and is fixed by the
concentration in the flow solution.

5.3

RESULTS AND DISCUSSION

5.3.1 Evaluation of Azacyanines
SPR was used to quantitatively evaluate the interaction between azacyanines (Figure
5.3) and a series of quadruplex-forming human telomeric DNA sequences (Tel24 and Tel26,
Materials and Methods) in order to gain insight into the selectivity of this class of ligands.
Tel24 (Figure 5.2A) and Tel26 (Figure 5.2A) have been shown to predominantly exist as a
hybrid-1 quadruplex conformation based on NMR structural characterization by independent
laboratories [41]. The three –TTA– loops between the guanine stretches of the hybrid-1 scaffold
are primarily oriented in 5‟-diagonal/lateral/lateral-3‟ manner, and the bases involved in the
tetrad formation retain the same glycosidic conformation and loop orientation in both the
sequences. However, the capping bases at the 5‟ and the 3‟-ends of Tel24 and Tel26 are very
different. Therefore compounds that can interact at the ends of either Tel24 or Tel26
conformation can have different binding affinities due to the structural variability at the ends
of these two sequences. These two oligonucleotides were immobilized in different flow cells on
the same sensor chip, and a range of compound concentrations were injected to monitor the
interactions with DNA. Suitable blank control injections with running buffer (HEPES buffer
containing 80 mM KCl at pH 7.4) were also performed, and the resulting sensorgrams were
subtracted from the compound sensorgrams to obtain the final concentration-dependent
graphs for azacyanines. The binding ratio arises from the RU as saturation of binding sites is
approached in SPR experiments. During SPR titration, the increase of RU values is directly
proportional to the amount of drug bound to DNA molecules immobilized on the sensor chip.
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The plot of RU versus the unbound concentration of each of the compounds was fitted to a
two-site binding model (Materials and Methods) and the binding constants were determined
by averaging the SPR response in the steady-state region. The compounds all showed rapid
association and dissociation kinetics with a steady-state plateau that is expected from their
planar structure with small substituents. The SPR response versus free compound
concentration curves were fit well for both DNA structures with one tight binding site and one
or two approximately degenerate, much weaker, secondary sites for both sequences. The
sensorgrams and binding plots for the concentration-dependent binding (two-site model,
Materials and Methods) of the azacyanines with Tel24, Tel26 and duplex DNA are shown in
Figures 5.8-5.10. All ligands tested exhibited a similar, strong primary association constant
(Table 5.1) with both DNAs, suggesting that G-quadruplex binding is general to this class of
compounds. However, Aza3 (Tel24, 1.34 x 106 M-1; Tel26, 1.74 x 106 M-1) and Aza4 (Tel24,
1.00 x 106 M-1; Tel26, 1.22 x 106 M-1) showed slightly higher affinities for Tel26 conformer
than Tel24 (Table 5.1); whereas, Aza5 (Tel24, 2.68 x 106 M-1; Tel26, 2.11 x 106 M-1)
exhibited a slightly higher affinity for Tel24 conformer than Tel26. The thermal melting
studies (data not shown) of Tel24 and Tel26 have shown that Tel24 is a much more stable
conformer than Tel26. The hybrid-fold of Tel26 as determined by NMR reveals the presence of
a novel A3·A9·A21 capping structure and covers the top G-quartet

[41a].

NMR structure of

Tel24 conformation shows the formation of an A·T basepair by T1 and A20 and a reverse A·T
basepair by T13 and A24 and the 5‟ and the 3‟ ends of this conformation, respectively

[41b].

This difference in the end structures between Tel24 and Tel26 might have an indirect effect on
the ligand stacking and the observed differences in the binding affinities. Aza5 also exhibited 2
times stronger binding to both the sequences than Aza3 or Aza4 (Table 5.1). This can be due to
the presence of additional methoxy groups on both ends of the Aza5, potentially contributing
towards more favorable hydrophobic interactions with the terminal G-quartet. Interestingly,
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Aza4 showed slightly weaker affinities for both the sequences compared to Aza3. This can be
due to a change in the stacking orientation of the molecule on the terminal G-quartet due to
the replacement of nitrogen by sulfur in Aza4. However, the small difference in the affinities of
Aza3 and Aza4 is not significant enough to make any valid arguments.

NMR studies of Aza3 with Tel24 sequence (conducted by Aaron Engelhart in Dr. Nick
Hud‟s lab at Georgia Institute of Technology) revealed that the ligand was in intermediate
exchange on the NMR timescale

[30].

A number of aromatic resonances broaden in a site-

specific fashion, consistent with the local chemical environment of various residues being
perturbed differentially by ligand binding. Interestingly, broadening occurs for both the
aromatic residues of the external G-tetrads (G3, G9, G17 and G21 of 5‟-tetrad and G4, G15
and G23 of 3‟-tetrad) and both A·T base pairs, providing support for a mixed intercalationexterior stacking mode of binding (i.e., between the exterior tetrads and the capping A·T base
pairs of the loops). The primary strong binding site obtained from SPR studies is in excellent
agreement with the NMR results and the observation of a weak secondary site also agrees with
the moderate NOE effects at the 5' end of the Tel24 conformation

[30].

A preliminary model

constructed based on the SPR and NMR data of Aza3 with Tel24 shows that compound
preferentially stacking on the terminal tetrad at the 3‟-end (Figure 5.6B).

SPR experiments were also performed with intramolecular duplex sequences
(Dickerson, GC20, (AT)7, Materials and Methods) with different groove widths to determine
the selectivity of these compounds. The duplex sequences with varying groove-widths were
chosen to eliminate any bias towards a particular groove dimension and, also, these strands
contain a variety of sites known to favor various modes of ligand binding in duplex DNA,
including A-tracts and both pyrimidine–purine steps. The azacyanine ligands bound poorly to
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all duplex DNA strands investigated and the SPR data could not be fit to an exponential binding
curve (Figure 5.8-5.10). The upper limit for the KA in each Aza3– and Aza4–dsDNA (double
stranded DNA) pair is in the range of 104 M-1. Remarkably, no Aza5–duplex interaction was
detected under the SPR conditions used (Figure 5.10, top right). Fluorescence binding data
from Dr. Nick Hud‟s group also confirm that these ligands exhibit marked selectivity for
quadruplex over duplex-DNA and over 100-fold in the case of Aza5

[30].

This group of

compounds is clearly quite promising for development as selective quadruplex targeting
agents.

5.3.2 Evaluation of Naphthalene Diimides
A series of di- (2ND), tri- (3ND) and tetra-substituted (4ND) analogs of naphthalene
diimides (Figure 5.4) with varying lengths of side-chains and end groups were synthesized in
Dr. Stephen Neidle‟s laboratory. SPR was used to quantitatively evaluate the interaction
between naphthalene diimides with a wide range of oncogenic and telomeric DNA sequences
(Materials and Methods) in order to gain insight into the selectivity of this class of ligands. The
conformational diversity exhibited by the various quadruplex-forming sequences (Figure 5.2)
makes them very interesting to characterize their ligand binding properties. Table 5.2 lists the
equilibrium binding constants of a series of naphthalene diimides with several sequences. The
binding constants were obtained using the procedure described in 5.2.2 and 5.3.1. From the
Table 5.2, it is readily apparent that all the NDs exhibit very little selectivity for duplex DNA the first requirement in developing ligands - to have virtually zero affinity for non-target
sequences. The response exhibited in SPR with increasing concentrations of the ligands were
very low (<5 RU) to obtain reliable binding data for interaction with duplex DNA
(sensorgrams for duplex not shown).
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SPR results of ND analogs with several quadruplex-forming sequences show that they
can selectively distinguish between quadruplex conformations and, particularly, with high
affinity for Tel22, c-kit1 and c-kit2 sequences (Figure 5.11-5.16, sensorgrams for 2ND01 not
included). Due to poor solubility of 3ND07 under SPR conditions, reliable sensorgrams could
not be obtained. The wild-type human telomeric sequence Tel22 is known to adopt multiple
conformations under physiological conditions of K+, with hybrid-1 and hybrid-2 (Figure 5.2A, B) as the major conformers

[41-42].

Exposed terminal quartets and the three accessible

grooves of the hybrid conformation should make it a relatively easy target for ligand
recognition. The oncogenic promoter quadruplex sequences of c-kit1 and c-kit2 folds into a
parallel topology also with exposed terminal quartets and accessible grooves [43] (Figure 5.2-C).
This scaffold can also be exploited for selective targeting with small molecules. SPR results
show all the compounds binding to the aforementioned quadruplex motifs, but significant
differences can be seen in the sensorgrams (Figure 5.11-5.16). The most striking is in the
dissociation rate, which is much slower for 4-ND and 3-ND analogs than for 2-ND (Table 5.2,
Tel22, kd). Because of surface absorption of the compounds in the initial period of injection, it
is not possible to quantitatively determine the association kinetics constants. For the
dissociation reaction, however, it is clear that the disubstituted ND dissociates in the first few
seconds of buffer flow while the apparent half-life for dissociation (1/kd) of the tetrasubstituted ND is approximately 35 s (Table 5.2, Tel22, kd). The 3ND03 (Figure 5.16, Table
5.2, kd = 0.046 s-1) analog has dissociation rates that are more similar to the 4-NDs. The
sensorgrams for all compounds reach a steady-state plateau between 100-200 s after initiation
of compound injection (Figure 5.11-5.16). The steady-state RU values were determined by
averaging in the steady state region and were plotted versus the free compound concentration
in the flow solution for determination of the equilibrium binding constants (Figure 5.11-5.16:
bottom left, bottom right panels). Analysis of the binding of ND analogs shows a single very
strong binding site and a weaker secondary site with a K ca. 50x weaker. 4ND analogs show
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much higher affinity than 3ND and 2ND counterparts. The binding of 2ND01 is almost 10x
lower with K= 4.5 x 106 M-1 and a still weaker second binding site. Interestingly, all the
compounds exhibited higher affinity for Tel22 conformation than the Tel24 sequence (Table
5.2). Tel24 is shown to predominantly fold into a hybrid-1 conformation with capping basepairs at the terminal quartets. The capping units might have a negative effect on the ligand
stacking at the terminal quartet resulting in lower binding affinities. It is also readily apparent
from equilibrium binding constants (Table 5.2) that all the ND analogs have very little
selectivity towards bcl-2 sequence. NMR structural studies have shown that bcl-2 sequence
folds into a very stable hybrid-2 type quadruplex conformation

[44]

(Figure 5.2, D). The

hybrid-2 core is usually comprised of three accessible grooves of varying geometries, but the
terminal tetrads are capped by loop bases that can further stabilize the conformation. Endstacking ligands typically require the terminal tetrads to be completely exposed in order to
have a maximum stacking effect, and any “blockage” would adversely affect their interaction
at the ends. In this bcl-2 sequence the terminal quartets are flanked by very stable capping
structures (A10·T15 base-pair at 5‟-end, and a stable G·C cap at the 3‟-end) that would
effectively prevent any ligand binding at the ends. Moreover, even with accessible grooves, ND
analogs exhibited very weak to zero binding (sensorgrams not shown with bcl-2 sequence) for
this conformation suggesting that the sidechains might be too bulky to effectively recognize the
grooves. All the ND analogs except 4NDO1 (Table 5.2, K=8.9 x 106 M-1) exhibited very weak
response (< 15 RU) even for some of the highest ligand concentrations (1 µM - 10 µM) to
accurately determine the binding constants and, in most cases, the binding constants were less
than 105 M-1.

SPR results of ND compounds show that the binding constants observed for the c-kit1
and c-kit2 are among the strongest observed for this quadruplex architecture

[38b]

(Table 5.2).
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The proto-oncogene promoter quadruplex forming sequences of c-kit1 and c-kit2 are shown
to fold into a parallel conformation

[43]

with accessible grooves and exposed terminal tetrads

(Figure 5.2-C). The tetra-substituted analogs displayed higher affinities for c-kit1 and c-kit2
than the tri-substituted and di-substituted counterparts (Table 5.2). The binding of 2ND01 is
almost 10x lower for c-kit2 in comparison with 4ND analogs, and exhibited virtually no
binding for c-kit1 sequence (sensorgrams not shown). Among all the tetra-substituted analogs,
4ND02 displayed the highest binding (c-kit1: K=34.3 x 106 M-1, c-kit2: K=47.3 x 106 M-1).
However, other tetra-substituted analogs also displayed high binding affinities for these two
sequences. Therefore, a clear correlation between the length of the alkylamino side-chain and
the binding affinities could not be established. However, tetra-substituted analogs generally
displayed an enhanced affinity relative to that of the di- or tri-substituted NDs. Interestingly,
SPR results also show the ND analogs with very little selectivity for c-myc quadruplex sequence
(Table 5.2).The 19mer c-myc also folds into a very stable parallel quadruplex topology as
shown from NMR studies [7, 45]. In this parallel topology (Figure 5.2, E), three of the grooves are
effectively blocked by the diagonally running loop bases, but the terminal tetrads are
completely exposed due to the absence of any capping structures. End-stacking ligands should
effectively recognize the terminal tetrads due to the lack of any steric hindrance from the
capping bases. Surprisingly, this was not observed with the ND analogs with the c-myc
sequence. A plausible explanation for this can be the long alkylamino sidechains tethered with
ring systems in the end being sterically hindered by the loop bases running along the
quadruplex grooves.

FRET thermal melting studies of naphthalene diimides were performed on selective
quadruplex systems and a duplex sequence by Dr. Stephen Neidle‟s group. The low affinity of
NDs for duplex DNA is clearly evident from the melting data (Table 5.3). All the NDs exhibited
very small increase in Tm upon complex formation with duplex DNA except for 3ND03 (∆Tm
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~ 11.5°C) and 4ND02 (∆Tm ~ 7.5°C). Systematic study of several other ND analogs has
shown that tri-substituted analogs showed slightly higher ∆Tm for duplex DNA than the tetrasubstituted or di-substituted analogs, probably because of steric reasons

[38b].

Thermal melting

analyses with various quadruplex systems show the ligands possess the highest stabilization
potential for the quadruplex systems. The tetra-substituted analogs showed highest ∆Tm for
both oncogenic and telomeric quadruplex conformations than the tri- or di-substituted
counterparts. 2ND01 showed very small change in ∆Tm for the different quadruplex systems
(Tel22-5.25; c-kit1-2.5; c-kit2-7.75), further validating the importance of increasing number
of sidechains in NDs contributing to maximize the potential interaction with the loops or the
grooves. These results are also in excellent correlation with the SPR studies for the high
selectivity exhibited by tetra-substituted analogs for the quadruplex systems. Interestingly,
4ND09 showed high selectivity for Tel22 (∆Tm ~27.8°C) than c-kit1 (∆Tm ~0°C) and c-kit2
(∆Tm ~4.25°C) sequences. It is important to design highly-tuned ligands to discriminate
between almost identical micro-environments of different target sequences, such as the ones
exhibited by terminal tetrads of Tel22 and c-kit1/2 conformations, and these compounds
illustrate one promising route for such design.

Figure 5.7-A shows a preliminary model of 4ND08 bound at the 3‟-end of the human
telomeric quadruplex model system after 5 ns of molecular dynamics simulation performed at
Dr. Stephen Neidle‟s lab. The naphthalene core of 4ND08 is optimally stacked on top of the
terminal tetrad with the four tethered alkyl-amino side chains making favorable hydrophobic
interactions with the loops or the grooves of the quadruplex system. These results are highly
encouraging because the ND platform can be further exploited to develop improved class of
ligands that can exhibit virtually zero affinity for the plethora of duplexes in the genome and
with greater selectivity for specific quadruplex systems.
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5.3.3 Evaluation of Diaryl Ureas
Several modifications were performed along the phenyl moieties of the 1,2-diphenyl
scaffold (Figure 5.5) by Dr. Stephen Neidle‟s group to evaluate the effect of the side chains and
ring systems on quadruplex recognition. SPR was used to quantitatively characterize the
interaction of these ligands against quadruplex sequences originating from the human
telomere (Tel22), as well as from the c-kit1, c-kit2 and c-myc proto-oncogenes. G-quadruplex
selectivity was further assessed using the Dickerson duplex sequence. Several of the
compounds with a triazole linker (Figure 5.2: WD419, WD422, WD423 and WD442) at the
phenyl rings exhibited poor solubility even at modest concentrations required for SPR, as a
result, these compounds could not be evaluated. In terms of G-quadruplex affinity, SPR
produced equilibrium binding constants which fit a single strong binding-site model with a
significantly weaker secondary binding observed in most cases (Figures 5.17-5.19, Table 5.4).
The SPR results for quadruplex sequences indicate the strongest binding for each compound is
to c-kit2, with c-myc, c-kit1 and Tel22 having weaker and more similar affinities. The SPR
results indicate a distinct order of selectivity with c-kit2 > c-myc > c-kit1 > Tel22, with the
interaction of ligand WD313 being particularly enhanced for the c-myc quadruplex (K=14.1
x 106 M-1), which also has slower dissociation kinetics. Interestingly, none of the compounds
exhibited any binding to Tel24 or bcl-2 quadruplex-forming sequences (sensorgrams not
shown), also observed in the case of naphthalene diimides (Section 5.3.2). The side-chain
length dependence of G-quadruplex interaction was also assessed by SPR measurements. SPR
demonstrated that the n = 1 side chain of WD313 was optimal for general G-quadruplex DNA
interaction over WD308 (n = 2) and WD263 (n = 3) (Table 5.4). SPR results further showed
the G-quadruplex:duplex DNA selectivity is significantly enhanced, with no duplex DNA
interaction detected (K = < 1 x 104) under the SPR experimental conditions used. This
represents at least 50-100 fold selectivity for G-quadruplex vs. duplex DNA.
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FRET based thermal melting studies were performed by Dr. Stephen Neidle‟s group to
assess the G-quadruplex stabilization and selectivity of the ligand library (Table 5.5). The ΔTm
values for the ligands showed that compounds with n = 1 side chain are less effective
quadruplex stabilizers than the n = 2/3 analogues, which show approximately equivalent
behavior. The FRET melting data are directly proportional to side-chain length, a trend which
is not consistent with the results from the SPR assay. The results are for different temperatures
and it may be that in this instance affinity and thermal stability cannot be directly compared.
For the Tel22, c-kit-1, c-kit-2 and duplex DNAs where FRET and SPR results can be compared,
however, there is good agreement (Table 5.4 and 5.5). Also, FRET-based assessment of the
interactions of these ligands with the c-myc G-quadruplex was not possible, due to the
exceptional stability of the c-myc quadruplex fold. The best agreement observed between the
FRET and SPR assays is for G-quadruplex vs. duplex DNA selectivity.

5.4

CONCLUSION
Azacyanines, naphthalene diimides and diaryl urea analogs have been well

characterized in this study using the biosensor technique. The high selectivity exhibited by
these classes of ligands over duplex-DNA, and also the selectivity exhibited between
quadruplex conformations makes them an interesting set of ligands to further develop as
potential therapeutic agents for a quadruplex-mediated mechanism of controlling biochemical
processes. The planar portion of DNA-directed drugs subtly modulates their ability to
recognize the terminal quadruplex structural arrangements. Quadruplex end-stacking ligands,
in most cases, have displayed better binding affinities when tethered with long side-chains. The
side chains have potential to make additional interactions with the grooves, loops or the
backbone of the quadruplex. Aza5, with a methoxy substituent, displayed slightly better
affinity than Aza3 or Aza4. Therefore, potential opportunities exist where the tethered side-
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chain moieties of azacyanines could be manipulated to increase their affinity for quadruplexes.
The extended, fused aromatic ring systems of naphthalene diimides have shown to have
affinities very similar to well known G-quadruplex binders structurally related to acridines or
TMPyP4. The tetra-substituted analogs displayed better quadruplex affinities than the tri- or
di-substituted counterparts. The additional side-chains of the 4NDs potentially engage in
additional interactions with various structural components of quadruplex systems. The
synthetic ease of naphthalene diimides can facilitate studying more systematic substitutions
along the planar ring systems, coupled with the opportunities to modulate side-chains for
better quadruplex affinities. Diarylurea-based scaffolds, which constitute non-polycyclic, nonfused ring systems, have been shown to have significant selectivity for parallel-type
quadruplex systems, with an almost 20-fold weaker selectivity for hybrid-type quadruplex
systems. The non-polycyclic ring systems are perhaps more optimized to recognize terminal
quartets of parallel quadruplex architecture. Therefore, diarylurea-based compounds can be
finely-tuned to discriminate between very similar quadruplex architectures with subtle
structural differences.

The number of quadruplex-interactive ligands has increased dramatically in the past
few years; however, there has been very limited success in effectively converting these ligands
into potential therapeutic agents. This is partially due to the lack of a better understanding of
quadruplex-ligand interactions at the molecular level. In addition, the „„off-target‟‟ effects of
these compounds could also contribute to the variations of cellular effects. Systematic
modification of ligands coupled with better methodologies to characterize quadruplex-ligand
complexes will significantly augment the current knowledge towards developing more potent
small molecules.
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Figure 5.1: Structures of (A) TMPyP4, (B) Telomestatin, (C) RHPS4, (D) Pt-MPQ, (E) BRACO19, and (F) G-quartet with bound cation shown as a blue circle.
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Figure 5.2: Folding patterns of different quadruplex-forming motifs used in SPR-Biosensor
studies.

(A) Tel24: Hybrid1 [41b], (B) Tel26: Hybrid1 [41a], (C) c-kit1/c-kit2: Parallel [43], (D) bcl-2:
Hybrid2 [44b], and (E) c-myc: Parallel [5b, 7, 45]. All the images are directly obtained from their
published journals without further permission.
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Aza3

Aza4

Aza5

Figure 5.3: Chemical Structures of Azacyanines.
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4ND01

4ND02

4ND08

4ND03

2ND01

4ND09

3ND03

3ND07

Figure 5.4: Chemical Structures of Naphthalene Diimides.
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WD313

WD308

WD442

WD263

WD422

WD419

WD423

Figure 5.5: Chemical Structures of Diaryl Ureas.

Compounds highlighted could not be evaluated with SPR due to solubility issues.
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(A)
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(B)

Figure 5.6: Interaction of Azacyanine-3 with Tel24 quadruplex motif.

(A) Aromatic region of 1H-NMR spectra of Tel24 in the presence of Aza3. (B) A schematic
representation of Aza3 bound Tel24 based on preliminary 1H-NMR studies [30].
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Figure 5.7: Molecular models of ligands complexed with a parallel topology of human
telomeric quadruplex conformation. (A) 4ND08 (B) WD313 (C) WD308 (D) WD263.
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Figure 5.8: SPR sensorgrams for binding of Aza3 to the immobilized G-quadruplexes formed by Tel26 (top left), Tel24 (top middle)
and GC(20) duplex (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in Aza3 concentration from 100 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.9: SPR sensorgrams for binding of Aza4 to the immobilized G-quadruplexes formed by Tel26 (top left), Tel24 (top middle)
and GC(20) duplex (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in Aza4 concentration from 100 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.10: SPR sensorgrams for binding of Aza5 to the immobilized G-quadruplexes formed by Tel26 (top left), Tel24 (top
middle) and GC(20) duplex (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in Aza5 concentration from 100 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.11: SPR sensorgrams for binding of 4ND01 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 4ND01 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.12: SPR sensorgrams for binding of 4ND02 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 4ND02 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.

170

70
4ND03_ckit-1

4ND03_Tel22

4ND03_ckit-2

60
50

RU

40
30
20
10
0
0

80

160 240 320
Time (sec)

400

480

0

80

160

70
Tel22
TwoSite
ckit-1
TwoSite
ckit-2
TwoSite

60
50

4ND03

RU

40

K1
K2
RU
Chisq
R

240 320
Time (sec)

400

10
0
0

2 10 -7 4 10 -7 6 10 -7 8 10-7 1 10-6
Conc (M)

0

Tel22 : Two Site
Value
Error
1.7397e+7
4.1755e+6
9.1459e+5
8.5395e+5
39.439
7.2506
8.0669
NA
0.99928
NA

30
20

480

K1
K2
RU
Chisq
R

80

K1
K2
RU
Chisq
R

160 240 320
Time (sec)

400

480

ckit-1 : Two site
Value
Error
1.4288e+7
7.5323e+6
8.118e+5
1.6826e+6
45.116
18.85
32.083
NA
0.99766
NA

ckit-2 : Two Site
Value
Error
1.889e+7
8.9048e+6
8.961e+5
1.5856e+6
39.247
13.479
33.201
NA
0.99705
NA

Figure 5.13: SPR sensorgrams for binding of 4ND03 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 4ND03 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.14: SPR sensorgrams for binding of 4ND08 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 4ND08 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.15: SPR sensorgrams for binding of 4ND09 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 4ND09 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.16: SPR sensorgrams for binding of 3ND03 to the immobilized G-quadruplexes formed by Tel22 (top left), ckit-1 (top
middle) and ckit-2 (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in 3ND03 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.17: SPR sensorgrams for binding of WD263 to the immobilized G-quadruplexes formed by c-myc (top left), Tel22 (top
middle) and Dickerson (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in WD263 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.

175
60

WD308_c-myc

WD308_Tel22

WD308_Dickerson

50

RU

40
30
20
10
0
0

200

400
600
800
Time (seconds)

1000 0

200

400
600
Time (seconds)

800

1000
0

200

400
600
800
Time (seconds)

1000

60
Dickerson
Tel22
c-myc
Two Site

50

WD308

RU

40
30
20

c-myc: Two Site (RU=45)
Value
Error
K1 3.7352e+6 2.7054e+5
K2 4.4138e+5
52571
Chisq
27.559
NA
R
0.9971
NA

10
0
0

2 10-7 4 10-7 6 10-7 8 10-7 1 10-6
Conc (M)

Figure 5.18: SPR sensorgrams for binding of WD308 to the immobilized G-quadruplexes formed by c-myc (top left), Tel22 (top
middle) and Dickerson (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in WD308 concentration from 10 nM for the bottom curve to 1 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Figure 5.19: SPR sensorgrams for binding of WD313 to the immobilized G-quadruplexes formed by c-myc (top left), Tel22 (top
middle) and Dickerson (top right) in HEPES buffer containing 80 mM KCl at 25 °C.

The quadruplex curves range in WD313 concentration from 10 nM for the bottom curve to 10 µM for the top curve. Steady-state
binding plots (bottom left) fit to a two-site model (Materials and Methods). The concentration values are for unbound compound
concentration in the flow solution. Binding parameters (bottom right) obtained by fitting to a two-site model.
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Table 5.1: Equilibrium binding constants determined by SPR for azacyanines with Tel26 and
Tel24.
Compound

Tel26

Tel24

Aza3

1.74

1.34

Aza4

1.22

1.00

Aza5

2.11

2.68

a

Binding Constants (K x 106 M-1) are for the single strong binding site. In addition to the K1
value shown for the single strong binding site, all compounds have one or two much weaker
binding sites with K = 2 x 105 ±1 x 105 M-1
b

Binding constants for the duplex sequences were not determined because of their very low
steady-state response even for high compound concentrations.
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Table 5.2: Equilibrium binding constantsa determined by SPR for Naphthalene Diimides with
several quadruplex-forming motifs.
Compound

AATTb

Tel22

4ND01

---

4ND02

bcl2-H2 c-myc c-kit1

c-kit2

Tel24-H1

21.1

Tel22
kd (s-1)
0.023

11.9

8.90

Weak

16.8

16.6

---

15.3

0.099

1.13

Weak

Weak

34.3

47.3

4ND03

---

17.4

0.019

12.7

Weak

Weak

14.3

18.9

4ND08

---

12.6

0.036

Weak

Weak

Weak

11.0

4.33

4ND09

---

21.3

0.077

0.69

Weak

Weak

22.7

15.4

3ND03

---

15.7

0.046

3.32

Weak

Weak

13.4

4.09

3ND07c

---

---

---

---

---

---

---

---

2ND01

---

4.00

---d

Weak

Weak

Weak

Weak

1.94

a

Binding Constants (K x 106 M-1) are for the single strong binding site. In addition to the K1
value shown for the single strong binding site, all compounds have one or two much weaker
binding sites with K2 ~ 105 M-1
b

Binding Constants for duplex sequence were too low to be determined using the same
experimental procedures due to very low response units.
c

Reliable sensorgrams could not be obtained due to the poor solubility of the compound even
at SPR concentrations.
d

Too fast to determine dissociation constant.

Weak: Response units were too low (< 15 units) even at 1 µM ligand concentration to
accurately determine the binding constants and in most cases the binding constants were in the
range of low 105 M-1
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Table 5.3: FRET melting studiesa,b of selective intramolecular quadruplex-forming sequencesc
and a duplex sequence with naphthalene diimides.

a

Compound

Duplexd

Tel22

c-kit1

c-kit2

ND01

4.50

33.2

29.8

36.5

4ND02

7.50

28.0

25.3

29.8

4ND03

4.25

35.2

33.8

36.3

4ND08

2.00

34.5

31.5

39.3

4ND09

0.25

27.8

0.00

4.25

3ND03

11.5

26.2

24.5

28.5

3ND07

-0.50

10.5

0.75

4.75

2ND01

2.75

5.25

2.50

7.75

Performed by members from Dr. Stephen Neidle‟s group at University of London.

b

∆Tm values (complex – free DNA, in °C) are estimated as the mid-points of the melting
transition and the values listed are the mean of two determinations.
c, d

Ligand free single-strand concentration in this study is 0.5 µM.
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Table 5.4: Equilibrium binding constantsa determined by SPR for Diaryl Ureas with several
quadruplex-forming motifs.
Compound

AATTb

Tel22

Tel24-H1

bcl2-H2

c-myc

c-kit1

c-kit2

WD263

---

0.40

NB

NB

1.90

1.22

3.87

WD308

---

1.10

Weak

Weak

3.73

2.36

7.61

WD313

---

1.47

Weak

Weak

14.5

2.10

9.66

WD419c

---

---

---

---

---

---

---

WD422c

---

---

---

---

---

---

---

WD423c

---

---

---

---

---

---

---

WD442c

---

---

---

---

---

---

---

a

Binding constants (K x 106 M-1) are for the single strong binding site. In addition to the K1
value shown for the single strong binding site, all compounds have one or two much weaker
binding sites with K2 ~ 105 M-1 or lower in some cases.
b

Binding Constants for duplex sequence were too low to be determined using the same
experimental procedures due to very low response units.
c

Reliable sensorgrams could not be obtained due to the poor solubility of the compound.

Weak: Response units were too low (< 15 units) even at 1 µM ligand concentration to
accurately determine the binding constants and in most cases the binding constants were less
than 105
NB: No binding was detected due to a very low response (< 5 units)
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Table 5.5: FRET melting studiesa,b of selective intramolecular quadruplex-forming sequencesc
and a duplex sequence with diaryl ureas.

a

Compound

Duplexd

Quadruplexe

c-kit1

c-kit2

WD263

0.00

12.0

10.1

17.1

WD308

0.40

13.5

10.2

18.7

WD313

0.00

7.90

3.60

11.3

Performed by members from Dr. Stephen Neidle‟s group at University of London.

b

∆Tm values (complex – free DNA, in °C) are estimated as the mid-points of the melting
transition and the values listed are the mean of two determinations.
c, d
e

Ligand free single-strand concentration in this study is 0.5 µM.

F21T, d[G3(T2AG3)3]
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6

NMR STRUCTURAL CHARACTERIZATION OF A NOVEL HETEROCYCLIC DIAMIDINE
THAT RECOGNIZES A UNIQUE GC/AT MOTIF AS AN ANTIPARALLEL STACKED DIMER

6.1

INTRODUCTION
Small molecules have proven to be extremely important to researchers to explore

biochemical processes at the cellular and molecular levels, both in vitro and in vivo. Such
molecules have also been proven to be valuable for treating diseases, and most medicines
marketed today are from this class. Over the past two decades, research on small molecules
acting on nucleic acids has not only led to therapeutically useful drugs but also provided an
invaluable source of structural and biological information on nucleic acids. DNA is an
intracellular target of many anticancer drugs, and the interaction between small molecules and
DNA has been shown to cause DNA damage in cancer cells by inhibiting their growth and
ultimately resulting in apoptosis. DNA binding anticancer drugs that can interact with DNA
can be categorized into compounds that bind non-covalently and those that bind covalently,
and it is interesting that within both categories some compounds can further bind to DNA
sequences selectively. The effectiveness of these compounds in potential anti-parasitic and
anti-cancer therapy is closely related to the mechanisms by which they induce cell death. In
some cases the interaction between drugs and DNA results in DNA structural distortion or
damage that inhibits replication or transcription[1]. Another possible mechanism is the selective
binding to abundant stretches of –AT– or –GC– repeat sequences that are essential for normal
chromosome metabolism or gene transcription

[2].

In particular, some compounds could

regulate nucleic acid function by targeting specific sequences such as particular genes or their
RNA products, or promoters for gene transcription or translation [3], and can be used to target
specific DNA sequences acting as important regulation factor in gene expression.
Characterization of the sequence specificity of drug–DNA interactions is essential for
understanding the drug mechanism of action. By elucidating the molecular determinants of
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that specificity, it will be possible to develop principles for the design of new drugs with
enhanced anticancer potency.
A number of natural and synthetic compounds which bind to the minor groove of DNA
are becoming an important class of tools with which to study ligand–DNA interactions, and
increasingly are also of interest as potential anticancer drugs[4]. Polyamides containing Nmethylpyrrole (Py) and N-methylimidazole (Im) amino acids bind to predetermined sequences
in the minor groove of DNA with affinities and specificities comparable to naturally occurring
DNA binding proteins[5]. Distamycin-A and netropsin, generally referred to as “shapeselective” binders, preferentially bind to the narrower minor groove of AT-rich sequences, and
the absence of the protruding 2-amino group of guanine based on the shape-fit for
maximizing stabilizing van der Waal's contacts[6]. Hydrogen bonding between the groove floor
base pairs and the linking amides, and electrostatic stabilizing interactions with the protonated
amines are primary contributors to the overall stability of the drug/DNA complex[7]. Hydrogen
bonds, van der Waal contacts, and electrostatic interactions between the oligopeptidic pyrrolecarbamoyl frame that ends with an amidine moiety and the DNA double helix result in secure
DNA minor groove binding with AT-rich preference. TATA box binding protein (TBP), a
component of the basal transcriptional machinery for RNA polymerase II transcribed genes,
binds to AT-rich target DNA sequence to promote the transcription, which could be inhibited
by some compounds that bind preferentially to AT sequences such as distamycin-A, netropsin,
Hoechst 33258, and Py-Im polyamides[8].
Aromatic diamidines, such as DAPI, berenil, pentamidine, and related compounds, were
discovered some years ago to have excellent activity against an array of infectious diseases
from Pneumocystis carinii pneumonia to trypanosomiasis[9]. All of the biologically active
aromatic diamidines studied to date have been found to bind strongly to AT-rich sequences in
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the minor groove of DNA, and it is clear that there is a correlation between DNA binding for
many compounds and the antiparasitic biological activities[10]. These compounds have been
discussed in great detail in Chapter 4.
In recent years compounds preferentially binding to GC sequences have piqued the
interest of scientific community to further understand the DNA recognition rules. Polyamines,
such as spermine, bind in the major groove of GC-rich regions and in the minor groove of ATrich regions[11]. It has been demonstrated that the binding of polyamines causes macroscopic
curvature and bending of DNA and, therefore, the action of polyamines could bring sequencespecific transcription factors and basal transcription factors in close proximity through DNA
structure modifications[12]. Trabectedin, an anticancer drug, preferentially binds to GC-rich
sequences in DNA, and further binds more strongly to CGG sites compared to GCG, showing
the importance of sequence selectivity[13]. The guanine amino group protrudes into the minor
groove and generally obstructs the access of drugs to the floor of the groove. The fact that the
amino group constitutes a critical negative recognition element for binding of many small
molecules in the minor groove of DNA has now been unambiguously demonstrated using DNA
molecules in which that group has been either deleted from guanines and/or added to
adenines[14]. Given both the strategic position of the amino group in the minor groove and its
potential to participate in hydrogen bonding, it was proposed that the introduction of an Hbond acceptor heteroatom in the pyrrole rings of netropsin might permit the drug to bind to
GC sequences[15]. Dervan‟s and Lown‟s group have extensively exploited this concept and
synthesized a series of lexitropsins that has increased selectivity for GC sequences[1, 16]. Among
the numerous lexitropsins synthesized so far, imidazole lexitropsins display the most
pronounced capacity for binding to GC-containing sequences[17]. Thiazole lexitropsins exhibit
a mixed GC recognition influenced by the position of the sulfur on the ring[18]. Despite the
elegant design strategy for lexitropsin/DNA complexes, the biological activity of this class of
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minor groove binders has not been much improved[4, 17]. So far, the lexitropsin approach has
not led to clinically useful drugs, although certain monomeric and dimeric lexitropsins exhibit
interesting antiviral or anticancer activities in vitro and sometimes in vivo [19].
Heterocyclic diamidines designed and developed by Boykin and coworkers have gained
significant momentum as a new class of DNA minor groove targeting agents with the
possibility of developing into potential antiparastic and antitrypanosomal agents [4, 20]. DB75, a
phenyl-furan-phenyl diamidine, is a therapeutically useful heterocyclic dication that has been
crystallized as an AATT complex[21]. A neutral, orally available prodrug of DB75 reached phase
III clinical trials against human African trypanosomiasis

[22].

DB293, a phenyl-furan-

benzimidazole dication of DB75, was surprisingly shown to bind to specific sequences of DNA
containing mixed GC/AT motif[23]. DNA recognition by DB293 was shown to be strongly
cooperative with the formation of a stacked dimer in the minor groove

[23-24].

This was a

surprising finding considering dications such as netropsin have not been discovered to form
stacked dimer with any DNA sequences. The importance of dications as potential antiparasitic
agents further necessitates the development of new dimer motifs.

DB832, a phenyl-furan-furan diamidine, was shown to recognize G-rich sequences
that can fold into a variety of quadruplex conformations (Chapters 2-4). DB832 was shown to
bind in the multiple grooves of human telomeric quadruplex conformation as stacked species;
however, a strong, initial end-stacking binding mode was also observed. The unique
recognition mode of DB832 coupled with a high binding stoichiometry deemed it difficult to
obtain detailed structural information by NMR methodology. The rational design of new
derivatives of DB832 to better recognize quadruplex grooves would require detailed structural
models for the drug/DNA complex. Structural information would provide the molecular basis
for specific recognition and can suggest possible modifications to extend and modify the
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sequence-specificity. The goal of understanding duplex groove-binding was probed with a
new duplex targeting compound, DB1878. DB1878, a phenyl-furan-indole analog of DB293,
was shown to recognize the mixed GC/AT motif as a stacked dimer, but with a significantly
higher affinity as seen from surface plasmon resonance studies. Here, we have conducted a
detailed 2D NMR analysis of the complex of DB1878 with the mixed GC/AT containing
sequence, oligo2-1. The structure reported here is completely different from the traditional
DNA recognition exhibited by lexitropsins, and represents an entirely new motif for DNA
minor groove recognition. Detailed structural information of the dimer complex of DB1878
with oligo2-1 could potentially aid in designing improved small molecules that can better
interact with the guanine-rich grooves of quadruplex structures.

6.2

MATERIALS AND METHODS

6.2.1 Surface Plasmon Resonance (SPR) Studies
Surface plasmon resonance experiments were conducted with a BIAcore T100
instrument as previously described

[25].

Biosensor experiments were conducted in filtered,

degassed HEPES buffer (10 mM HEPES, 100 mM NaCl, 3 mM EDTA, 0.005 v/v of 10% P20
BIACORE surfactant, pH 7.3) at 25 °C. Flow cell 1 was left blank as a reference, while flow
cells 2-4 were immobilized with DNA on a streptavidin-derivatized gold chip (SA chip from
BIAcore) by manual injection of DNA stock solutions (flow rate of 1 µL/min) until the desired
value of DNA response was obtained (350-400 RU). Typically, a series of different ligand
concentrations (1 nM to 10 µM from 20 mM H2O stock) were injected onto the chip (flow rate
of 50 µL/min, 5-10 min) until a constant steady-state response was obtained followed by a
dissociation period (buffer, 10 min). After every cycle, the chip surface was regenerated (20 s
injection of 10 mM glycine solution, pH 2.0) followed by multiple buffer injections. The RU
values in steady-state regions at each concentration were averaged over a 60-sec time zone
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and converted to r (moles of compound bound per mole of DNA hairpin) as previously
described

[25].

The binding affinities were determined by the best fitting plot of r versus free

compound concentration with a single site binding model (K2 = 0) or a two-site (K1 ≠ K2)
binding model.
One site:

r = (K1Cfree)/(1 + K1Cfree)

Two site:

r = (K1Cfree + 2K1K2Cfree2)/(1 + K1Cfree + K1K2Cfree2)

where K1 and K2 are the macroscopic equilibrium binding constants; Cfree is the
concentration of the compound in equilibrium with the complex and is fixed by the
concentration in the flow solution.

6.2.2 Nuclear Magnetic Resonance (NMR) Studies
All NMR experiments were done at 5 °C (unless stated otherwise) on a Bruker
Avance™600 using a 5 mm QXI triple resonance z-gradient probehead (Bruker). Oligo2-1,
d[CTATGACTCTCGTCATAC], hairpin was purchased from Integrated DNA Technologies with
IE purification and mass spectrometry characterization. The DNA was further dialyzed in over
long periods of time to further remove any remaining impurities. The final hairpin
concentration for all experiments was 1.35 mM. All NMR samples were prepared in 10 mM
NaHPO4 buffer containing 20 mM NaCl and 0.1 mM EDTA. The final pH of the NMR samples
was adjusted to 7.0 and the sample was annealed prior to collecting data. A 30 mM stock
solution of DB1878 was prepared in 99.99% D2O to perform titrations. Water suppression for
samples in 90% H2O/10% D2O was achieved with a 1-1 spin-echo or WATERGATE pulse
sequences. For experiments in 99.99% D2O, residual D2O resonance was suppressed with a
low power presaturation pulse. All one-dimensional NMR experiments were collected over 8k
or 16k data points with spectral width of 11 ppm (D2O samples) or 24 ppm (H2O samples)
with a relaxation delay time of 2.5 seconds. Phase-sensitive Double Quantum Filtered
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COrrelated SpectroscopY (DQF-COSY)[26], Total Correlated SpectroscopY (TOCSY)[27], NOE
SpectroscopY (NOESY)[28], and

31P−1H

HETCOR experiments were performed by collecting

either 1024 or 2048 points in f2, and between 512 and 800 points in f1. NOESY spectra at
mixing times ranging from 50 ms to 300 ms were collected with a spectral width of 10 ppm
(for D2O samples) or 24 ppm (for H2O samples) in each dimension, with a delay time of 3
seconds. Heteronuclear single quantum correlation (HSQC) spectra using echo-antiecho mode
for the

13C

inversion were recorded using z-gradients (2K × 256, 160 scans, 4 seconds delay)

were performed on a Bruker Avance™ 600 equipped with a cryoprobe at Vanderbilt
University. Quadrature detection in f1 was achieved using states time-proportional phase
increment (states-TPPI). Two-dimensional data were zero-filled to 4k x 4k points prior to
Fourier transformation, optimized with a SSB function (2, 2) in both dimensions, and treated
with automatic baseline correction. All data were processed on a DELL precision T7400
Workstation with RHEL5 kernel using Bruker TOPSPIN™ processing software and peak
assignments were performed using SPARKY (UCSF) and MNova (Mestrelab Research, Spain)
software.

6.3

RESULTS AND DISCUSSION

6.3.1 Proton Assignments of Oligo2-1
The NMR investigations of the drug-DNA complexes were undertaken by first
characterizing the free oligonucleotide. This was followed by examination of the complex
formed upon reaction with DB1878. The hairpin duplex and drug-DNA complex were fully
assigned using a combination of through space and through bond interactions from NOESY,
TOCSY and DQF-COSY spectra, using the method formulated by Wuthrich and coworkers[29].
It has previously been shown that H1' protons of B-form DNA typically resonate between 6.5
and 5.0 ppm, while H6/H8 protons resonate in the range 8.5-6.5 ppm[29]. Consequently, the
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starting point for the assignment of the oligo2-1 sequence was the NOE interactions in this
region of the NOESY spectrum i.e. the H6/H8-H1' assignment pathway (Figure 6.2). The
H6/H8 of the 5'-terminal residue will interact through space with the H1' of its own
deoxyribose only, whereas subsequent H6/H8 protons will interact with both their own H1'
protons and with the sugar protons of the preceding residue. The four bases in the loop of
oligo2-1, however, are independent of each other and only have cross peaks to their own H1‟
resonance. Using this assignment strategy, the backbone connectivity of oligo2-1 has been
completely assigned (Figure 6.2-A) at 5 °C. A temperature of 5 °C was employed for all NMR
experiments to reduce the effects of chemical exchange and also to reduce the amount of
minor species that was constantly observed at room temperature. The connectivity followed the
standard patterns as for B-DNA duplexes and complete assignment of base and sugar protons
for the oligo2-1 sequence was obtained.

The exchangeable proton signals for the imino protons were also assigned from NOESY
spectra of oligo2-1 obtained in 90% H2O sample at 5 °C (Figure 6.3). Imino protons in a
Watson-Crick type base-pairing generally resonate in the region between 11.5-14.5 ppm[29].
The imino-imino connectivities for the six base-pairs in the stem region of oligo2-1 can be
followed in Figure 6.3, where the corresponding cross-peaks are well resolved. A clear
pathway can be established starting from the imino of T2 until the imino of G12, where the
stem of oligo2-1 ends. The imino proton signal of the last base-pair in the stem, G18 is absent
in the pathway due to the fraying of helix at the ends and also due to high susceptibility for
solvent exchange. However, the imino proton of G18 can be seen in 1D spectrum as a broad
peak (~ 12.9 ppm, Figure 6.3-B), and undergoes further broadening as higher temperatures,
indicating duplex opening at higher temperatures. The imino proton resonances of all the
base-pairs involved in Watson-Crick base-pairing disappear around 45 °C suggesting the
significant exchange with the solvent around this temperature.
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The sequential assignments of other non-exchangeable sugar protons (H2‟/H2‟‟, H3‟
and H4‟) were also performed for oligo2-1 at 5 °C using the backbone connectivity method,
and all the assignments are listed in Table 6.1. The sugar H5‟/H5‟‟ protons could not be
unambiguously assigned due to significant overlap.

6.3.2 Proton Assignments of DB1878
The assignments of non-exchangeable protons of DB1878 were performed using the

through bond connectivity COSY experiment and the expanded aromatic region is shown in
Figure 6.4. The B1 proton of DB1878 does not have any COSY-type connections (three-bond
coupling) with any other protons of the molecule and therefore appears as a singlet in the
spectrum. The same holds true for indole proton (In) of the molecule and appears as singlet
upfield of all the protons. Three bond connectivities for F1/F2 and B2/B3 pairs can be clearly
established. The phenyl ring of DB1878 rotates rapidly in solution, and, therefore, the two
magnetically equivalent ring protons P1/P3 and P2/P4 are not distinguishable. All the proton
assignments of DB1878 are further verified with 1D-13C experiment (spectrum not shown).
The complete assignment of free DB1878 is listed in Table 6.2.

6.3.3 DB1878 Binds as a Highly Cooperative Dimer
To quantitatively evaluate the binding of DB1878, SPR studies (by Dr. Yang Liu from
Dr. Wilson‟s laboratory) were conducted with oligo2-1, and the sensorgrams are shown in
Figure 6.5-A. Binding of DB1878 was highly cooperative and saturates at two molecules per
oligo2-1 hairpin. Fitting the steady-state response values to a two-site model gave an initial
weak binding with K1=9.4 x 105 M-1, followed by a strong binding with K2=5.1 x 108 M-1.
The binding of DB1878 to oligo2-1 was strongly cooperative with a cooperativity factor of
greater 500 (K2/K1). The concave shape of the Scatchard plot further confirms the strong
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positive cooperativity for ligand binding. Cooperative binding of stacked dimers by polyamides
and an heterocyclic diamidine, DB293, with GC-containing sequences has been observed and
suggests that the relatively wider grooves of GC base-pairs facilitates the formation of stacked
dimers.

To further confirm the cooperativity, NMR studies of DB1878 with oligo2-1 were
conducted. Figure 6.5-B shows the 2D COSY spectra of the methyl and aromatic proton
interactions of the six thymine residues of oligo2-1 at different ratios of DB1878 at 5 °C. In the
absence of any ligand (ratio 0:1), the scalar coupling peaks of methyl-to-aromatic protons are
clearly observed corresponding to the six thymine residues. At the intermediate ratio (ratio
1:1), two distinct set of cross-peaks are observed suggesting the presence of two different
species and the ligand bound in an intermediate exchange. One set of these peaks correspond
to the uncomplexed DNA, whereas, the other set is the 2:1 species based on the 2:1 ratio.
Further titration of DB1878 (ratio 2:1) resulted in complete disappearance of the peaks from
the unbound DNA species, suggesting the complete saturation of the DNA. The clear saturation
of the DNA at this ratio suggests that two distinct molecules are bound per mole of DNA. The
new set of peaks in the final ratio corresponds to the second set of peaks observed at the
intermediate ratio. Therefore, the two sets of peaks in the intermediate ratio correspond to the
unbound and completely bound DNA suggesting a strong positive cooperativity as seen from
SPR studies.

6.3.4 Characterization of the 2:1 Complex
DB1878 was titrated to oligo2-1 at 5 °C to form the 2:1 complex for further NMR
analysis. The aromatic region of the titration spectra of DB1878 to oligo2-1 is shown in Figure
6.6-A at different ratios, along with the spectra of free DB1878 (25 °C). As seen from the
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spectra of DB1878, distinct number of protons is seen for the ligand maybe suggesting that the
ligand does not form stacked species in solution. Closer inspection of the titration spectra
reveals interesting information about the binding of DB1878. The intermediate ratio (ratio 1)
spectrum is a mixture of signals for unbound and the completely bound oligo2-1. The
unbound to the completely bound oligo2-1 transition can be monitored by some well defined
peaks in the spectra. The peak labeled with a “*” belongs to the A17H8 of the unbound oligo21. At the intermediate ratio, this peak broadens to some extent and decreases in the intensity.
Simultaneously, a new peak is seen in the spectra at the intermediate ratio, labeled with “#”.
This peak also belongs to the same proton, A17H8, but from the bound oligo2-1, and is not
seen in the unbound species (ratio 0). The intensities of the two peaks at the intermediate ratio
suggest that an equal population of the bound and unbound oligo2-1 is present and the
ligands are in the slow-exchange regime with the DNA. Upon further titration of the ligand
(ratio 2), the unbound peak (*) broadens further and its intensity is significantly reduced.
Concomitantly, the bound peak (#) sharpens further and is at maximum intensity at the final
ratio. A very similar trend is also observed with the A3H8 protons in the bound (†) and the
unbound (‡) DNA. This suggests that the DNA is completely saturated upon 2 mole equivalents
of DB1878. Thus, the titration spectra of DB1878 with oligo2-1 clearly illustrate that the 2:1
complex and the free DNA are the only species observed in the 1:1 spectrum. The equal
population of the completely bound and unbound DNA at the intermediate ratio also confirms
the strong cooperative dimerization of the compound.

The aromatic to aromatic region of a COSY spectrum of the 2:1 complex is shown in
Figure 6.6-B. This region consists of cross peaks only from the drug protons bound to the DNA.
When compared to the COSY spectra of the free DB1878 (Figure 6.4-A), there are clearly
twice the number of cross peaks in the new spectrum. This also clearly suggests that there are
two distinct DB1878 molecules bound to the DNA. The proton assignments for the two bound
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molecules were made using a combination of COSY and NOESY (not shown) and HSQC
spectra (Figure 6.7). Every proton resonance of the two molecules is easily distinguishable due
to the slow exchange in the bound form. The phenyl ring protons, which are not well resolved
in the free DB1878, are clearly distinguishable for both the bound DB1878 in the 2:1 complex
due to slow-exchange. The

13C-1H

correlation spectra of oligo2-1 with 2:1 ratio of DB1878

(Figure 6.7) shows a total of 20 decoupled peaks. Since each drug molecule has 10 C-H bonds,
the 20 peaks that are observed also suggest that two distinct ligands are bound in the complex.
Some of the protons resonate very close to each other and therefore have very similar chemical
shift values. As a result, data analysis proved difficult to some extent due to the overlapping of
the drug proton peaks (discussed later).

6.3.5 Detailed Assignment of DB1878:Oligo2-1 Complex
Non-exchangeable proton peaks of DB1878 complexed with oligo2-1 were assigned
using a combination of homonuclear NOESY and TOCSY spectra at different mixing times. The
H5-H6 cross peak of C1 provided the entry point for the backbone assignment in the NOESY
spectrum (Figure 6.8). The through space connection between the base aromatic protons and
the sugar H1‟ proton was clearly traced from C1 to T4 bases. The connection between the G5H1‟ and G5-H8 was interrupted since the G5-H1‟ proton was significantly perturbed and
exhibited an extreme upfield shift (~1.2 ppm), indicating a possible ligand induced
perturbation. Similarly, C7-H1‟ also exhibited a significant upfield shift (~1 ppm), possibly
suggesting some ring current effect on the H1‟ proton. The loop bases of oligo2-1 again did not
show any inter-base connectivity and had only cross-peaks to their own H1‟. On the 3‟-strand
of oligo2-1, two interruptions were observed. The H1‟ protons of C14 and T16 again exhibited
significant upfield shifts (~1.1 and ~1.3 ppm respectively), suggesting a site-specific, ligandmediated perturbation of the H1‟ protons and possible interaction site of the second DB1878
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molecule. The combined H1‟ chemical shift perturbations suggest that the possible interaction
site of the two DB1878 molecules is centered between A3•T16 and C7•G12 base pairs. The H1‟
protons of A6 and A15 also undergo significant upfield shifts (~0.5 and ~0.7 ppm), since they
are embedded within the binding site. Interestingly, the H1‟ protons of G12 and A3 does not
exhibit any shifts, considering their base-paired counterparts exhibit tremendous upfield shifts
with their H1‟. This suggests that, even though the two DB1878 molecules are bound side-byside in the minor groove, the two ligands are offset from each other and do not completely
span the entire proposed binding site: between A3•T16 and C7•G12 base pairs. The offset of the
ligands seems rational assuming the positively charged diamidine moieties of the two ligands
would avoid each other to reduce charge repulsion, while concurrently maintain a favorable
stacking with their overlapped ring systems.

The assignments of the non-exchangeable protons for the 2:1 complex are shown in
Table 6.3. To gain better understanding of DB1878 binding site within the minor groove of
oligo2-1, the NMR „footprint‟ from ligand-induced perturbations to the minor groove proton,
H1‟, is plotted against the sequence position in Figure 6.9-A. Aromatic protons which resides in
the major groove were also plotted as a function of sequence position (Figure 6.9-B). The loop
regions were not included since they were not likely the binding site for the ligand. The H1‟
sugar protons reside deeply in the DNA minor groove. Minor groove binding ligands upon
complex formation significantly perturbs the local chemical environment of these protons, and
therefore, ligand induced changes should be readily observable in the NMR spectra. Several of
the sugar H1‟ protons come into direct contact with the aromatic rings of either of the bound
ligands and experience significant upfield ring current perturbations to their chemical shifts.
These changes in the chemical shifts are particularly sensitive to the position of the ligand in
the minor groove. On the 5‟-strand, significant perturbation of the H1‟ protons are observed
starting from the G5 residue and extends until the terminal residue of the stem, C7. On the 3‟-
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strand, significant perturbations are observed starting from the C14 residue and extends until
T16. This strongly suggests the binding site of the two DB1878 molecules is from A3•T16 to
C7•G12. Each ligand is able to recognize a minimum of 3 residues on each of the strands based
on the chemical shift perturbations. The terminal base-pair does not exhibit any perturbations.
In contrast, the aromatic protons, which are located in the DNA major groove, experience
smaller effects upon complex formation. The small changes observed might be due to
structural perturbations in the DNA or changes in the base stacking interactions, however, a
similar pattern of perturbations as observed in the minor groove H1‟ protons are seen with the
major groove aromatic protons.

6.3.6 Extreme Ring Current Effects on H4‟ Protons
The NOESY spectra of the 2:1 complex were used to comprehensively assign all the
non-exchangeable protons of the complex, except for some of the sugar protons that resonate
around the water chemical shift that could not be unambiguously assigned. The NOESY spectra
of the 2:1 complex exhibited two extremely upfield shifted resonances (~0.85 and 1.09 ppm)
with strong NOE cross peaks all along the spectra with various sugar protons and protons from
the bases (Figure 6.10-A). The protons that have the most upfield chemical shifts in a normal
Watson-Crick B-DNA are the –CH3 protons of thymine residue (in the range of 2.5 - 1.5
ppm). However, all the thymine methyl protons of oligo2-1 in the complex were accounted for
and, therefore, the two most upfield proton resonances were considered to be from a minor
species of DNA or due to some impurity. A

31P-1H

spectrum collected to assign some of the

ambiguous sugar protons revealed, surprisingly, two extremely upfield shifted resonances
corresponding to the chemical shifts observed in the NOESY spectrum (Figure 6.10-B).

31P

spectra is routinely collected to obtain vicinal spin-spin 3-bond (H3‟, H5‟/H5‟‟) or 4-bond
(H4‟) coupling. After careful analysis of the spectra supplemented by 3-bond spin-spin
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interactions from COSY data of the 2:1 complex, the two upfield shifted resonances were
finally assigned to the H4‟ sugar protons of C7 (0.85 ppm) and T16 (1.09 ppm). H4‟ sugar
protons in B-DNA generally resonate between 4 - 4.5 ppm and in extreme cases have exhibited
upfield or downfield shifts within 1.0 – 1.5 ppm of the normal range, as in the case of
intercalators with large ring systems

[30].

However, here we have identified H4‟ sugar protons

exhibiting an impressive 2.5 – 3.0 ppm upfield shifts. Such a dramatic upfield shift is observed
only if there is an extremely shielded ring current effect on protons, and therefore, in this case
the shielding of those protons has to be from the ring systems of the bound ligand. The two
bases, C7 and T14, are located at the edges of the proposed binding site of DB1878 with their
H4‟ lying along the walls of the DNA minor groove. The stacking of the two DB1878 molecules
in an antiparallel manner would put the two indole ring systems on the opposite ends of the
binding site and directly on top of the 4‟ sugar protons (Figure 6.10-C). The orientation of the
indole rings in the DNA minor groove reasonably explains the extreme upfield shifts exhibited
by the H4‟ protons due to the large ring current effect. The H1‟ sugar protons of the same two
bases also exhibited significant upfield shifts upon complex formation (Section 6.3.5). This
further validates the presence of the ring system of the two molecules in a distinct orientation
near the H1‟ and H4‟ protons of the two bases to have such a dramatic effect.

6.3.7 Major Ligand-DNA and Ligand-Ligand Interactions
The NOESY spectrum of the 2:1 complex contains several intermolecular DB1878:DNA
crosspeaks as well as numerous crosspeaks between the two ligands. Figure 6.11 shows the
important drug:DNA and drug:drug interactions in the NOESY spectra of the aromatic and H1‟
region of the 2:1 complex at 5 °C. All of the NOEs can be used to identify contact points
between the DNA and two bound ligands. The terminal diamidines of the two molecules
require a novel stacking for binding side-by-side to DNA. From the intermolecular NOEs
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between the two DB1878 molecules, the M1B1 resonance signal has a strong crosspeak with
the M2P3 resonance. This puts the phenyl ring of M2 molecule in close proximity to the indole
ring of M1. Similarly, the M2B1 resonance signal has a strong crosspeak with the M1P2
resonance. These crosspeaks indicate that the two DB1878 molecules are stacked with an offset
and make it possible for the terminal diamidines of each molecule to be separated when
binding side-by-side into the minor groove. There are two crucial crosspeaks between M1B1 to
A6H2 and M2B1 to A15H2 protons. A-H2 protons reside deeply in the minor groove of the
DNA and are excellent probes for analyzing small molecules that bind in the DNA minor
groove. The high intensity of the two crosspeaks between the B1 of each DB1878 molecule and
AH2 protons, place the two B1 protons in direct contact with the two adenine residues. Figure
6.11-B shows the NOESY spectra of the base aromatic to sugar proton region. The three
crosspeaks between the G5H1‟ and M1P1, M1P2 and M1F1 protons place those three protons
deep into the minor groove. The crosspeak between C14H1‟ and M2F1 is of significantly lower
intensity than the G5H1‟ and M1F1 protons. Since the G5 and C14 are involved in a base-pair
and the intensities of their H1‟ protons with the two furan protons from different ligands are
not the same, the M2 furan protons are pointing outside the minor groove of the DNA.
However, the M2F2 proton exhibits a stronger intensity with the C14H1‟ proton. This might be
due to some spin-diffusion effects. Strong NOE crosspeaks are observed between the drug
protons facing outside the minor groove and some of the sugar protons that are located along
the walls and the exterior of the minor groove. The M2F1 resonance, which was shown to be
facing outside the minor groove, shows NOE crosspeaks with H5‟/H5‟‟ protons of A15.
Similarly, M2In shows NOE contacts with H5‟/H5‟‟ protons of T16 residue, suggesting that the
indole proton of M2 is facing outside the minor groove. Several strong NOE crosspeaks are
observed between the two NH protons of the two molecules and DNA protons (spectra not
shown). Important NOE crosspeaks are observed between the minor groove protons A6H1‟ to
M1NH and A15H1‟ to M2NH, suggesting that the NH protons of the two molecules are
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oriented into the minor groove of the DNA. Major intermolecular NOEs between the two drug
molecules and the drug:DNA are listed in Table 6.4 and Table 6.5 respectively. Important NOE
contacts between the two drug molecules and the DNA protons are depicted in Figure 6.12.

6.3.8 Importance of the Central G•C Basepair
The Watson-Crick base-pairing scheme of GC base-pair generally results in the bulky
amino group of the guanine residue directly point into the minor groove of the DNA. As a
result, this bulky amino group acts as a steric hindrance for minor groove targeting small
molecules. However, the amino group can also potentially participate in hydrogen bonding if
small molecules can be effectively developed to selectively recognize such systems[14a]. There
has been very little success so far in developing small molecules that can sequence specifically
interact with GC containing sequences, until recently. The Dervan‟s and Lown‟s group have
developed a broad class of lexitropsin derivatives for selectively targeting both AT and GC
base-pairs

[1, 6b, 6d, 31].

NMR studies of polyamides have shown ligands sequence specifically

interacting with the G-NH2 groups, and upon complex formation, the G-NH2 protons
undergo small downfield chemical shift changes, providing indirect evidence for the specific
hydrogen bonds to the acceptors on the ligands. We have also recently reported a heterocyclic
diamidine, DB293, to sequence-specifically interact with a GC-containing sequence

[23-24].

Systematic mutation studies of the binding site residues critically highlighted the requirement
of the central GC base-pair for the cooperative dimerization of DB293. DB1878 has been
reported here to form an antiparallel stacked dimer with same sequence, with the central
furan rings of the two molecules pointing in the opposite directions. NOESY spectra of free
oligo2-1 in 90% water sample shows that the G5 amino resonance completely broadened due
to the exchange through the rotation about the N-C bond (spectra not shown). The amino
protons generally show a broad cross-peak in the range of 7.0 to 8.0 ppm with the
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neighboring imino proton of the guanine, while the basepaired amino proton generally
downfield shifted than the non-basepaired proton. Figure 6.13 shows the expanded iminoamino correlation NOESY spectra of the 2:1 complex of DB1878 with oligo2-1. A strong NOE
crosspeak is observed to the G5 imino proton from the amino region. The crosspeak of the
amino proton is significantly downfield shifted by more than 1 ppm (9.16 ppm) when
compared to the broad resonance (7-8 ppm) in the free DNA. This extreme downfield shift of
the amino proton is due to the consequence of a direct hydrogen-bonding with the furan
oxygen that is pointed into the minor groove. The resonance at 9.16 ppm also has a strong
NOE crosspeak with the H1‟ sugar proton of G5 (not shown). Since the H1‟ and the NH2
protons point into the minor groove of the DNA, the strong crosspeak to the H1‟ proton from
the 9.16 ppm resonance further confirms the resonance belonging to the amino proton of G5.

6.3.9 Docking Studies
Preliminary docking studies with SYBYL software were conducted using the NMR data.
The two DB1878 molecules were carefully positioned in the grooves of the oligo2-1 sequence
to qualitatively visualize the NMR results and the ligands were energy minimized while
holding the DNA fixed. The final structure of the complex is presented using VMD software
(Figure 6.14). A complete detailed NMR structural analysis of the complex is in progress.

6.4

CONCLUSION
DNA minor groove binders have biological activities that range from anti-opportunistic

infection to anticancer properties. These compounds have also provided a wealth of
fundamental information about nucleic acid recognition properties, and they continue to be
important models in the study of nucleic acid complexes. Until recently, the lexitropsins have
remained the only class known to recognize both strands of the DNA double helix through
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stacked dimer formation. A dimer motif that recognizes both the strands allows much greater
selectivity in targeting desired sequences of DNA. DB293 was the first unfused dication that
was shown to form stacked dimers with GC-containing sequences. Structurally related
dications have been found to have a range of therapeutic properties and, therefore,
development of the new dimer motif is of importance. DB1878, an indole analog of DB293, is
reported here to bind very strongly and cooperatively to specific sequences of DNA that
contain GC base pairs. The unique recognition mode of DB1878 offers new possibilities for
development of agents for recognition of mixed base pair sequences of DNA and can help in
establishing new set of recognition rules for sequence specific DNA recognition.
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Figure 6.1: Chemical structure of DB1878 with the atom naming and coloring schemes used in
this study and the hairpin duplex, Oligo2-1. The possible binding site of DB1878 is
highlighted in green.
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(A)

(B)

Figure 6.2: (A) Aromatic (H6/H8) to H1‟ backbone connectivity region of oligo2-1 at 5 °C. (B) Schematic H6/H8-H1‟ connectivity
observed.

Similar connectivity is also observed for H2‟/H2‟‟ and H3‟ sugar protons with the aromatic H6/H8 protons.
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(A)

(B)

Figure 6.3: Expanded region of the observed exchangeable proton 2D NOESY spectrum of free
oligo2-1 at 5 °C (A), and imino proton spectra of free oligo2-1 as a function of temperature
(B).

NOESY spectrum conditions: mixing time: 300 ms, water suppression with 1-1 pulse sequence,
relaxation delay: 2.5 seconds, temperature: 5 °C and [DNA]=1.5 mM
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(A)

(B)

Figure 6.4: The expanded aromatic region of COSY spectrum of DB1878 in D 2O at 25 °C (A),
and the corresponding 1D proton spectra (B).

The three bond coupling observed between the protons in the ligand is shown as an inset in the
COSY spectrum.
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Figure 6.5: SPR sensorgrams of DB1878 binding to oligo2-1 with the corresponding Scatchard
plot (A), and the 2D COSY spectra of the T: CH3-H6 region for DB1878-oligo2-1 interaction
at 5 °C with listed ratios (B).

From the Scatchard plot and the COSY spectrum it is clear that the binding of DB832 to
oligo2-1 is positively cooperative.
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(A)
†

†

‡

‡
‡

†

(B)

Figure 6.6: Aromatic proton spectra of DB1878 with oligo2-1 at 5 °C (A), and the aromatic
region of the COSY spectrum of 2:1 complex at 5°C (B).

Peaks labeled with † and ‡ indicates the shift of bound and unbound A3H8 respectively, and
the peaks labeled with # and * indicates the shift of bound and unbound A17H8 respectively.
The peak labeled with $ belong to C14H6 of the free DNA and is significantly reduced at
saturation ratios of DB1878. All cross peaks in the aromatic region of the complex correspond
to the bound DB1878 molecules.
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Figure 6.7: Expanded region of the 1H-13C-HSQC spectrum of oligo2-1 with 2:1 ratio of
DB1878 at 5 °C without decoupling.

A total of 20 decouple C-H correlation pairs (10 for each bound molecule) are observed
accounting for both of the drug molecules bound to the DNA. This experiment was performed
at Vanderbilt University.
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G5:H1‟-H8

T16:H1‟-H6
C14:H1‟-H6
C7:H1‟-H6

Figure 6.8: The aromatic to H1‟ backbone connectivity region of 2:1 complex of DB1878 with
oligo2-1 at 5 °C.

Some of the sugar H1‟ protons that exhibit significant upfield shifts are labeled in red. H1‟
protons of the sugar deeply reside in the minor groove of duplex DNA, and minor groove
binding ligands can significantly perturb the chemical environment of these protons as
observed. A schematic representation (right) of the possible binding site of two DB1878
molecules in the minor groove of oligo2-1 based on the H1‟ chemical shift perturbations.
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Figure 6.9: Plot of ligand induced changes for H1‟ (A), and H6/H8 (B) in the 1H-NMR
chemical shifts for the 2:1 complex of DB1878 with oligo2-1. The loop residues are not
included.
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(A)

(B)

Figure 6.10: Expanded NOESY spectrum of the upfield region (A), and
with oligo2-1 at 5 °C.

(C)

31P-1H

correlation spectrum (B) of 2:1 complex of DB1878

The blue dotted lines in (A) indicate extreme upfield shifts exhibited by C7H4‟ (0.85 ppm) and T16H4‟ (1.09 ppm). The purple box
in (B) indicates the same two proton signals in the 31P-1H correlation spectrum. A schematic representation (C) of a possible ring
current effect of the two DB1878 molecules on the two H4‟ protons to exhibit such extreme upfield shifts.
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(A)

(C)

(B)

M1B1-A6H2
M2B1-A15H2

C1:H5-H6
Shown for reference

Figure 6.11: Intermolecular crosspeaks between the two DB1878 molecules and between DB1878 and DNA protons in the
aromatic region (A), H1‟ region (B) of the NOESY spectrum of the 2:1 complex at 5 °C. The 2D stacked plot illustrating the strong
interactions between the B1 protons and adenine residues are in (C).
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Figure 6.12: Some of the major NOE interactions observed between the two drug protons and
the DNA.

Strong interactions are observed between the NH and B1 protons of the two molecules with
AH2 and some of the H1‟ protons of the DNA. The G5NH2 is proposed to form a hydrogenbond with the furan oxygen pointed into the minor groove based on the chemical shift analysis
if G5-NH2. The terminal diamidines are also proposed to potentially participate in hydrogen
bonding with acceptors on the DNA bases.
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Figure 6.13: Expanded NOESY spectrum of the imino proton region of 2:1 complex of DB1878 with oligo2-1 at 5 °C.

The red dotted lines connect the G5-NH2 proton with G5-NH proton. The G5-NH2 proton is proposed to be involved in hydrogenbonding with the furan oxygen of DB1878. A schematic representation of the G•C base-pair important for the dimer formation by
DB1878.
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(A)

(B)

(C)

(D)

Figure 6.14: Preliminary docking studies of DB1878 complexed with oligo2-1 based on NMR
data. (A) View into the groove of oligo2-1 with the two DB1878 molecules (B) View along the
groove of the helix (C) interaction between M2B1 and M2NH with A15H2 and (D) possible Hbond between G5NH2 and furan oxygen.
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Table 6.1: Exchangeable and non-exchangeable proton assignment of free oligo2-1 at 5 °C.
Base

H1'

H2'

H2''

H3'

H4'

H6/H8

H2

H5/CH3

NH

C1

5.58

2.01

2.34

4.42

3.88

7.63

--

5.66

--

T2

5.55

2.11

2.41

4.70

3.97

7.43

--

1.49

13.58

A3

6.09

2.52

2.77

4.90

4.22

8.21

7.10

--

--

T4

5.48

1.73

2.14

4.65

4.05

6.90

--

1.21

13.23

G5

5.32

2.46

2.51

4.79

4.12

7.66

--

--

12.31

A6

5.98

2.38

2.61

4.96

4.18

7.91

7.65

--

--

C7

5.67

1.81

2.08

4.57

3.91

6.99

--

4.97

--

T8

5.85

1.85

2.10

4.51

4.01

7.30

--

1.58

--

C9

5.83

1.90

2.26

4.37

3.86

7.61

--

5.84

--

T10

5.69

1.86

2.04

4.42

3.80

7.12

--

1.35

--

C11

5.87

1.89

2.26

4.49

3.96

7.47

--

5.67

--

G12

5.71

2.43

2.61

4.58

4.05

7.82

--

--

12.62

T13

5.95

2.01

2.36

4.69

4.02

7.12

--

1.11

13.65

C14

5.42

1.94

2.25

4.66

3.90

7.38

--

5.84

--

A15

6.00

2.48

2.71

4.81

4.12

8.16

7.32

--

--

T16

5.31

1.77

2.09

4.62

3.84

7.00

--

1.28

13.31

A17

5.83

2.46

2.66

4.80

4.13

7.95

7.15

--

G18

5.76

2.20

2.02

4.40

3.91

7.46

--

--

12.96
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Table 6.2: Assignments of the free drug and the bound drugs in the complex.
DB1878 (25 °C)

Complex (at 5 °C)
M1

M2

F1

7.035

6.615

6.476

F2

6.912

7.105

6.978

B1

7.767

7.126

6.981

B2

7.683

6.915

6.831

B3

7.346

6.975

6.932

P1

7.825

7.146

6.985

P2

7.701

7.296

7.552

P3

7.825

7.549

7.588

P4

7.701

7.267

7.312

In

6.888

6.775

6.625

NH

----

12.32

12.18
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Table 6.3: Exchangeable and non-exchangeable proton assignment of the 2:1 complex of
DB1878 with oligo2-1 at 5 °C.
Base

H1'

H2'

H2''

H3'

H4'

H5'

H5''

C1

5.54

2.04

2.27

4.43

3.98

H6
/H8
7.58

T2

5.64

2.15

2.49

4.74

4.05

7.45

A3

6.10

2.62

2.77

4.90

4.27

8.31

T4

5.40

1.56

1.85

4.65

4.18

7.01

G5

4.12

2.31

2.83

4.37

3.98

7.84

A6

5.45

1.96

2.28

4.33

C7

4.69

1.31

1.63

4.04

0.85

T8

5.86

1.94

2.19

4.47

3.92

C9

6.02

1.90

2.26

4.37

T10

5.68

1.80

2.12

4.39

C11

6.02

1.95

2.27

G12

5.76

2.55

T13

6.02

C14

H2

H5
/CH3
5.59

NH

1.48

13.43

1.16

13.88

7.31

13.69

3.29

3.08

7.75

3.09

2.63

6.75

5.10

7.17

1.46

7.61

5.81

7.09

1.41

4.41

7.56

5.73

2.75

4.74

7.91

2.05

2.27

4.75

7.23

1.14

4.33

2.00

2.06

4.39

7.54

5.53

A15

5.35

1.95

2.32

4.33

T16

3.97

1.23

1.37

4.03

A17

5.79

2.29

2.60

4.75

G18

5.71

2.21

2.02

4.43

3.64

1.09

3.29

3.12

7.82

3.21

2.97

6.56
7.74

3.85

7.43

8.11

12.49
13.81

8.07
1.36

13.31

7.08
12.95
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Table 6.4: Major intermolecular crosspeaks between two DB1878 molecules.
M2B1 6.98

M1P2 7.29

Strong

M2In 6.62

M1P3 7.55

Strong

M1In 6.77

M2P3 7.89

Strong

M1In 6.77

M2In 6.62

Medium

M2F1 6.47

M1In 6.62

Medium

M1B1 7.13

M2F1 6.47

Weak

M1In 6.77

M2P4 7.31

Medium

M1B1 7.13

M2P3 7.59

Medium
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Table 6.5: Major intermolecular crosspeaks between the two ligands and DNA protons.
M2B1 6.98
M1B1 7.13
M1F1 6.61
M2F1 6.47
M1B3 6.97
M1P1 7.14
M1P1 7.14
M1P2 7.29
M1F1 6.61
M2F1 6.47
M2F2 6.97
M2B1 6.98
M1B1 7.12
M1B3 6.97
M1B2 6.91
M1F1 6.61
M2B2 6.83
M2In 6.62
M2F1 6.47
M2F1 6.47
M2In 6.62
M2B2 6.83
M1NH 12.32
M1NH
M1NH
M1NH
M1NH
M1NH
M1NH
M1NH
M1NH
M2NH 12.18
M2NH
M2NH
M2NH
M2NH
M2NH
M2NH
M2NH

A15H2 8.06
A6H2 8.11
A15H2 8.06
A6H2 8.11
A6H2 8.11
A15H2 8.06
G5H1‟ 4.12
G5H1‟ 4.12
G5H1‟ 4.12
C14H1‟ 4.32
C14H1‟ 4.32
T16H1‟ 4.02
C7H1‟ 4.68
A6H5‟‟ 3.08
A6H5‟‟ 3.08
G5H2‟‟ 2.83
T16H5‟‟ 2.96
T16H5‟‟ 2.96
A15H5‟‟ 3.12
A15H5‟ 3.29
T15H5‟ 3.21
T16H5‟ 3.21
A6H2 8.11
A6H1‟ 5.44
C7H1‟ 4.68
G5H1‟ 4.12
A6H5‟ 3.29
A6H5‟‟ 3.07
A6H2‟ 1.96
A6H2‟‟ 2.27
C7H4‟ 0.85
T16H1‟ 3.97
A15H1‟ 5.34
T16H5‟ 3.21
T16H5‟‟ 2.96
A15H2‟ 1.95
A15H2‟‟ 2.32
T16H4‟ 1.09
A15H2 8.06

Strong
Strong
Weak
Weak
Weak
Weak
Medium
Strong
Medium
Very Weak
Medium
Medium
Medium
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Medium
Medium
Strong
Strong
Medium
Weak
Medium
Medium
Medium
Medium
Medium
Medium
Strong
Medium
Medium
Medium
Medium
Medium
Strong
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